Novel Mechanisms Regulating Dopamine Transporter Endocytic Trafficking: Ack1-Controlled Endocytosis And Retromer-Mediated Recycling by Wu, Sijia
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2017-01-12 
Novel Mechanisms Regulating Dopamine Transporter Endocytic 
Trafficking: Ack1-Controlled Endocytosis And Retromer-Mediated 
Recycling 
Sijia Wu 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Biochemistry Commons, Cell Biology Commons, Molecular and Cellular Neuroscience 
Commons, and the Molecular Biology Commons 
Repository Citation 
Wu S. (2017). Novel Mechanisms Regulating Dopamine Transporter Endocytic Trafficking: 
Ack1-Controlled Endocytosis And Retromer-Mediated Recycling. GSBS Dissertations and Theses. 
https://doi.org/10.13028/M2J01G. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/887 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
 
 
NOVEL MECHANISMS REGULATING DOPAMINE TRANSPORTER 
ENDOCYTIC TRAFFICKING: ACK1-CONTROLLED ENDOCYTOSIS 
AND RETROMER-MEDIATED RECYCLING 
 
A Dissertation Presented  
By 
SIJIA WU 
 
 
Submitted to the Faculty of the 
Graduate School of Biomedical Sciences, Worcester 
In partially fulfillment of the requirement of the degree of  
 
 
DOCTOR OF PHILOSOPHY 
 
 
JANUARY 12TH, 2017 
 
PROGRAM IN NEUROSCIENCE 
  
 
 
NOVEL MECHANISMS REGULATING DOPAMINE TRANSPORTER ENDOCYTIC 
TRAFFICKING: ACK1-CONTROLLED ENDOCYTOSIS AND RETROMER-MEDIATED 
RECYCLING 
A Dissertation Presented  
By 
SIJIA WU 
Dissertation Defense Committee GSBS Members 
 Mary Munson, Ph.D. 
Biochemistry and Molecular Pharmacology 
David G. Lambright, Ph.D. 
Program in Molecular Medicine 
Vivian Budnik, Ph.D. 
Program in Neuroscience 
Chair of the Dissertation Committee 
Andrew R. Tapper, Ph.D. 
Program in Neuroscience 
External Dissertation Committee Member 
Aurelio Galli, Ph.D.  
Professor, Vanderbilt University 
Thesis Advisor  
Haley E. Melikian, Ph.D. 
Program in Neuroscience 
Student Program  
Program in Neuroscience 
January 12th, 2017  
 
iii 
 
Acknowledgements 
First and foremost, I would like to thank my thesis advisor Haley, who guided me 
through my graduate research, kindled my scientific curiosities, trained me to 
think rigorously, and most importantly, taught me how to be a good scientist. Her 
mentoring definitely changed me beyond the scientific research and molded me 
into who I am now, and showed me who I can be. 
When I first joined the Melikian lab, back in 2011, I did not have a lot of bench 
work experience and Haley walked me through most of the experiments. Haley is 
always available to answer questions and give advice. Even so, I had three 
binders of failed cloning and western blots. She told me to work harder and so I 
did. But being persistent is not enough, I learn from her over years that I also 
need to be a keen observer, be patient and think experiments steps ahead. 
Haley is also very supportive of my own ideas. The breakthrough of my graduate 
research was the discovery of a protein called Ack1 as a DAT endocytic brake 
molecule. I still remember on that Friday, during our weekly one-to-one meeting, I 
proposed the idea to her and she was very supportive and ordered two 
antibodies and an inhibitor for pilot experiments right away. This was the first 
time that I got a taste of scientific discovery and I was so thrilled! We eventually 
turned this idea into my first publication in PNAS and there is one more on the 
way. I owe much gratitude to Haley. 
iv 
 
I would like to thank the previous and current members of the Melikian lab. Luke, 
who overlapped with me for three years and was literally a walking encyclopedia. 
Thank you for answering my silly questions.  Carolyn and Rita, I enjoyed our 
discussions about experiments, projects and of course, the gossips. My thanks 
also go to Patrick, Brian, Allyson and Joanna. Thank you all and I was so lucky to 
have such wonderful and trustworthy labmates. 
I would also like to acknowledge members of my TRAC/DEC committees: 
Andrew, who has being my chair since the qualify exam; Mary, David and Vivian 
have been in my TRAC for four years and Dr. Galli, thank you for traveling all the 
way from Tennessee to attend my defense. Your encouragement and advice 
over the years have been instrumental in my success.  
Finally, I would like to dedicate this thesis to my husband Lukai and my parents 
Xiaoping and Jianmin. Thank you for keeping me company, for cheering me up 
when I am down. Without your love and support, I would not be able to succeed.  
  
v 
 
Abstract 
Dopamine transporters (DAT) facilitate high-affinity presynaptic dopamine (DA) 
reuptake in the central nervous system, and are required to constrain 
extracellular DA levels and maintain presynaptic DAergic tone. DAT is the 
primary target for addictive and therapeutic psychostimulants, which require DAT 
binding to elicit reward. DAT availability at presynaptic terminals ensures its 
proper function, and is dynamically regulated by endocytic trafficking. My thesis 
research focused on two fundamental questions: 1) What are the molecular 
mechanisms that control DAT endocytosis? and 2) what are the mechanism(s) 
that govern DAT’s post-endocytic fate? Using pharmacological and genetic 
approaches, I discovered that a non-receptor tyrosine kinase, activated by cdc42 
kinase 1 (Ack1), stabilizes DAT plasma membrane expression by negatively 
regulating DAT endocytosis. I found that stimulated DAT endocytosis absolutely 
requires Ack1 inactivation. Moreover, I was able to restore normal DAT 
endocytosis to a trafficking dysregulated DAT coding variant identified in an 
Attention Deficit Hyperactivity Disorder (ADHD) patient via constitutively 
activating Ack1. To address what mechanisms govern DAT’s post-endocytic fate, 
I took advantage of a small molecule labeling approach to directly couple 
fluorophore to the DAT surface population, and subsequently tracked DAT’s 
temporal-spatial post-endocytic itinerary in immortalized mesencephalic cells. 
Using this approach, I discovered that the retromer complex mediates DAT 
recycling and is required to maintain DAT surface levels via a DAT C-terminal 
vi 
 
PDZ-binding motif. Taken together, these findings shed considerable new light 
on DAT trafficking mechanisms, and pave the way for future studies examining 
the role of regulated DAT trafficking in neuropsychiatric disorders. 
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CHAPTER I  
INTRODUCTION 
I.A Dopamine System in the CNS and Related diseases 
Over sixty years ago, Arvid Carlsson discovered dopamine (DA) as a 
neurotransmitter. Since then, research on DA neurotransmission and signaling 
mechanisms have greatly impacted the development of neuropharmacology and 
psychiatry. Some of the medicines that are most widely prescribed in modern 
neurology and psychiatry, including L-DOPA, Ritalin and antipsychotic drugs, act 
on the brain DA system. In this section of the introduction, I will give an overview 
of the DA system in the central nervous system (CNS) then focus on the two 
major dopaminergic projections, the nigrostriatal pathway and the 
mesocorticolimbic pathway, and their implications in neuropsychiatric disorders. 
OVERVIEW OF THE DOPAMINE SYSTEM IN THE CNS 
Anatomical studies have greatly helped us to understand the contribution of 
dopaminergic pathways to behavior. Before the era of immunohistochemistry, 
sensitive visualization of neurotransmitter in a neuron was achieved by the Falck 
–Hillarp method developed in the early 1960s. By exposure of freeze-dried tissue 
to formaldehyde vapor, Falck showed that DA and norepinephrine could be 
transformed into fluorophores that emitted yellow-green fluorescence (Falck and 
Torp, 1962). Later modification of this technique with improved sensitivity and 
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precision enabled visualization of DA axon terminals in great details (Lindvall and 
Bjorklund, 1974).  
Anterograde and retrograde tracing are also one of the most widely used 
methods to map neuronal circuitry. Based on intra-axonal transport, tract-tracing 
methods utilized the uptake and transport of horseradish peroxidase (HRP) to 
trace neuronal projections (LaVail and LaVail, 1972). More recently, a series of 
trans-synaptic tracers have been developed that allow identification of 
synaptically connected cells (Zou et al., 2001; Braz et al., 2002). Among them, 
Wickersham and colleagues constructed a viral tracer that crossed only one 
synaptic step to neurons directly connected to the starting population 
(Wickersham et al., 2007). Based on rabies virus, this technology enables a more 
detailed understanding of neuronal connectivity. 
Using those techniques, DA neurons were identified and mapped in the brain. 
The major dopaminergic projection, the nigrostriatal pathway, consists of 
dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the 
midbrain that project to the dorsal striatum (caudate nucleus and putamen). The 
nigrostriatal pathway is responsible for voluntary movement. In addition, 
dopaminergic neurons in the ventral tegmental area (VTA) projection to the 
ventral striatum (nucleus accumbens, NAc) and prefrontal cortex (PFC) form the 
mesocorticolimbic pathway, which is associated with reward-related behavior  
(Moore and Bloom, 1978). The tuberoinfundibular pathway, which transmits DA 
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from hypothalamus to the pituitary gland (Bjorklund et al., 1970; Jonsson et al., 
1972), controls secretion of certain hormones like prolactin (Takahara et al., 
1974). Other than the three major dopaminergic projections, DA neurons also 
exist in retina and the olfactory bulb for vision and odor processing (Hokfelt et al., 
1975; Bauer et al., 1980). These different dopaminergic pathways are illustrated 
in a simplified diagram in Figure I-1. 
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Figure I-1. DAergic pathways in the rodents brain. Cell bodies of DA 
neurons localize primarily in the midbrain substantial nigra and ventral 
tegmental area and they project to brain regions including dorsal striatum, 
median prefrontal cortex (mPFC), nucleus accumbens (NAc), hippocampus 
(Hipp) as well as amygdala (Amy). There are also DA neurons in 
hypothalamus (HTH) that project to pituitary gland (PIT). Two main DAergic 
pathways: nigrostriatal pathway and mesocorticolimbic pathway are illustrated 
in green.  
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THE NIGROSTRIATAL PATHWAY AND PARKINSON’S DISEASE (PD) 
The nigrostriatal projection from the SNpc to the dorsal striatum was discovered 
by Hornykiewcz and colleagues, who correlated the drastic reduction of DA 
content in the dorsal striatum of PD patients with the degeneration of SNpc 
(Hornykiewicz, 1966). With the help of the Falck –Hillarp method, this projection 
was rapidly confirmed (Anden et al., 1966). The terminals of the nigrostriatal 
projection locate to the dorsal striatum which consists of the caudate and 
putamen. As the axons enter the dorsal striatum, they collateralize into branches 
that contain numerous small varicosities, 0.5-0.7 µm in diameter (Anden et al., 
1966).   
The use of the chemical neural toxin, 6-hydroxydopamine (6-OHDA), greatly 
helped to understand the physiological function of nigrostriatal DA neurons on 
their target cells in the striatum (Bloom, 1975; Ungerstedt, 1976). 6-OHDA is a 
hydroxylated analog of DA and selectively destroys DA and norepinephrine 
neurons by inducing oxidative stress and mitochondria defects in those neurons 
(Blum et al., 2001). When injected into the DA bundle or SN in rat, firing rates of 
striatal neurons increased ipsilateral to the lesion, suggesting the inhibitory 
nature of the nigrostriatal DA system (Arbuthnott, 1974). We now know that the 
nigrostriatal projection releases DA that activates dopamine receptors on the 
medium spiny neurons in the dorsal striatum. 6-OHDA lesions of the nigrostriatal 
pathway is also widely used as a behavior model that demonstrates the 
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importance of the nigrostriatal pathway in movement initiation and balance 
maintenance (Alexander et al., 1990).  
Severe damage to SNpc was not generally accepted as one of the hallmarks of 
PD pathology until neuropathological studies of Hassler, Greenfield and 
Bosanquet (Greenfield and Bosanquet, 1953). It is now known that neuron loss in 
SNpc starts about six years before the first motor symptom is clinically detectable, 
at which point around 75% of the SNpc DA neurons have died (Lees, 2007). Loss 
of DA in the dorsal striatum alters the downstream neurotransmission and leads 
to symptoms like tremor, bradykinesia and muscle rigidity (Dauer and 
Przedborski, 2003).   
In summary, the DA nigrostriatal pathway regulates motor behavior, and aberrant 
DAergic neurotransmission in this pathway leads to the pathological conditions 
that contribute to PD. 
THE MESOCORTICOLIMBIC PATHWAY AND DRUG OF ABUSE 
The nucleus accumbens, also called ventral striatum, arises developmentally 
with the dorsal striatum, has neurons similar to the dorsal striatum, and receives 
a DA innervation from VTA DA neurons (Heimer et al., 1997). In 1954, Olds and 
Milner carried out pioneering experiments revealing that rats repeatedly press 
levers to stimulate certain brain regions including NAc and septum (Olds and 
Milner, 1954). Later studies using direct brain stimulation mapped brain regions 
containing reward-relevant neurons. Those studies mainly focused on the 
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diencephalic medial forebrain bundle where we now know as part of the 
mesolimbic pathway (Wise and Rompre, 1989). 
Our knowledge of the neurochemical subtypes of reward-relevant neurons 
primarily derived from pharmacological studies, especially studies using drugs of 
abuse. Abusive drugs, like psychostimulants, opiates and nicotine, act through 
distinct molecular mechanisms to modulate DA levels within certain brain regions 
(Heikkila et al., 1975a; Heikkila et al., 1975b; Marks et al., 1986). 
Mesocorticolimbic DA pathways, which project mainly from VTA to the NAc and 
PFC, were soon identified as the reward-seeking pathways for psychostimulants 
cocaine and amphetamine. Lesions in the NAc blocked cocaine- and 
amphetamine- induced reward behavior (Lyness et al., 1979; Roberts et al., 
1980). Rats could learn to self-administer amphetamine into the NAc (Hoebel et 
al., 1983) as well as lever-press for cocaine into mPFC (Goeders and Smith, 
1983). These results demonstrate that DAerigc neurotransmission in the 
mesocorticolimbic pathway is a key regulator for reward, and recently studies 
have shown that repeated exposure to drugs of abuse alters brain reward 
pathways and often leads to drug addiction (Hyman et al., 2006). 
In summary, the two major DA pathways, the nigrostriatal pathway and the 
mesocorticolimbic pathway, are essential for key brain functions such as 
locomotion, reward and cognition. Dysregulation of DAergic neurotransmission in 
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these pathways contribute to neurological disorders such as PD, schizophrenia 
and drug addiction. 
I.B Presynaptic Dopaminergic Neurotransmission 
Dopaminergic neurotransmission is characterized by dopamine release from the 
presynaptic terminal, binding of DA to multiple pre- and post-synaptic receptors 
and reuptake of DA by the presynaptic dopamine transporter (DAT). DA and 
other monoamine neurotransmitters activate G-protein coupled receptors 
(GPCR), but not ligand-gated ion channels, to achieve their modulatory effects at 
the order of subseconds to minutes. This slow-acting nature of DA requires a 
more complicated sequence of biochemical steps including secondary 
messengers, protein kinases and phosphatases (Greengard, 2001). DA neurons 
carry two distinct firing patterns, tonic firing, in which DA neurons fire in a single 
spiking mode, and burst firing, consisting of consecutive spikes with decreasing 
amplitude and increasing duration (Grace and Bunney, 1984b, a). In this section, 
I will mainly focus on presynaptic DA neurotransmission with an emphasis on 
reuptake of neurotransmitters as a primary mechanism to terminate 
dopaminergic neurotransmission. 
DA SYNTHESIS AND METABOLISM 
The biosynthesis of DA has been established for over fifty years (Molinoff and 
Axelrod, 1971). The DA precursor, L-tyrosine, is converted to L-DOPA by the 
enzyme tyrosine hydroxylase (TH). Then, aromatic L-amino acid decarboxylase 
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(AADC) transforms L-DOPA to DA. The metabolism of DA involves primarily two 
enzymes: monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT). 
In the 1950s, it was already known that MAO deaminated all catecholamines 
including DA, norepinephrine and epinephrine. However, even after the 
administration of MAO inhibitor, increase in the blood pressure induced by 
norepinephrine to cats was still rapidly reverted, which prompted researchers at 
that time to search for another unknown enzyme that metabolized and 
inactivated norepinephrine (Axelrod, 2003). Axelrod and colleagues soon purified 
COMT and demonstrated that it O-methylated catechols in vitro and in vivo 
(Axelrod and Tomchick, 1958; Axelrod and Laroche, 1959). The main metabolite 
for DA is homovanillic acid (HVA), which could be easily detected in urine. 
DISCOVERY OF DA UPTAKE 
The discoveries of enzymes like MAO, COMT and acetylcholinesterase (AchE) 
convinced researchers that termination of neurotransmission was mediated by 
enzymatic inactivation of neurotransmitters. This is true for acetylcholine (Ach) 
since Ach is rapidly degraded into choline and acetyl CoA by AchE.  However, 
similar to MAO inhibition, inhibition of COMT activity also failed to block the blood 
pressure-elevating action of norepinephrine, suggesting other mechanisms are 
responsible for terminating norepinephrine action. It was not until the late 1950s, 
when tritium labelled catecholamines became available, that the neurotransmitter 
uptake mechanism was discovered. Axelrod’s group first found that radioactive 
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norepinephrine was accumulated by sympathetic nerve terminals after 
intravenous injection in mice and cats (Hertting and Axelrod, 1961). Removing 
those sympathetic nerves strikingly reduced 3[H]-norepinephrine and epinephrine 
in those chronically denervated structures (Hertting et al., 1961). Based on these 
observations, they proposed that the reuptake of norepinephrine by the same 
nerve that released it was a novel mechanism that terminated neurotransmission. 
Soon, DA and serotonin were also found to be inactivated by uptake into their 
respective presynaptic terminals (Snyder and Coyle, 1969; Iversen, 1971).  
MEASURING DA UPTAKE IN VIVO 
Studying DA uptake using in vitro systems, like brain homogenates and 
synaptosome preparations (Snyder and Coyle, 1969; Bonanno and Raiteri, 1987), 
gave important information in terms of substrate and drug affinity on the transport 
system, but it cannot tell how DA release and reuptake are regulated 
physiologically. To address this question, multiple approaches have been 
developed over years to measure DA release and reuptake in vivo. These 
approaches provide the temporal-spatial resolution of DA release in brain regions 
of interest, and measure the amount of DA that is released during neuronal 
stimulation.  
Starting in the early 1980s, fast scan cyclic voltammetry (FSCV), in which a 
carbon fiber electrode implanted in the brain detects surrounding DA by 
oxidization, has been used to measure electrically evoked DA release and 
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reuptake (Marsden et al., 1988). With the subsecond temporal resolution and 
micrometer-dimension spatial resolution, FSCV allows acute kinetic 
characterization of DA release and reuptake (Nicholson, 1995). Estimates for the 
Km of DA uptake ranges from 0.2 to 2 µM, depending on the brain region 
(McElvain and Schenk, 1992; Wu et al., 2001). Vmax, which indicates maximum 
rate of release, can also be calculated from DA voltammetric recordings. DA 
uptake in the ventral striatum was reported to be less efficient than in the dorsal 
striatum (Stamford et al., 1988; Cass et al., 1992), whereas in the amygdala and 
mPFC, DA uptake appeared to be very low (Garris and Wightman, 1994; Jones 
et al., 1995). It was suggested that in regions with low dopamine transporter 
(DAT) expression and activity, the norepinephrine transporter (NET) may take 
over DAT’s role to facilitate DA uptake (Yamamoto and Novotney, 1998; Moron 
et al., 2002). Enzymatic inactivation of DA by COMT is also involved in these 
brain regions (Wayment et al., 2001; Matsumoto et al., 2003). Moreover, FSCV 
can be achieved in a freely moving awake animal that allows studies correlating 
the time-course of behavior and DA signals (Robinson et al., 2003).  
Another common method to monitor extracellular DA levels in vivo is 
microdialysis, in which a semi-permeable membrane containing probe is 
surgically implanted into the brain region of interest and perfused with fluid 
(Bourne, 2003). Dialysate is collected over time and analyzed using high-
performance liquid-chromatography (HPLC) to quantify DA concentration 
changes as a function of time. This method has slow temporal resolution 
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(minutes to hours) and a larger dialysis probe leads to more tissue damage. 
However, it can also be achieved in a freely moving awake animal that allows 
studies correlating the time-course of behavior and events in neurochemistry.  
Neither of the invasive methods mentioned above can be used in human brain. 
However, the development of positron emission tomography (PET) imaging and 
a series of radiotracers that labels dopamine receptors, DAT or precursors of DA 
enables direct measurement of components of the DA system in the living human 
brain (Volkow et al., 1996). 
Taken together, the strength of presynaptic DA neurotransmission is controlled 
by molecular mechanisms regulating DA synthesis, release as well as reuptake. 
Presynaptic DA reuptake is the primary mechanism to temporally and spatially 
restrain DA neurotransmission. Techniques such as FSCV and microdialysis help 
us to elucidate mechanisms controlling DA release and reuptake in vivo. 
I.C Dopamine Transporter: Pharmacology, Structure and Function 
The discovery of a neurotransmitter reuptake mechanism by Axelrod started an 
area of research investigating the pharmacological properties of the reuptake 
sites in the brain. However, genes that encode proteins that are required for high-
affinity neurotransmitter reuptake were not identified until the early 1990s, with 
the help of molecular biology. Using expression cloning techniques, Amara and 
colleagues first isolated a single cDNA clone that encoded the human 
norepinephrine transporter (NET) (Pacholczyk et al., 1991). The amino acid 
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sequence of NET shared significant amino-acid identity with the previously 
published rat γ-aminobutyric acid transporter (GAT) (Guastella et al., 1990). 
These observations led to the identification of a new gene family for 
neurotransmitter transporters, the SLC6 (solute carrier 6) gene family. Using 
conserved sequences in NET and GAT, genes that encode DAT and the 
serotonin transporter (SERT) were soon discovered through homology screening 
in mammalian cDNA libraries, starting the era of structure, function and genetic 
studies of the neurotransmitter transporters (Blakely et al., 1991; Kilty et al., 1991; 
Shimada et al., 1991; Usdin et al., 1991). The human DAT gene (SLC6A3) maps 
to chromosome 5p15.3. It spans over 64 kilo base pairs, consisting of 15 exons 
separated by 14 introns (Kawarai et al., 1997). Hydrophobicity analysis revealed 
that DAT protein, as well as other neurotransmitter transporters in the same gene 
family, contained twelve putative transmembrane domains (TMDs), one large 
glycosylated loop between TMD3 and TMD4, and cytoplasmic amino and 
carboxyl termini. In this section, I will discuss the pharmacological properties of 
DAT, especially how psychostimulants cocaine and amphetamine interact with 
DAT and alter transporter function. Then I will focus on the structure/function 
analysis of DAT with an emphasis on DA transport mechanism.  
PHARMACOLOGY 
DAT is a well-established molecular target for many pharmacological agents that 
affect brain function including psychostimulants, antidepressants and neurotoxins 
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(Amara and Sonders, 1998). The pharmacology of DAT is mainly examined in 
brain synaptosome preparations or heterologous expression systems expressing 
DAT cDNAs. Generally, the results from the two systems agree with each other. 
Ritz and colleagues first related the effect of cocaine with DAT inhibition (Ritz et 
al., 1987). Cocaine is a non-selective, competitive inhibitor for all three 
monoamine transporters including DAT, SERT and NET. Tricyclic antidepressant, 
methylphenidate (Ritalin), nomifensine and bupropion are selective inhibitors for 
DAT and NET while GBR12909 and WIN35,426 have been developed as 
selective DAT inhibitors (Kristensen et al., 2011). Some of these compounds are 
currently used in the treatment of neuropsychiatric disorders such as depression 
and attention deficit hyperactivity disorder (ADHD). 
Amphetamines, on the other hand, are substrates for DAT. These drugs are 
weak bases that can reverse the direction of neurotransmitter transport through 
monoamine transporters and release vesicular monoamines into the cytoplasm 
(Sulzer et al., 1995; Jones et al., 1998a). Amphetamines’ effect on blocking 
uptake of catecholamine into different brain regions was known long before the 
identification of the transporter proteins (Ferris et al., 1972). At that time, it was 
experimentally difficult to discriminate between release and uptake inhibition by 
simply measuring [3H]-DA uptake since a drug that causes release and blocks 
uptake could release part of the previously taken up [3H]-DA, making it appears 
as though there is uptake inhibition. Superfusion technique was first developed to 
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address this problem. It is based on the presumption that if the rate of perfusion 
is rapid enough, DAT uptake could be ignored and any change from the baseline 
is considered as additional release (Raiteri et al., 1974). Using this technique, it 
was demonstrated that amphetamine caused DA release and this release could 
be blocked by uptake inhibitors like cocaine (Parker and Cubeddu, 1986).  In vivo 
microdialysis experiments confirmed these results and further showed that 
amphetamine-induced release is independent of neuron firing (Nomikos et al., 
1990).  
After the cloning of DAT, [3H]-1-methyl-4-phenylpridinium ion (MPP+), which 
could be taken up by DAT, was discovered and used to measure amphetamine-
induced release or efflux. Neurotoxin MPP+ is a major metabolite of neurotoxin 1-
methyl-4-phenyl-1,2,3,6-tetrahydropridine (MPTP) that can cause permanent 
symptoms of  PD in human and mammals. Amphetamine and its derivatives 
inhibited uptake of substrate [3H]-MPP+ and stimulated transporter-mediated 
efflux of the preloaded [3H]-MPP+ in cell lines that stably express DAT (Wall et al., 
1995). The effect of cocaine and amphetamines on DAT is illustrated in Figure I-
2.  
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Figure I-2. DAT is a direct molecular target for psychostimulants cocaine 
and amphetamines. A. Normally, released DA is removed from synapses 
through DAT-mediated high affinity reuptake. B. Cocaine is a competitive 
inhibitor for DAT. It directly binds to DAT and inhibits DAT reuptake function 
that results in elevated synaptic DA levels and prolonged effect on target 
neurons. C. Amphetamines are DAT substrates that are transported into the 
presynapse by DAT and cause DAT-mediated DA efflux. The dual effects of 
uptake inhibition and DA efflux result in enhanced synaptic DA levels and 
prolonged stimulation on pre- and post-synaptic receptors. 
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STRUCTURE/FUNCTION OF NEURONAL DAT 
The first insight into a DA transport mechanism came from the observation that 
extracellular sodium was required for substrate translocation (Wheeler et al., 
1993). It is well-established that DAT requires sequential binding of two sodium 
ions and cotransport of one chloride ion to translocate DA across the plasma 
membrane. The driving force for DAT-mediated reuptake is the sodium 
concentration gradient across the plasma membrane generated by Na+/K+ 
ATPase. Extensive biochemical and mutagenesis studies in heterologous 
expression systems have been performed aiming to elucidate the secondary 
structure of DAT. The substituted cysteine accessibility method (SCAM) was 
used to determine residue accessibility and define the role of individual residues 
for binding of substrates or inhibitors. The Cysteine 342 at the third intracellular 
loop of DAT were more reactive to the thiol-modifying agents during uptake, 
suggesting this residue may be located on part of DAT associated with 
cytoplasmic gating (Chen et al., 2000). Using site-directed mutagenesis, Loland 
et al. showed that mutation of intracellular tyrosine to alanine (Y335A) completely 
abolished DA uptake, further supporting the third intracellular loop’s role in the 
substrate translocation (Loland et al., 2002). In search for the DA binding site, 
studies were conducted by mutating aromatic and acidic amino acids in 
transmembrane domains (TMDs). Replacement of aspartate and serine residues 
in TMD1 and TMD7, respectively drastically reduced DA uptake (Kitayama et al., 
1992) and mutating phenylalanine155 in TMD3 to alanine also abolished DA 
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affinity, suggesting these residues are required for substrate recognition (Lin et 
al., 1999).  
A major breakthrough to determine the tertiary structure of DAT came from the 
high resolution crystal structure of bacterial Leucine transporter (LeuT) with 
sequence homology and functional similarities to the SLC6 transporters 
(Yamashita et al., 2005). It was reported from the LeuT crystal structure that 
TMD1, TMD3, TMD6 and TMD8 formed the central substrate binding pocket to 
accommodate the substrate (Leucine) and two sodium ions. Three states of 
transport mechanisms were proposed: outward-facing, occluded and inward-
facing. Substrate and sodium binding happened in an occluded state devoid of 
water. 
However, the LeuT model has limitations in terms of answering questions like 
some parts of the structures of SLC6 transporters that share minimum similarity 
to LeuT, as well as substrate selectivity and transport inhibition by addictive 
compounds. In 2013, a 3.0 Å x-ray crystal structure of the Drosophila 
melanogaster dopamine transporter (dDAT) in complex with TCA nortriptyline 
was reported (Penmatsa et al., 2013). It captured dDAT in an inhibitor-bound, 
outward facing conformation and showed TCA nortriptyline targeted the substrate 
binding site and stabilized the open conformation. Two sodium and one chloride 
ions were located adjacent to the nortriptyline binding pocket, indicating direct 
coupling of ions and inhibitor binding. Intriguingly, this crystal structure also 
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revealed a cholesterol binding site and a C-terminal latch that interacted with the 
cytoplasmic face of the transporter, presumably for modulation of transport 
function. More recently, the same group published another dDAT crystal 
structure in complex with its substrate DA, as well as psychostimulants cocaine 
and amphetamine (Wang et al., 2015).  The DAT central binding pocket was 
further divided into three subsites and the subsites were responsible for defining 
ligand specificity. Substrates including DA, DA analogue 3,4-
dichlorophenethylamine (DCP) and amphetamine were bound to DAT prior to full 
closure of the extracellular gate, rather than the occluded state shown in LeuT. In 
contrast, inhibitors like cocaine were bound to the outward-facing DAT, acting 
like a wedge to block DAT in an outward-open conformation. Altogether, the 
structural information of DAT provides a molecular basis for designing more 
selective monoamine transporter inhibitors. 
Other than the classic transport mechanism, DAT also exhibits channel-like 
activity. In human DAT-expressing Xenopus laevis oocytes, two-electrode 
voltage-clamp recording revealed a constitutive leak current that was different 
from transport-associated current in terms of ion and voltage dependence 
(Sonders et al., 1997). The physiological consequences of both transport-
associated current and constitutive leak current was shown to modulate DA 
neuron excitability, as DAT substrates DA and amphetamine increased the firing 
rate of cultured rat DA neurons (Ingram et al., 2002; Carvelli et al., 2004).  
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In summary, DAT belongs to the SLC6 gene family of sodium and chloride-
dependent symporters. It is a direct molecular target for psychostimulants 
cocaine and amphetamines. Cocaine acts as a competitive inhibitor that binds 
DAT at its outward facing state, whereas amphetamines are DAT substrates that 
could be transported through DAT and subsequently lead to DA efflux. ADHD 
therapeutic agents Ritalin (methylphenidate) and Adderall 
(amphetamine/dextroamphetamine) also directly act on DAT, making DAT an 
important molecular target for treating certain types of neuropsychiatric disorders. 
I.D Dopamine Transporter: Role In Neuropsychiatry Disorders 
The physiologic role of DAT in an intact animal was first studied in DAT knock-
out (KO) mice generated by in vivo homologous recombination technique (Giros 
et al., 1996). These mice exhibited spontaneous hyperlocomotion. Biochemical 
changes in striatal DA neurotransmission assessed by FSCV showed drastically 
increased extracellular DA clearance time in KO animals, which could explain the 
marked increase in the spontaneous locomotor activity. Intriguingly, KO mice 
also displayed significant reduction in evoked DA release, suggesting that the 
tissue content of DA or the releasable pool of DA were decreased. Direct 
measurement of DA content by HPLC revealed that DA levels were reduced by 
95% in the dorsal striatum of KO mice compared with wild-type (wt) mice(Jones 
et al., 1998b). These results demonstrated that DAT is a key regulator of 
maintaining presynaptic DA homeostasis and when inactivated, profound 
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neuronal plasticity occurs. In this section, I will discuss DAT’s role in drug 
addiction as well as recent human genetic studies that link DAT to multiple 
neuropsychiatric disorders. 
DOPAMINE TRANSPORTER IN DRUG ADDICTION 
As discussed previously, psychostimulants cocaine and amphetamine inhibit 
DAT function through different mechanisms. The net effect is a marked increase 
of synaptic DA levels that leads to prolonged stimulation of dopaminoceptive 
neurons. This event is considered as the basis for the rewarding effect of cocaine 
and amphetamine.  
Early attempts to understand DAT’s role in drug addiction came mainly from 
studies in DAT-KO mice. In homozygous mice, psychostimulants cocaine and 
amphetamine failed to further increase locomotor activity, suggesting DAT plays 
a vital role of locomotor effects of psychostimulants (Giros et al., 1996). 
Paradoxically, the rewarding property of cocaine remained. DAT KO mice still 
self-administrated cocaine (Rocha et al., 1998) and cocaine conditioned a place 
preference in these animals (Sora et al., 1998). Even though analysis of released 
DA by microdialysis in DAT KO mice clearly showed cocaine and amphetamine 
failed to increase DA levels in dorsal striatum, they still elevated DA levels in NAc 
(Carboni et al., 2001), probably through indirect regulation on the DA neurons in 
VTA (Budygin et al., 2002). Mapping of the sites of cocaine binding and neuronal 
activation suggested serotonergic brain regions might be involved in this 
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response (Rocha et al., 1998). Further studies reported that DAT and SERT 
double KO mice eliminated cocaine-induced CPP, indicating both dopaminergic 
and serotonergic mechanisms are required for the rewarding effect of cocaine 
(Sora et al., 2001).  
Using DAT-KO mice as a model to study DAT’s role in addiction raised some 
concerns. Most of all, complete deletion of DAT caused tremendous adaptive 
changes in DA neurotransmission in terms of DA synthesis, storage and receptor 
expression and function (Jones et al., 1999). These adaptive changes may 
significantly alter the normal reward pathway. Thus, Chen at al. proposed 
another way to test the DA hypothesis of cocaine reward by generating a knock-
in (KI) mouse line expressing a mutant DAT (L104V/F105C/A109V) that could 
still transport DA but had substantially reduced affinity for cocaine (Chen et al., 
2006). Therefore, doses of cocaine that normally inhibit wild-type DAT would not 
have an effect on this mutant DAT. The cocaine-insensitive DAT KI mice 
completely abolished cocaine-induced CPP while maintaining amphetamine’s 
effect. Cocaine also failed to stimulate locomotor activity in these mice. 
Biochemically, in the NAc, there was no significant increase in extracellular DA 
levels following cocaine but not amphetamine treatment in the KI mice, 
consistent with the behavior results. These data demonstrated that blockade of 
DAT is required for cocaine reward in mice with a functional DAT, and further 
confirmed the idea that cocaine-induced increase in extracellular DA in the NAc 
is critical in mediating cocaine reward. 
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Amphetamine’s action on DA neurotransmission is more complicated than 
cocaine. Amphetamine acts both on vesicular storage of DA and directly on DAT. 
Using the DAT KO mice, Jones et al determined that the vesicle-depleting action 
was the rate limiting factor in amphetamine’s biochemical effect (Jones et al., 
1998a). Since vesicular monoamine transporter (VMAT) functions to concentrate 
cytoplasmic DA into synaptic vesicles (Eiden et al., 2004), studies have focused 
on VMAT’s role in amphetamine’s locomotor and rewarding properties. 
Heterozygous VMAT2 KO mice, which expressed ~50% of VMAT2 compared to 
wt littermates, displayed enhanced amphetamine-induced locomotion but 
diminished reward behavior as measured by CPP (Takahashi et al., 1997). More 
recently, a selective VMAT2 inhibitor, (+)-CYY477, blocked both locomotor and 
self-administration behaviors stimulated by amphetamines without affecting those 
induced by cocaine (Freyberg et al., 2016). These results indicate that VMAT2, 
but not DAT, plays a critical role in the acute actions of amphetamines but not 
those of cocaine. 
DOPAMINE TRANSPORTER IN NEUROPSYCHIATRIC DISORDERS 
The fact that DAT is an important target site for some therapeutic agents makes 
it a candidate gene for neuropsychiatric disorders. In vivo brain imaging 
techniques, such as PET, using selective DAT ligands, have been wildly used to 
measure monoamine transporter levels in neuropsychiatric disorders (Laakso 
and Hietala, 2000). These studies reported reduced DAT densities in patients 
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with ADHD, PD and major depression (Kim et al., 1997; Dougherty et al., 1999; 
Laasonen-Balk et al., 1999). Based on this evidence, studies have been focused 
on the identification of polymorphic variants in the coding and non-coding regions 
of DAT. The first discovery that linked a DAT polymorphism to ADHD was the 
association between ADHD and the 10-repeat allele variable number tandem 
repeat (VNTR) in the 3ʹ-untranslated region (3ʹ-UTR) of human DAT (Cook et al., 
1995; Curran et al., 2001). Studies examining the functional variants in hDAT 
coding sequence might help clarify relationships between DAT activity and the 
risk for neuropsychiatric disorders. Using temperature gradient capillary 
electrophoresis, Mazei-Robison and colleagues screened 112 subjects that were 
diagnosed with ADHD and identified one nonsynonymous single nucleotide 
polymorphism (SNP) A559V in two male siblings (Mazei-Robison et al., 2005). 
Biochemical and function analysis in heterologous expression system showed 
that this A559V DAT coding variant had normal DA uptake and surface 
expression but exhibited anomalous DA efflux (Mazei-Robison et al., 2008). 
Remarkably, the two most common ADHD medications, amphetamine and 
methylphenidate, both blocked A559V DAT-mediated DA efflux, whereas these 
drugs had opposite actions at wt-DAT. To pursue the significance of this finding 
in vivo, the same group generated an A559V DAT KI mouse line and observed 
elevated extracellular DA levels, lack of amphetamine-stimulated DA efflux and 
disruptions in basal and psychostimulant-evoked locomotor behavior in these 
animals compared with wild-type littermates (Mergy et al., 2014). Additional DAT 
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coding variants have been identified that are associated with ADHD, autism 
spectrum disorder (ASD) and adult Parkinsonism (Sakrikar et al., 2012; Hamilton 
et al., 2013; Hansen et al., 2014).  
Other than polymorphism studies, human molecular genetic studies have 
recently discovered an autosomal recessive disorder that is directly caused by 
missense DAT mutations. To understand molecular basis of infantile 
parkinsonism-dystonia (IPD), Kurian and colleagues identified two DAT 
homozygous missense mutations (L368Q and P395L) in two relating families 
using autozygosity mapping techniques (Kurian et al., 2009). As a severe 
neurological syndrome that usually involves complex movement disorder with 
dystonia, axial hypotonia and limb hypertonicity, IPD is rare but is often 
misdiagnosed since the clinical symptoms can mimic certain types of cerebral 
palsy (Assmann et al., 2004). Functional analysis of mutant DAT proteins 
showed that both mutants were devoid of uptake activity and failed to express at 
the plasma membrane. This disorder was named dopamine transporter 
deficiency syndrome and the same group later identified eleven more children 
with this disorder (Kurian et al., 2011). These findings further demonstrate the 
importance of DAT in DA homeostasis in humans. 
Together, the findings described above demonstrate that inhibition of DAT 
function in NAc is a prerequisite for the rewarding property of cocaine but not 
amphetamine. Loss-of-function DAT mutations cause dopamine transporter 
27 
 
deficiency syndrome in humans and multiple DAT coding variants are associated 
with neuropsychiatric disorders such as ADHD, ASD and adult parkinsonism. 
I.E Dopamine Transporter: Regulation 
Shortly after the cloning of the gene encoding DAT, much effort has been 
directed towards understanding the molecular and cellular mechanisms for 
regulating DAT activity and membrane availability at the presynaptic membrane. 
These studies have resulted in identification of kinases, receptors, lipids and 
scaffolding proteins that modulate DAT biosynthesis, targeting to the plasma 
membrane and endocytic trafficking. Key domains and residues have also been 
found in the DAT amino acid sequence that allows regulation of transporter 
function through direct protein-protein interactions. In this section, I will discuss 
DAT regulatory mechanisms at three different stages: synthesis and targeting to 
the plasma membrane, endocytosis, as well as post-endocytic sorting. Finally, I 
will review known DAT interacting proteins and how they regulate DAT activity. 
SYNTHESIS AND TARGETING DAT TO THE PLASMA MEMBRANE 
Biosynthesis and assembly of DAT, as well as other plasma membrane proteins, 
occurs at the endoplasmic reticulum (ER) and Golgi apparatus inside the cell. 
Compelling evidence suggests that DAT exists as oligomeric complexes inside 
the cell and oligomerization is required for successful export of transporters from 
the ER. The apparent molecular weight of DAT increased from approximately 
85kDa to approximately 195kDa determined with nonreducing SDS-PAGE after 
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cross-linking with either copper phenanthroline or bis-(2-
methanethiosulfonatoethyl) amine hydrochloride, indicating the transporters 
formed a homodimer (Hastrup et al., 2001). Cysteine 306 (Cys306) at the 
extracellular end of TMD6 was then identified to function at the dimerization 
interface. This result was confirmed later using co-immunoprecipitation (Co-IP) of 
DAT with different tags as well as Fluorescent Resonance Energy Transfer 
(FRET) on live cells (Sorkina et al., 2003; Torres et al., 2003b). FRET data 
suggested that DAT oligomerized both at the plasma membrane and ER and that 
co-expression of an ER-retained DAT blocked ER exit of wt-DAT, suggesting a 
role for oligomerization in efficient ER export (Sorkina et al., 2003). DAT 
sequence that is responsible for efficient ER export was examined using 
systematic deletions and alanine substitutions in the DAT C-terminus and 
subsequently looking at cellular localization with live cell fluorescent microscopy 
and cell surface biotinylation (Miranda et al., 2004). The C-terminal glycine 585, 
lysine 590 and glutamine 600 were identified and, when mutated into alanine, 
these three DAT mutants failed to traffic to the dendrites or axon processes in 
cultured primary rat midbrain neurons. 
Anterograde transport of cargos from ER to Golgi is mediated by specific coat 
protein complexes (COP). Sec24 is one of the components and is involved in 
cargo recognition and recruitment at the ER (Lord et al., 2013). It was shown that 
DAT and NET, but not SERT, used Sec24D for ER export (Sucic et al., 2011). 
Knocking down Sec24D, but not Sec24C in Hela cells decreased DA uptake. 
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Moreover, the DAT C-terminal lysine leucine (KL) sequence was proposed to 
interact with the COPII machinery. 
At the Golgi, transporters undergo post-translational modifications. N-linked 
glycosylation sites in the second extracellular loop were found in all monoamine 
transporters. Different glycosylation patterns of DAT were identified in different 
species, different brain regions and during development (Lew et al., 1991; Patel 
et al., 1993; Patel et al., 1994). Functional importance of N-linked glycosylation 
was examined using transporter mutants that abolished these sites. These 
mutants displayed reduced expression at the plasma membrane but retained 
ligand binding and substrate transport properties, suggesting N-linked 
glycosylation is essential for transporter membrane targeting (Tate and Blakely, 
1994; Melikian et al., 1996; Li et al., 2004)  
Following the synthesis and export from ER and the Golgi apparatus, DAT is 
targeted to the plasma membrane. Electron microscopy studies using 
immunogold labeling showed that DAT was localized at the plasma membrane of 
both perisynaptic region of presynaptic membrane as well as somatodendritic 
compartments (Hersch et al., 1997; Nirenberg et al., 1997b). Yet, the molecular 
mechanisms that are responsible for targeting DAT to these different subcellular 
locations are not clear.  
Using DAT C-terminus as bait in a yeast two-hybrid screening, PICK1, a PDZ 
domain protein interacting with C-kinase 1, was identified as a DAT interacting 
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protein (Torres et al., 2001). The PDZ binding site in DAT was mapped to the last 
three residues at the C-terminus (LKV). Coexpression of DAT and PICK1 in 
HEK293 cells promoted DAT surface levels. Deletion of the PDZ-binding site of 
DAT abolished the PICK1 association and failed to target DAT to the axons. 
These results suggested that the PDZ-mediated DAT-PICK1 interaction might be 
involved in the presynaptic targeting of DAT. However, subsequent investigation 
of DAT C-terminus function revealed that disruption of the PDZ-binding domain 
either through addition of an alanine to the hDAT C terminus (+Ala), or alanine 
substitutions of LKV (AAA_618-620) affected neither plasma membrane targeting 
nor targeting into sprouting neurites of differentiated N2A cells (Bjerggaard et al., 
2004). Instead, alanine substitutions of RHW (615-617) caused transporter ER 
retention while preserving its ability to bind PICK1. Thus, although residues in the 
hDAT C-terminus are indispensable for proper targeting, PDZ domain 
interactions are not required. In order to understand the functional significance of 
the PDZ-binding domain in DAT in vivo, Rickhag et al. generated two different 
DAT KI mice with disrupted PDZ-binding motif (DAT-AAA and DAT+Ala) 
(Rickhag et al., 2013). Surprisingly, both mice lines exhibited drastic loss of DAT 
expression in striatum that led to hyperlocomotion and attenuated response to 
amphetamine. These phenotypes were not dependent on PICK1 since PICK KO 
mice displayed normal DAT immunoreactivity both in the DA neuron cell body 
and terminals. These findings suggest that PDZ-domain interactions are critical 
for synaptic distribution of dopamine transporter in vivo, but DAT-PICK1 
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interaction may not be required. How the DAT PDZ-domain modulates its plasma 
membrane targeting is still not clear. I will address this question in Chapter III. 
Taken together, these studies demonstrate that DAT oligomerization is required 
for transporter ER export and the DAT C-terminal sequence contain residues 
important for ER export and subsequent plasma membrane targeting. 
DAT ENDOCYTOSIS 
Plasma membrane DAT undergoes constitutive and regulated endocytic 
trafficking between plasma membrane and endosomal compartments. 
Elucidation of DAT primary sequence revealed potential phosphorylation sites for 
protein kinases such as protein kinase A and C (PKA and PKC) and calmodulin-
dependent kinase II (CaMKII), indicating that phosphorylation may regulate DAT 
function (Gorentla et al., 2009). In COS cells transiently expressing DAT, 
Kitayama et al. first observed that activation of PKC using phorbol 12-myristate 
13-acetate (PMA) decreased ligand binding and uptake velocity (Kitayama et al., 
1994). This downregulation of DAT activity was also reported in other 
heterologous cell lines as well as synaptosome preparations (Copeland et al., 
1996; Vaughan et al., 1997; Zhu et al., 1997). Kinetic studies of [3H]-DA uptake 
showed that the PMA-induced reduction of DAT activity was due to a decrease in 
maximum uptake velocity (Vmax) with no change in substrate affinity (Km), 
suggesting PKC regulated DAT activity by decreasing DAT surface levels 
(Copeland et al., 1996). In addition, electron microscopy studies revealed a 
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significant intracellular/endosomal DAT pool in DA neurons, further supporting 
that DAT may undergo regulated endocytosis (Nirenberg et al., 1997b). Direct 
examination of DAT endocytosis using either biochemical tools or 
immunofluorescence demonstrated that PKC activation reduced steady-state 
DAT surface levels (Daniels and Amara, 1999; Melikian and Buckley, 1999). The 
mechanisms facilitating this sequestration were first demonstrated by Loder and 
Melikian. They showed that DAT robustly internalized at basal state and PKC 
activation accelerated DAT endocytosis and that these two processes were 
mediated by distinct mechanisms (Loder and Melikian, 2003).  
Given that PKC activation increased DAT phosphorylation (Huff et al., 1997; 
Vaughan et al., 1997), it was hypothesized that the functional effect of PKC 
activation on DAT was directly coupled to phosphorylation. Using peptide 
mapping and epitope-specific immunoprecipitation, Foster et al. identified a 
group of six serines clustered at the distal end of the cytoplasmic N terminus that 
were responsible for most of the basal and PKC-stimulated DAT phosphorylation 
(Foster et al., 2002). However, truncation of the first 22 amino acids at the N-
terminus containing these serines abolished detectable phosphorylation without 
affecting the PMA-induced reduction in transport capacity and endocytosis. In 
this background truncation construct, systematic mutation of all the 
phosphorylation consensus serines and threonines (Thr) in hDAT, alone and in 
various combinations, also did not alter the PMA effect in either HEK293 or N2A 
cells (Granas et al., 2003). These results indicate that PKC-stimulated DAT 
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endocytosis is not directly mediated by phosphorylation. The underlying 
mechanism and role of phosphorylation is not entirely clear. Thr53 was reported 
to be strongly phosphorylated by PMA in rodent striatal tissue and heterologous 
expression system and mutation of this residue reduced DAT Vmax and abolished 
amphetamine-induced substrate efflux, suggesting Thr53 is required for transport 
mechanism (Foster et al., 2012).  Ser6 was also reported to modulate transporter 
kinetics (Moritz et al., 2015). 
Most of the studies mentioned above used phorbol esters such as PMA to 
activate PKC, which mimics diacylglycerols (DAG). There are two classes of PKC 
that require DAG to be activated, the conventional PKC isoforms that requires 
both DAG and Ca2+, as well as the novel PKC isoforms that do not require Ca2+ 
for activation (Dempsey et al., 2000). What is the isoform specificity for PKC 
regulation of DAT? Different PKC isoform-specific inhibitors were used to identify 
specific PKC isoforms that could block PMA’s effect on DAT-associated transport 
current (Doolen and Zahniser, 2002). Selective inhibitors of conventional PKC, 
novel PKC isoform PKCδ and Ca2+ chelator EGTA significantly reversed PMA’s 
effects while novel PKC isoform, PKCε had no effect. Thus the primary PKC 
isoforms that regulate DAT activity and function are the conventional PKC 
isoforms. Further work exploring PKC isoform specificity revealed a more 
complicated mechanism of these kinases.  Conventional PKC isoform PKCβ KO 
mice had reduced striatal surface DAT, [3H]-DA uptake and amphetamine-
induced DA efflux yet exhibited higher novelty-induced locomotor activity, 
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supporting the role of PKCβ in DAT regulation (Chen et al., 2009). Moreover, 
PKCβ specific inhibitor LY279196 blocked the D2 agonist quinpirole-induced 
increase in DAT surface levels and activity, indicating that PKCβ functioned to 
elevate DAT surface levels, opposite to phorbol ester stimulation (Chen et al., 
2013).  
In addition to basal and PKC-stimulated endocytosis (Loder and Melikian, 2003; 
Sorkina et al., 2005), substrates and inhibitors also dynamically regulate DAT 
surface levels. Substrates such as DA and amphetamine promoted DAT 
endocytosis (Saunders et al., 2000; Chi and Reith, 2003; Johnson et al., 2005; 
Furman et al., 2009b), whereas cocaine exposure was reported to increase DAT 
surface levels (Daws et al., 2002; Little et al., 2002). Since endocytic trafficking 
acutely regulates plasma membrane protein availability, providing means of 
enhancing or diminishing DA neurotransmission, much effort has been directed 
towards understanding the molecular mechanisms of basal and regulated DAT 
endocytic trafficking. Specifically, studies have focused on two fundamental 
questions: 1) what are the endocytic signals that target DAT for basal and 
regulated endocytosis? And 2) what are the endocytic machineries that mediate 
basal and regulated DAT endocytosis?  
By overexpressing a dominant negative dynamin-1 mutant (K44A), Daniels and 
Amara showed that PKC-stimulated DAT endocytosis was abolished and thus 
concluded that PKC-stimulated DAT endocytosis is clathrin-mediated (Daniels 
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and Amara, 1999). However, some forms of clathrin independent endocytosis 
pathways also require dynamin (Sauvonnet et al., 2005; Fattakhova et al., 2006). 
In clathrin-mediated endocytosis (CME), cargo protein is recruited by clathrin 
adaptor proteins into clathrin-coated pits (CCP). The membrane then invaginates 
and pinches off the plasma membrane via GTPase dynamin, giving rise to 
clathrin-coated vesicles (CCV). The clathrin coat eventually disassociates from 
the vesicle and matures into early endosomes (Saheki and De Camilli, 2012). For 
cargo proteins that internalize through the clathrin-dependent pathway, they 
usually contain two classes of endocytic signals, the dileucine and tyrosine-
containing motifs, that allow clathrin adaptor proteins to recognize and recruit to 
CCP (Bonifacino and Traub, 2003). In searching for the DAT endocytic signals, 
Holton et al. tested candidate dileucine-type endocytic motifs in DAT (Holton et 
al., 2005). Surprisingly, after alanine-scanning mutagenesis of all the potential 
dileucine-type endocytic motifs, DAT still underwent basal and PKC-stimulated 
endocytosis tested through cell surface biotinylation, suggesting the DAT 
endocytic signal may not confine to the classically defined motifs. Instead, they 
conducted a gain-of-function screen by fusing the DAT N- and C- termini to the 
endocytic-defective membrane proteins and looked for robust internalization. 
Their results revealed that the DAT C-terminal FREKLAYAIA sequence is a novel 
endocytic signal for both basal and PKC-stimulated DAT endocytosis. To further 
define residues that governed basal and PKC-stimulated DAT endocytosis, the 
same group performed systematic alanine scanning mutagenesis within the 
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FREKLAYAIA motif and showed that alanine substituting DAT residues FREK 
(587-590) abolished PKC-stimulated DAT endocytosis, and markedly accelerated 
basal DAT internalization, comparable to that of wt-DAT during PKC activation 
(Boudanova et al., 2008b). Based on these results, the PKC-sensitive DAT 
endocytic brake model was proposed where PKC activation releases the DAT 
endocytic brake and the brake requires DAT FREK (587-590) residues. 
Consistent with the endocytic braking mechanism, DAT N-terminus was shown to 
negatively regulated DAT endocytosis and when deleted, DAT internalized more 
rapidly (Sorkina et al., 2009). These studies strongly suggested that both the 
intracellular DAT N- and C- termini are required for the DAT endocytic brake. 
Nevertheless, cellular factors that control this endocytic brake is unknown. I will 
address this question in Chapter II. 
The fact that DAT does not contain classic endocytic signals for clathrin-
mediated endocytosis raises questions about whether DAT internalizes through 
clathrin-dependent or independent pathways as well as whether DAT uses 
different endocytic machineries for basal vs. regulated endocytosis. Other than 
the dominant negative dynamin I mutant (K44A) (Daniels and Amara, 1999; 
Eriksen et al., 2009), knocking down endogenous clathrin heavy chain and 
dynamin II in cells lines with small interference RNA (siRNA) abolished basal and 
PKC-stimulated DAT endocytosis (Sorkina et al., 2005). Nonetheless, clathrin 
depletion over days could potentially affect other membrane trafficking processes 
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that also require clathrin. Thus, control experiments are necessary to test 
whether clathrin-independent endocytic mechanisms are intact.  
On the other hand, studies that examined DAT plasma membrane distribution 
and microdomain association revealed that DAT at least partially resided within 
the membrane lipid raft microdomains in neuronal derived cell line and 
synaptosomes (Adkins et al., 2007; Foster et al., 2008; Navaroli et al., 2011). 
Given that clathrin-independent endocytosis usually occurs at the lipid raft 
microdomains (Doherty and McMahon, 2009), Cremona et al. sought to 
understand the functional importance of DAT microdomain association and 
identified a lipid raft associated protein, flotillin-1 (Flot-1) as a mediator for PKC-
stimulated DAT endocytosis (Cremona et al., 2011). Either knocking down Flot-1 
with siRNAs or alanine substitution of a Flot1 palmitoylation site (C34A) 
abolished PKC-stimulated DAT endocytosis. Nonetheless, this result was 
challenged by a follow-up study done by Sorkina et al. They also used siRNAs to 
knockdown endogenous Flot1 and saw no inhibition of PKC-stimulated DAT 
endocytosis measured by a fluorescent antibody feeding assay (Sorkina et al., 
2013).  
The controversial results from the early studies may arise from the fact that 
dominant-negative protein overexpression and siRNA knockdown experiments 
require multiple days of treatments that could potentially affect normal cell 
function and protein trafficking in general. Development of specific inhibitors to 
38 
 
acutely block clathrin-mediated endocytosis provided a better way to answer 
these questions (Hill et al., 2009; Dutta et al., 2012). In fact, using ex vivo mouse 
striatal slice biotinylation, Gabriel et al. showed that acute dynamin inhibition with 
specific inhibitor, dynole, blocked PKC-stimulated DAT endocytosis but basal 
DAT endocytosis was unaffected (Gabriel et al., 2013). Although this study 
demonstrated a differential dependence upon dynamin for basal vs. PKC-
stimulated DAT endocytosis, it still did not address whether clathrin was required, 
since there are dynamin-dependent mechanisms that are independent of clathrin 
(Sauvonnet et al., 2005; Fattakhova et al., 2006). I will address this question in 
studies in Chapter II.  
Additional kinase pathways have been reported to modulate DAT endocytosis. 
Acute inhibition of phosphatidylinositol (PI) 3-kinase (PI3K), a component of the 
insulin pathway, triggered DAT endocytosis in synaptosomes and HEK cells 
(Carvelli et al., 2002). Further investigation of the downstream signaling of the 
insulin pathway revealed that Akt/PKB, a protein kinase effector immediately 
downstream of PI3K, also negatively regulated DAT endocytosis (Garcia et al., 
2005). Moreover, expression of a constitutively active Akt mutant reduced the 
ability of AMPH to decrease hDAT cell-surface expression, suggesting that Akt 
not only regulated basal DAT endocytosis but also modulate amphetamine-
stimulated DAT endocytosis. These results were confirmed in vivo using 
hypoinsulinemia rats that were depleted of insulin through the diabetogenic agent 
streptozotocin (STZ) (Williams et al., 2007). STZ treated rats exhibited reduced 
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striatal Akt function, decreased DAT surface levels and impaired amphetamine-
induced DA efflux and self-administration, suggesting that the insulin signaling 
pathway dynamically regulates DAT function and DA neurotransmission. There is 
also evidence that mitogen-activated protein kinase (MAPK) and tyrosine kinases 
negatively regulated DAT function and surface levels, reported in both 
heterologous expression systems and synaptosomes (Doolen and Zahniser, 
2001; Moron et al., 2003; Hoover et al., 2007).  
DAT POST-ENDOCYTIC SORTING 
After endocytosis, cargo proteins can be sorted for degradation or export to other 
cellular membrane compartments like the trans-Golgi network (TGN) (retrograde) 
or the plasma membrane (recycling). Different endocytic trafficking pathways are 
illustrated in Figure I-3. Many studies have investigated DAT’s post-endocytic 
itinerary, each with its own strengths and weaknesses. Studies have aimed to 
answer two fundamental questions: 1) how does DAT interact with the sorting 
machineries? And 2) what are the DAT post-endocytic itineraries under basal 
and regulated conditions? 
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Figure I-3. Overview of endocytic trafficking pathways. Internalized cargo 
proteins are either sorted for degradation through the late 
endosome/lysosome pathway or exported to other organelles for reuse. 
Recycling pathways reinsert cargo protein back to the plasma membrane 
while retrograde pathways transport cargos to the trans-Golgi network.  
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Melikian et al. first showed that after subcellular fractionation, the internalized 
DAT was enriched in transferrin receptor (TfR)-positive endosomal recycling 
compartments in PC12 cells (Melikian and Buckley, 1999). Using a biotinylation 
assay, Loder and Melikian reported that DAT constitutively recycles and PKC 
activation decreased DAT recycling rate, suggesting that DAT recycles back to 
the plasma membrane under basal and PKC-stimulated conditions (Loder and 
Melikian, 2003). Consistent with this result, Lee et al. reported that DAT 
interacted with the DA D2 receptor and this interaction promoted DAT reinsertion 
into the plasma membrane (Lee et al., 2007). This process was modulated by 
PKCβ activity (Chen et al., 2013). More recently, Richardson et al. showed that 
membrane potential changes alone rapidly drive DAT internalization from and 
reinsertion to the plasma membrane (Richardson et al., 2016). These function 
studies strongly suggest that DAT recycles back to the plasma membrane after 
endocytosis. 
Conversely, Miranda et al. showed that DAT was constitutively ubiquitinated and 
PKC activation drastically increased DAT ubiquitination that led to rapid 
transporter degradation (Miranda et al., 2005). Ubiquitination is a form of post-
translational modification that is associated with the cell’s major degradation 
pathways including lysosomes, proteasomes and autophago-lysosomes (Clague 
et al., 2012). Later, the same group identified an E3 ubiquitin ligase, Nedd4-2 
(neural precursor cell expressed, developmentally downregulated 4-2), in a RNA 
interference screen, that was required for PKC-mediated DAT ubiquitination and 
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endocytosis (Sorkina et al., 2006). These results indicate that DAT is sorted for 
degradation through ubiquitin-dependent pathways. 
Another set of studies aimed to understand DAT post-endocytic sorting via 
dynamic imaging experiments to track labeled DAT. Using a green fluorescent 
protein-tagged DAT (GFP-DAT), Daniels et al. reported that in an epithelia cell 
line, the internalized transporters were targeted to the lysosomal pathway and 
were completely degraded within 2 hrs of PKC activation (Daniels and Amara, 
1999).  
More recently, Eriksen et al. developed a fluorescent cocaine analog, JHC1-64, 
that enabled selective labeling of plasma membrane DAT. Using this compound, 
they reported that constitutively internalized DAT was primarily colocalized with 
late endosome marker rab7, less with short-loop recycling endosome marker 
rab4 and little with long-loop recycling endosome marker rab11 in AN27 cells as 
well as in primary cultured midbrain neurons (Eriksen et al., 2010b). Nonetheless, 
given the fact that cocaine itself increases DAT surface levels (Daws et al., 2002; 
Little et al., 2002), inhibitor analog could potentially mistarget DAT post-
endocytosis. A complimentary approach was used where one transmembrane 
protein, Tac, was fused to the DAT N-terminus (Tac-DAT), followed by an 
antibody-feeding assay to track the Tac-DAT post-endocytic route (Eriksen et al., 
2010b). Functional characterization revealed that the Tac-DAT fusion protein had 
drastically reduced uptake activity and increased apparent affinity for cocaine, 
43 
 
questioning the viability of this approach. Nonetheless, the same colocalization 
pattern was observed with Tac-DAT compared with the JHC1-64 compound. 
Based on these results, they concluded that constitutively internalized DAT was 
sorted to late endosomes/lysosomes and in part to a Rab4-mediated short loop 
recycling pathway.  
Studying DAT post-endocytic itinerary in heterologous expression systems may 
not reflect what really happens in native DA neurons. To address this question, 
Rao et al. generated a KI mouse line  expressing a hemagglutinin (HA)-tagged 
DAT (HA-EL2-DAT) (Rao et al., 2012). The HA epitope was inserted into the 
second extracellular loop (EL2) of DAT to allow selective labeling of plasma 
membrane DAT and subsequently tracking the transporter regional and 
subcellular distribution using an antibody feeding assay (Sorkina et al., 2006). 
Immunofluorescence and electron microscopy data revealed that in midbrain 
somatodendritic regions, a small fraction of HA-EL2-DAT was present in early 
and recycling endosomes and little in late endosomes and lysosomes (Block et 
al., 2015). In the dorsal striatum, little intracellular DAT was observed. However, 
it is unknown whether internalized DAT bound to a bulky antibody would 
accurately reflect native DAT endocytic targeting, particularly in light of recent 
studies demonstrating that proteins which undergo endocytic recycling target to 
degradation if they internalize bound to antibody (St Pierre et al., 2011). 
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Given the caveats in all of these studies, and limitations of the approaches they 
used, there is still an open question as to how DAT traffics in the absence of 
bound inhibitor analog or bulky antibodies. These questions will be addressed in 
the studies described in Chapter III. 
REGULATION OF DAT THROUGH PROTEIN-PROTEIN INTERACTIONS 
The discovery of regulated DAT trafficking indicated the involvement of transport-
interacting proteins. In addition, DAT expression at the presynaptic sites of DA 
neurons presumably involves interactions with other intracellular proteins in DA 
neurons. 
To test potential direct protein–protein interactions between α-synuclein and  
DAT, Lee et al. incorporated different domains of hDAT into the DNA binding 
domain of a yeast two hybrid system and examined their abilities to interact with 
the DNA-activating domains expressing full-length α-synuclein (Lee et al., 2001). 
Their results showed that DAT C-terminus directly bound to α-synuclein. The 
functional consequences of this interaction are unclear. In mouse fibroblast LtK(-) 
(leukocyte tyrosine kinase) cells, α-synuclein was reported to negatively 
modulate DAT activity (Wersinger and Sidhu, 2003), whereas a study in human 
neuronal cells revealed a 50% reduction of DAT activity upon siRNA knockdown 
of α-synuclein, suggesting endogenous α-synuclein promotes DAT activity 
(Fountaine and Wade-Martins, 2007). Nonetheless, α-synuclein KO mice did not 
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show any changes in DAT function (Dauer et al., 2002), questioning the 
importance of DAT-α-synuclein interaction in vivo. 
Since then, yeast two hybrid screenings were widely used in search of DAT 
interacting proteins. Using hDAT C-terminus as a bait against human brain cDNA 
library, CaMKII was identified and shown to direct interacted with the DAT C-
terminus last 11 amino acids and colocalize with DAT in cultured DA neurons 
(Fog et al., 2006). The DAT/CaMKII interaction promoted amphetamine-induced 
DA efflux. In addition, CaMKII phosphorylated serines in DAT distal N termini in 
vitro, and mutation of these serines abolished the stimulatory effects of CaMKII 
on amphetamine-induced DA efflux. These data suggest that CaMKII binding to 
the DAT C-terminus facilitates phosphorylation of the DAT N terminus and 
mediates amphetamine-induced DA efflux. Interestingly, mice that lack αCaMKII 
or express a permanently self-inhibited αCaMKII exhibited significantly reduced 
amphetamine-induced MPP+ efflux (Steinkellner et al., 2012). Consistent with 
these findings, coexpression of a CaMKII inhibitory peptide and hDAT in DA 
neurons of dDAT KO larvae blunted amphetamine-induced hyperlocomotion, 
demonstrating the importance of DAT/CaMKII interaction in amphetamine-
induced reward behavior (Pizzo et al., 2014). 
Syntaxin1A was also one of the proteins that was identified through a yeast two 
hybrid screening and was shown to interact with the DAT N-terminus (Lee et al., 
2004). Amphetamine was reported to increase the syntaxin1A/DAT association in 
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a cell line and in striatal synaptosomes, probably through a CaMKII-dependent 
mechanism (Binda et al., 2008).  
Using the hDAT C-terminal novel endocytic signal sequence FREKALAYAIA as a 
bait to probe a human substantial nigra cDNA library, Ras-like GTPase, Rin (for 
Ras-like in neurons; Rit2), was identified as a protein that interacted with DAT C-
terminal endocytic signal (Navaroli et al., 2011). Disruption of Rin function with 
GTPase mutants and shRNA-mediated Rin knockdown revealed that Rin was 
critical for PKC-mediated DAT internalization and functional downregulation.  
Since DAT and the DA D2 receptor both localize at the presynaptic membrane of 
DA neurons, Lee et al. sought to test whether there was a interaction between 
the two. Co-IP and domain analysis revealed a interaction between the DAT N-
terminus and the third intracellular loop of D2 receptor (Lee et al., 2007). This 
physical coupling facilitated the reinsertion of intracellular DAT to the plasma 
membrane and led to enhanced DA reuptake. Injecting inhibitory peptides into 
mice that disrupt the DAT-D2 receptor interaction resulted in decreased 
synaptosome DA uptake and enhanced locomotor activity, suggesting this 
interaction affects DA neurotransmission in vivo. Supporting this idea, D2 
receptor KO mice displayed decreased DAT function (Dickinson et al., 1999).  
Other DAT interacting proteins include protein phosphatase 2A (PP2A) (Bauman 
et al., 2000), LIM domain-containing adaptor protein Hic-5 (Carneiro et al., 2002), 
E3 ubiquitin ligase Parkin (Moszczynska et al., 2007) and synaptic vesicle protein 
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synaptogyrin-3 (Egana et al., 2009). The functional importance of the interactions 
of these proteins with DAT, especially in vivo, remains to be carefully 
characterized. 
Although much progress has been made to understand how DAT surface 
availability and function are regulated, important questions regarding the 
molecular mechanisms of DAT endocytosis and post-endocytic itinerary under 
basal and regulated conditions remain to be elucidated. This thesis aims to 
address some of these questions and controversies in the field and provide 
insight into future studies on DAT endocytic trafficking.  
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CHAPTER II 
Ack1 Is A Dopamine Transporter Endocytic Brake That Rescues  
A Trafficking-Dysregulated ADHD Coding Variant 
II.A Summary 
DAT stringently controls brain dopamine levels. Several addictive 
psychostimulants, antidepressants and ADHD therapeutics inhibit DAT function 
and multiple DAT mutants have been reported in ADHD, ASD, and Infantile 
Parkinsonism. Given that aberrant DAT function underlies many pathological 
conditions, it is critical to understand intrinsic regulatory mechanisms that 
modulate DAT function. DAT availability at the cell surface is dynamically 
modulated, but the mechanisms controlling this process are not well understood. 
In the current study, we identified the penultimate mechanism that controls DAT 
stability at the cell surface. Moreover, by genetically manipulating this 
mechanism we successfully rescued an ADHD-associated DAT mutant with 
intrinsic membrane instability. Thus, targeting DAT regulatory mechanisms may 
be a viable approach for treating dysregulated DAT.  
  
50 
 
II.B Introduction 
Dopamine (DA) is a modulatory neurotransmitter critical for locomotion and 
reward (Hyman et al., 2006) and DAergic dysregulation is linked to multiple 
neuropsychiatric disorders, including Parkinson’s Disease, schizophrenia, 
attention deficit-hyperactivity disorder (ADHD) and autism spectrum disorder 
(ASD) (Snyder, 2002; Iversen and Iversen, 2007). Presynaptic recapture, 
facilitated by the high-affinity DA transporter (DAT) spatially and temporally 
restricts extracellular DA availability (Amara and Kuhar, 1993; Kristensen et al., 
2011; Broer and Gether, 2012). Addictive psychostimulants that target DAT and 
its monoamine transporter homologs for 5HT (SERT) and NE (NET) are either 
competitive ligands, such as cocaine, or competitive substrates, such as 
amphetamine (Torres et al., 2003b). Although these drugs interact with DAT, 
SERT and NET with equimolar affinity, their binding to DAT is requisite for 
reward (Chen et al., 2006; Thomsen et al., 2009). Transporter inhibitors with 
differential DAT, SERT and NET specificity are widely used to treat 
neuropsychiatric disorders (Gether et al., 2006; Iversen, 2006). However, their 
therapeutic efficacy differs significantly among patients, consistent with the model 
that monoamines may differentially contribute to the pathogenesis of these 
disorders (Tamminga et al., 2002; Iversen, 2006). Thus, regulatory mechanisms 
specific to DAT, SERT or NET may provide a novel route to develop transporter-
specific therapeutics.  
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DAT plasma membrane expression is requisite for efficacious extracellular DA 
removal and to replenish presynaptic DA stores (Jones et al., 1998b). Indeed, 
DAT allelic and coding variants have been identified in a variety of 
neuropsychiatric disorders, including ADHD, ASD, Infantile Parkinsonism and 
bipolar disorder (Mazei-Robison et al., 2008; Pinsonneault et al., 2011; Sakrikar 
et al., 2012; Hamilton et al., 2013; Bowton et al., 2014; Hansen et al., 2014; 
Mergy et al., 2014), underscoring that even subtle DAT functional changes exert 
impactful consequences on dopaminergic neurotransmission. DAT is acutely 
regulated by membrane trafficking, and either protein kinase C (PKC) activation 
or AMPH exposure rapidly depletes DAT surface expression (Torres et al., 2003b; 
Melikian, 2004; Kristensen et al., 2011; Rudnick et al., 2014). Intriguingly, a DAT 
coding variant, R615C, identified in an ADHD proband, exhibits profound 
membrane instability, due to highly accelerated basal endocytosis (Sakrikar et al., 
2012), suggesting that dysregulated DAT membrane trafficking may contribute to 
the etiology of DA-related disorders. 
Studies from our lab (Boudanova et al., 2008b) and others (Sorkina et al., 2009) 
indicate that a unique negative regulatory mechanism, or “endocytic brake”, 
stabilizes DAT surface expression. PKC activation releases the endocytic brake, 
accelerates DAT internalization, and thereby reduces DAT surface levels and 
function. The cellular mechanisms facilitating this negative regulatory mechanism 
are completely undefined. Moreover, it is unknown whether the endocytic brake 
exists in DAergic terminals and whether it is specific to DAT.  
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Activated by cdc42 kinase 1 (Ack1) is a non-receptor tyrosine kinase that is a 
major cdc42 effector activated via EGF, PDGF and m3 muscarinic receptor 
stimulation (Linseman et al., 2001; Galisteo et al., 2006). Ack1 binds directly to 
clathrin heavy chain (Teo et al., 2001; Yang et al., 2001) and is enriched in 
presynaptic terminals (Urena et al., 2005). Importantly, Ack1 is inactivated by 
PKC (Linseman et al., 2001) and a recent study demonstrated that Ack1 
overexpression suppresses endocytosis (Shen et al., 2011). Given these 
attributes, we asked whether Ack1 activity is the penultimate step engaging the 
DAT endocytic brake. 
II.C Material And Methods 
Materials:  Full length human Ack1 (hAck1) wild-type, K158A cDNAs in pEF-
1α/pENTRA vector were kindly provided by Dr. Ingvar Ferby (Ludwig Institute for 
Cancer Research, Uppsala UP, Sweden) and were subcloned into pcDNA3.1(+) 
at BamH1/EcoR1 sites. hAck1 S445P pcDNA3.1(+) cDNA was generated from 
wildtype hAck1 by Quikchange mutagenesis (Agilent Technologies). Human DAT 
(hDAT) cDNA cloned into pcDNA3.1(+) was previously described (Gabriel et al., 
2013), and hSERT and hDAT(R615C) cDNAs were the generous gift of Dr. 
Randy Blakely (Vanderbilt University). Rat anti-DAT (MAB369) and rabbit anti-
phospho-Ack1 (pY284) were from EMD Millipore. Mouse anti-Ack1 (clone A11) 
and mouse anti-actin were from Santa Cruz Biotechnology. Horseradish 
peroxidase (HRP)-conjugated secondary antibodies were from EMD Millipore 
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(anti-rat), Santa Cruz (anti-rabbit) and Pierce (anti-mouse). [3H]DA 
(dihydroxyphenylethylamine 3,4-[ring-2,5,6-3H]) and L-[3H]alanine were from 
Perkin Elmer Life and Analytical Sciences. Sulfo-NHS-SS-biotin, Tris(2-
carboxyethyl)phosphine hydrochloride (TECP), and streptavidin agarose were 
from Thermo Fisher Scientific. AIM-100, phorbol 12-myristate 13-acetate (PMA), 
casin and GBR12909 (1-[2-[Bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-
phenylpropyl)piperazine dihydrochloride) were from Tocris Bioscience. Pirl1 (8-
cyclopentyl-2,3,3a,4,5,6-hexahydro-1H-pyrazino[3,2,1-jk]carbazole 
methanesulfonate) was from ChemBridge Corporation and pitstop2 was from 
Abcam. All other chemicals and reagents were from Sigma-Aldrich or Thermo 
Fisher Scientific and were of highest grade possible. 
Cell Culture and Transfections: SK-N-MC cells were from American Type Culture 
Collection (ATCC) and were maintained in MEM (Sigma-Aldrich M2279) 
supplemented with 10% fetal bovine serum (Invitrogen), 2mM L-glutamine, 102 
U/ml penicillin/streptomycin, 37°C, 5% CO2. Clonal #12 and pooled stable SK-N-
MC cell lines expressing either hDAT or hSERT, respectively, were generated by 
transfecting 1×106 cells/well in 6-well culture plate with 3µg plasmid DNA using 
Lipofectamine 2000, at lipid:DNA ratio of 2:1 (w/w). Stably transfected cells were 
selected with 0.5 mg/ml G418 (Invitrogen) and resistant cells were either pooled 
or selected by single colonies and maintained under selective pressure in 0.2 
mg/ml G418. For DAT/Ack1 transient co-transfection studies, 4x105 cells were 
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transfected with a total of 1.5µg plasmid DNA at a DAT:Ack1 (or vector) ratio of 
1:4 and were assayed 48 hours post-transfection. 
[3H]DA and [3H]alanine Uptake Assays in Cell lines: DAT-SK-N-MC cells were 
seeded in 96-well tissue culture plates at a density of 7.5×104 cells/well one day 
before performing assays. Cells were washed twice with Krebs-Ringer-HEPES 
(KRH) buffer (120mM NaCl, 4.7mM KCl, 2.2mM CaCl2, 1.2mM MgSO4, 1.2mM 
KH2PO4, 10mM HEPES, pH 7.4) and incubated in KRH supplemented with 0.18% 
glucose (KRH/g), 37°C for the indicated times with indicated drugs. DA transport 
was initiated by adding either 1µM [3H]DA or 0.5mM [3H]alanine in KRH/g 
supplemented with 10µM each pargyline and sodium L-ascorbate and proceeded 
for 10 min, 37°C. Transport was terminated by rapidly washing cells with ice-cold 
KRH buffer, cells were solubilized in scintillation fluid, and accumulated 
radioactivity was measured by liquid scintillation counting in a Wallac MicroBeta 
scintillation plate counter (Perkin Elmer). 100nM desipramine was included in all 
samples to block uptake contributed by endogenously expressed NET. Non-
specific DA uptake was defined with 10µM GBR12909 and Na+-dependent 
alanine transport was defined by substituting NaCl with 120 mM choline chloride. 
Lentiviral production and transduction:  Short hairpin RNA (shRNA) targeting 
hAck1 from Open Biosystems were purchased from University of Massachusetts 
Medical School RNAi Core. All shRNAs were cloned into the pGIPZ vector which 
co-expresses turbo GFP (tGFP). shRNA sequences were as follows: 
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Non-silencing (Luciferase 693): 
TGCTGTTGACAGTGAGCGCTCTAAGAACGTTGTATTTATATAGTGAAGCCAC
AGATGTATATAAATACAACGTTCTTAGATTGCCTACTGCCTCGGA 
Ack sh#10: 
TGCTGTTGACAGTGAGCGATACCTGCTTCTTCCAGAGAAATAGTGAAGCCA
CAGATGTATTTCTCTGGAAGAAGCAGGTACTGCCTACTGCCTCGGA 
Ack sh#12: 
TGCTGTTGACAGTGAGCGAAAGGTGTTCAGTGGAAAGCGATAGTGAAGCCA
CAGATGTATCGCTTTCCACTGAACACCTTATGCCTACTGCCTCGGA 
For lentivirus production: Replication incompetent lentiviral particles were 
produced according to the Addgene 2nd generation pLKO.1 protocol 
(https://www.addgene.org/tools/protocols/plko/). Briefly, 4.4x106 HEK293T 
cells/dish were seeded in 150mm dishes one day prior to transfection and were 
co-transfected with 6.25µg shRNA (or control) plasmid, 4.7µg psPAX2 packaging 
plasmid, 1.56µg pMD2.G envelope plasmid, combined in Opti-MEM reduced 
serum media (Invitrogen) with 37.5µl Fugene 6 (Promega). Transfection mixtures 
were added dropwise to cells, incubated at 37°C, 5% CO2, and were removed 
and replaced with fresh growth medium 12-16 hours post-transfection. Viral 
supernatants were collected 48 and 72 hours post-transfection, aliquoted and 
stored at -80°C. Titers were determined by transduction into HEK293T cells and 
counting GFP-positive cells 48 hours post-transduction. Experiments were 
performed using a minimum of three independent viral preparations. 
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For Lentiviral Transduction:  5x106 DAT-SK-N-MC cells/dish were seeded into 
100mm dishes one day prior to viral transduction and were infected with 50ml of 
the indicated crude lentivirus supplemented with 8µg/ml polybrene. Virus was 
removed 24 hours post-infection and transduced cells were enriched by selecting 
with 1µg/ml puromycin for 48 hours. Cells were replated into 6 well dishes 48 
hours post-infection and were assayed 72 hours post-infection.  
Cell Surface Biotinylation: DAT surface levels in SK-N-MC cells were determined 
by steady state biotinylation as previously described (Navaroli et al., 2011; 
Gabriel et al., 2013). Briefly, cells were treated with the indicated drugs for the 
indicated times in PBS2+/g/BSA (phosphate-buffered saline, pH 7.4, 
supplemented with 1mM MgCl2 and 0.1mM CaCl2, 0.18% glucose, 0.1% IgG-
/protease-free BSA), and were rapidly cooled by repeated washing in ice-cold 
PBS2+. Cells were labeled twice, 15 min, 4°C with 1.0 mg/ml sulfo-NHS-SS-biotin 
in PBS2+ and excess biotinylation reagent was quenched twice, 15 min, 4°C with 
PBS2+/100mM glycine. Excess glycine was removed by washing three times in 
ice-cold PBS2+ and cells were lysed in RIPA buffer (10mM Tris, pH 7.4, 150mM 
NaCl, 1mM EDTA, 0.1%SDS, 1%Triton-X-100, 1% sodium deoxycholate) 
containing protease inhibitors. Lysates were cleared by centrifugation and protein 
concentrations were determined by BCA protein assay kit (Pierce). Lysate 
aliquots were stored in denaturing SDS-PAGE sample buffer at -20°C until 
analysis. Biotinylated proteins from equivalent amount of cellular protein were 
recovered by batch streptavidin affinity chromatography (overnight, 4°C) and 
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bound proteins were eluted in denaturing SDS-PAGE sample buffer, 30 min, 
room temperature with rotation. Samples were analyzed by SDS-PAGE and 
indicated proteins were detected by immunoblotting. Immunoreactive bands were 
detected with SuperSignal West Dura (Pierce) and were captured using the 
VersaDoc Imaging station (Biorad). Non-saturating bands were quantified using 
Quantity One software (Biorad). 
Mouse Striatal Slice Assays: All animals were handled in accordance with 
University of Massachusetts Medical School IACUC protocol A-1506 (H.E.M.). 
P21-P38 male C57BL/6 mice were sacrificed by cervical dislocation and 
decapitation and mouse brains were rapidly removed and immediately chilled in 
ice cold sucrose- and kynurenic acid (1mM)- supplemented artificial CSF 
(SACSF) (2.5mM KCl, 1.2mM NaH2PO4, 1.2mM MgCl2, 2.4mM CaCl2, 26mM 
NaHCO3, 11mM glucose, 250mM sucrose) saturated with 95% O2/5% CO2. 
Brains were mounted on Leica VT1200S Vibratome and 300µm coronal sections 
were prepared. Striatal sections corresponding to the range between Bregma 
1.54–0.34 (using corpus callosum as a landmark) were harvested, hemisected 
along the midline, and recovered 40min, 31°C in 95%O2/5%CO2-saturated ACSF 
(125mM NaCl, 2.5mM KCl, 1.2mM NaH2PO4, 1.2mM MgCl2, 2.4mM CaCl2, 
26mM NaHCO3, 11mM glucose) containing 1mM kynurenic acid. Hemi-slices 
were treated with the indicated drugs for the indicated times and temperatures in 
oxygenated ASCF, using the contralateral hemi-slice as the control.  
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For pAck1 and total Ack1 assessment: Slices were lysed in RIPA buffer 
containing protease inhibitors and Phosphatase Inhibitor Cocktail V (EMD 
Millipore) by triturating through a 200µl pipet tip and rotating 30min, 4°C. Protein 
concentrations were determined using the BCA protein assay and equivalent 
amounts of lysate were resolved by SDS-PAGE and underwent immunoblot with 
the indicated antibodies.  pAck1 levels were normalized to total Ack1 levels, 
developed in parallel. 
For striatal slice biotinylation: Surface proteins were covalently labeled with 
1.0mg/ml sulfo-NHS-SS biotin in ice-cold ACSF, 45min, 4°C. Residual reactive 
biotin was quenched by incubating twice with ice-cold ACSF supplemented with 
glycine, 20min, 4°C. Slices were then washed with ice-cold ACSF and lysed in 
RIPA buffer containing protease inhibitors by triturating through a 200µl pipet tip 
and rotating 30min, 4°C. Protein concentrations were determined using the BCA 
protein assay and biotinylated proteins were isolated as described for cell lines, 
above, using a striatal lysate:streptavidin agarose bead ratio of 20µg lysate:30µl 
streptavidin agarose in order to quantitatively recover all biotinylated DAT in the 
linear range of recovery. 
Striatal Slice [3H]DA uptake: DA uptake was determined in 300µm striatal hemi-
slices from P21-P24 male C57BL/6 mice, prepared as described above. 
Following recovery, hemi-slices were pretreated ±20μM AIM-100, 1 hr, 37°C in 
oxygenated ASCF, using the contralateral hemi-slice as the vehicle control. DA 
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transport was initiated by adding 1μM [3H]DA in ACSF supplemented with 10μM 
each pargyline and sodium L-ascorbate and proceeded for 10min, 37°C. 100nM 
desipramine was included in all pretreatments to block uptake contribution from 
the norepinephrine transporter. Uptake was terminated by rapidly washing slices 
with ice-cold ACSF, followed by three 5 min incubations in ice-cold ACSF with 
gentle shaking. Slices were lysed in RIPA buffer containing protease inhibitors, 
30 min, 4°C, and insoluble material was removed by centrifugation at 18,000 x g, 
10 min, 4°C. Protein concentrations were determined using the BCA protein 
assay (Pierce) and accumulated [3H]DA was quantified, in triplicate, from each 
hemi-slice lysate (150 µg total tissue lysate per replicate) by liquid scintillation 
counting.  Given that DAT expression is highly variable along the rostral-caudal 
axis, relative DAT levels for each hemi-slice were determined in parallel by 
immunoblotting, using actin as a loading control. Hemi-slice uptake values were 
subsequently normalized to their respective relative DAT expression levels so 
that bona fide differences in uptake across slices could be accurately determined. 
Non-specific [3H]DA accumulation was defined in the presence of 10μM 
GBR12909, averaged from two independent hemi-slices per mouse.  
Internalization Assays: Cells were plated onto 6-well tissue culture plates at a 
density of 1x106 cell/well one day prior to assays. Cells were biotinylated twice, 
15min, 4°C with 2.5 mg/ml sulfo-NHS-SS-biotin. After glycine quenching, zero 
time points and strip controls remained at 4°C, and internalized samples were 
warmed to 37°C by multiple rapid washes in prewarmed PBS2+, 0.18% glucose, 
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0.1% IgG/protease-free BSA with the indicated drugs. Internalization proceeded 
in the same solutions for 10 min, 37°C, was stopped by washing repeatedly with 
ice-cold NT buffer(150mM NaCl, 20mM Tris, pH 8.6, 1mM EDTA, 0.2% IgG-
/protease-free BSA), and residual surface biotin on experimental and strip control 
samples was cleaved by reducing twice for 25min, 4°C in 100mM TCEP in NT 
buffer. Cells were washed thrice in PBS2+, lysed in RIPA buffer with protease 
inhibitors and biotinylated proteins were isolated and analyzed by immunoblot as 
described for steady state biotinylation, above. Stripping efficiencies were 
calculated for each sample and were >95% of total surface protein labeled at t=0. 
Internalization rates were calculated as the percentage DAT internalized over 
10min as compared to total surface DAT labeled at t = 0.  
TIRF microscopy studies: SK-N-MC cells stably expressing either TagRFP-T-
DAT and eGFP-clathrin, or eGFP-clathrin alone, were plate on glass coverslips 
one day prior to imaging and media was replaced with KRH/0.18% glucose/0.1% 
BSA, 37°C for live imaging. To label transferrin receptors in eGFP-clathrin SK-N-
MC cells, 1µg/ml human transferrin-Alexa594 (Life Technologies) was added in 
the imaging solution. TIRF images in red and green channels were captured 
using TESM microscope (Biomedical Imaging Group, University of 
Massachusetts Medical School) (Navaroli et al., 2012). Briefly, images of 
through-the-lens TIRF were generated using 491nm (for eGFP-clathrin) and 
561nm (for TagRFP-T-DAT or transferrin-Alexa594) laser illumination together 
with an Olympus TIRF 60 X objective (N.A. = 1.49) at an angel set to visualize 
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around 200nM from the glass coverslip. Focus stabilization was controlled by an 
in-house made software called pgFocus (Biomedical Imaging Group, 
http://big.umassmed.edu/wiki/index.php/PgFocus). PgFocus is an open source 
and open hardware focus stabilization device that autonomously adjusts a piezo-
positioned objective in response to the positional change of a reflected 808nm 
laser beam.  PgFocus is able to modify and pass on piezo-positon control signals 
from other devices, which allows pgFocus to identify the expected focus position 
and adjust accordingly. PgFocus operates at 30Hz with ±3nm accuracy and 
integrates with MicroManager. Time-lapse image data were acquired at 1Hz 
using MicroManager open source microscopy software (https://www.micro-
manager.org/). Images were then exported as tiff files and analyzed in ImageJ. 
II.D Results 
Ack1 negatively regulates DAT, but not SERT endocytosis. 
Ack1 and its active, autophosphorylated form, pY284-Ack1 (pAck1) (Yokoyama 
and Miller, 2003; Galisteo et al., 2006), were readily detected in both the 
dopaminergic cell line SK-N-MC and mouse striatum (Figs. II-1A, II-1B). PKC 
activation significantly decreased pAck1 in both SK-N-MC cells (46.5±3.0% 
control levels, Fig. II-1A) and mouse striatum (78.3±5.2% control levels, Fig. II-
1B). Likewise, the highly specific Ack1 inhibitor AIM-100 (Mahajan et al., 2010) 
dose-dependently decreased pAck1 in SK-N-MC cells (Fig. II-1C), and 
dramatically decreased mouse striatal pAck1 to 13.2±2.2% control levels (Fig. II-
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1D). Thus, Ack1 is expressed in dopaminergic cell lines and striatum, and either 
PKC activation or AIM-100 inactivate Ack1 in both these model systems.  
We predicted that if Ack1 imposes the DAT endocytic brake, then Ack1 
inactivation would release the brake and decrease both DAT function and 
surface expression. Indeed, AIM-100 significantly decreased [3H]DA uptake in 
SK-N-MC cells (IC50 = 50.2 ±9.9 μM) and striatal slices (Fig. II-2A, 2B), and 
significantly reduced DAT surface levels to 72.5±6.4% control levels in mouse 
striatum (Fig. II-2C). DAT surface loss in response to AIM-100 was due to a 
significant increase in the DAT internalization rate, to 192.9±28.6% control levels 
(Fig. II-2D), demonstrating that Ack1 negatively regulates DAT endocytosis. AIM-
100 effects were specific to DAT, and had no effect on the SERT endocytic rate 
measured in SERT-SK-N-MC cells (Fig. II-2D, p=0.89). Interestingly, high AIM-
100 concentrations (>20µM) inhibited DAT function to a much larger degree than 
what could be attributed to membrane trafficking. This was not due to 
transmembrane Na+ gradient disruption, as AIM-100 had no effect on Na+-
dependent alanine uptake (Fig. II-3A). To our surprise, AIM-100 also dose-
dependently inhibited SERT function (Fig. II-3B), despite exerting no effect on 
SERT trafficking (Fig. II-2D). We noted that AIM-100 bears DAT and SERT 
pharmacophore properties similar to piperazine derivatives, such as GBR12909 
(Fig. II-3C). We therefore hypothesized that, in addition to its known function as a 
high affinity Ack1 inhibitor, AIM-100 may also be a low affinity, competitive DAT 
and SERT inhibitor.  Whole cell binding studies revealed that AIM-100 
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competitively inhibited DAT and SERT binding to [3H]WIN 35428 and 
[3H]imipramine, respectively, (Fig. II-3D), supporting the premise that AIM-100 is 
a DAT and SERT inhibitor. However, GBR12909 had no effect on pAck1 levels 
(Fig. II-3E), indicating that DAT ligand binding does not globally inactivate Ack1.  
Moreover, a ten-fold lower AIM-100 concentration that efficaciously decreased 
p284-Ack1 levels (2µM, Fig. II-1C), also significantly increased DAT 
internalization rates (Fig. II-3F). Thus, distinct endocytic mechanisms regulate 
DAT and SERT, and Ack1 activity is required to impose the DAT endocytic brake. 
Moreover, AIM-100 is, coincidentally, a low affinity, competitive DAT and SERT 
inhibitor. 
Constitutive and regulated DAT endocytosis are differentially dependent on 
clathrin 
Ack1 is recruited to clathrin-coated-pits via clathrin heavy chain interactions (Teo 
et al., 2001; Yang et al., 2001). Thus, we hypothesized that clathrin is required to 
release the Ack1-imposed brake. To test this, we acutely inhibited clathrin with 
pitstop2 and measured DAT internalization ±AIM-100 and ±PMA. Pitstop2 
pretreatment significantly attenuated both AIM-100- and PKC-stimulated DAT 
internalization, but had no effect on basal DAT endocytosis (Figs. II-4A, 4B) 
suggesting that stimulated DAT endocytosis is clathrin-dependent whereas 
constitutive DAT endocytosis is clathrin-independent. We further used TIRFM to 
examine clathrin and surface DAT under basal conditions, compared to 
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transferrin receptor (TfR), a protein known to undergo robust clathrin-mediated 
endocytosis. Alexa594-Tf co-localized markedly with eGFP-clathrin across the 
plasma membrane, and distinct Tf/clathrin puncta moved away from the TIRF 
field during imaging; consistent with clathrin-mediated endocytosis (Fig. II-4C). In 
contrast, TagRFP-T-DAT was diffusely distributed across the plasma membrane 
and was enriched in cellular microspikes, with little apparent clathrin co-
localization (Fig. II-4C). Taken together with the pitstop2 data, these data support 
that constitutive DAT endocytosis is clathrin-independent, whereas stimulated 
DAT endocytosis requires clathrin. 
Cdc42 negatively regulates DAT, but not SERT, endocytosis. 
Ack1 is a major cdc42 effector, suggesting that cdc42 may contribute to the DAT 
endocytic brake, upstream of Ack1. To test this possibility we measured DAT 
surface levels in DAT SK-N-MC cells and striatal dopaminergic terminals 
following acute treatment with two structurally distinct cdc42 inhibitors, casin and 
pirl1. Both casin and pirl1 significantly reduced DAT surface levels in SK-N-MC 
cells (Fig. II-5A, 5B) and casin significantly decreased surface DAT in mouse 
striatum (Fig. II-5C). DAT surface loss was due to profound DAT endocytic 
acceleration (238.0±15.5% control levels, Fig. II-5D). In contrast, pirl1 did not 
significantly affect SERT internalization (Fig. II-5E). We further tested whether 
PKC and cdc42 impact DAT surface stability in independent or convergent 
manners. Pretreatment ±casin (Fig. II-5A) or ±pirl1 (Fig. II-5B) significantly 
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attenuated PKC-stimulated DAT endocytosis. Moreover, pirl1 and PMA co-
application had no additive effect on DAT internalization (Fig. II-5D). Taken 
together, these results demonstrate that cdc42 activity is required to impose the 
DAT endocytic brake, likely via the same pathway as PKC and potentially 
upstream of Ack1. Moreover, these results further support that distinct endocytic 
mechanisms govern DAT and SERT surface stability. 
Ack1 inactivation is required to release the DAT endocytic brake, 
downstream of PKC or cdc42. 
We next used two efficacious hAck1-targeted shRNAs, #10 and #12 (Fig. II-6A), 
to test whether Ack1 is required to 1) engage the DAT endocytic brake, and 2) 
stimulate DAT endocytosis by PKC activation or cdc42 inhibition. The most 
efficacious hAck1 shRNA, #10, significantly increased basal DAT endocytosis to 
138.7±12.3% control levels (Fig. II-6C), consistent with Ack1’s requisite role as 
the DAT endocytic brake. Moreover, Ack1 depletion with either shRNA #10 or 
#12 significantly attenuated stimulated DAT endocytosis, either via PKC 
stimulation (Fig. II-6D) or cdc42 inhibition (Fig. II-6E). In sum, these results 
support that Ack1 is required to engage the DAT endocytic brake. 
Although perturbing Ack1 enhanced DAT endocytosis, we next asked whether 
there is a direct causal link between Ack1 inactivation and either cdc42 inhibition 
or PKC activation in order to release the DAT endocytic brake. To test this, we 
co-expressed DAT with either wildtype, constitutively active (S445P) or kinase 
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dead (K158A) Ack1 isoforms (Lin et al., 2012) (See Fig II-7A,7B,7C, for Ack1 
mutant overexpression profiles). We predicted that if Ack1 inactivation were 
required to release the DAT endocytic brake, then S445P-Ack1 would block 
accelerated DAT internalization in response to either PKC activation or cdc42 
inhibition. Wildtype Ack1 overexpression had no effect on basal or accelerated 
DAT endocytosis in response to PKC activation or cdc42 inhibition (Fig. II-7E, 7F, 
7G). In contrast, S445P-Ack1 significantly attenuated both PKC-stimulated (Fig. 
II-7F) and pirl1-stimulated (Fig. II-7G) DAT internalization. K158A-Ack1 had no 
significant effect either basal (p=0.30) or pirl1-stimulated (p=0.30) DAT 
internalization (Fig. II-7E, II-7G), but significantly inhibited PKC-stimulated DAT 
endocytosis (100.1±5.2% control level, Fig. II-7F). Although the K158A mutant 
lacks kinase activity (Mahajan et al., 2005), it was unknown, a priori, whether this 
mutant would exert a dominant negative effect. Ack1 activation is required for 
targeting to clathrin-coated pits (Shen et al., 2011). Thus, it is not surprising the 
kinase dead mutant failed to exert a dominant effect on DAT internalization. 
Taken together, these results provide a causal link between upstream PKC, or 
cdc42, stimuli and Ack1 inactivation as requisite steps in releasing the DAT 
endocytic brake. 
Ack1 activity restores normal trafficking to a DAT coding variant expressed 
in an ADHD proband 
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A recent study reported that a DAT coding variant, R615C, identified in an ADHD 
proband, lacks endocytic braking, resulting in enhanced basal endocytosis and 
inability to undergo PKC- and AMPH-stimulated endocytosis (Sakrikar et al., 
2012). We asked whether constitutive Ack1 activation could restore the endocytic 
brake and thereby rescue the DAT(R615C) gain-of-function endocytic phenotype. 
DAT(R615C) expressed in SK-N-MC cells internalized significantly faster than 
wildtype DAT (Fig. II-10E, 10F) and was defective in PKC-stimulated endocytosis 
(Fig. II-7B), consistent with the previous report (Sakrikar et al., 2012). 
Remarkably, S445P-Ack1 significantly decreased DAT(R615C) basal 
endocytosis to wildtype DAT levels (Fig. II-8B), but did not restore PKC-
stimulated endocytosis (Fig. II-8C).  
II.E Discussion 
Reuptake inhibitors are used to treat a variety of neuropsychiatric disorders, 
including depression, obsessive-compulsive disorder and ADHD (Iversen, 2000, 
2006). These agents are differential selective for SERT, NET and DAT, and their 
clinical efficacy varies considerably across the population (Tamminga et al., 2002; 
Iversen, 2006). Transporter-specific cellular regulation has the potential to lead to 
novel and selective therapeutic approaches that manipulate transporters 
intrinsically, rather than extrinsically. In the current study, we identified an 
endocytic regulatory mechanism that is selective for DAT, but not SERT. We 
previously reported that PKC-stimulated DAT internalization is also selectively 
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dependent upon binding to the neuronal GTPase, Rin, whereas neither SERT 
nor the GABA transporter binds Rin (Navaroli et al., 2011). Taken together with 
our current findings, this is consistent with a model wherein distinct mechanisms 
differentially regulate DAT and SERT surface stability. 
Conflicting reports regarding whether constitutive and regulated DAT 
internalization are clathrin-dependent. Gene silencing studies suggest that both 
constitutive and PKC-stimulated DAT internalization in non-neuronal cell lines are 
clathrin-dependent (Sorkina et al., 2005); although whether chronic clathrin 
depletion artifactually skews these studies is uncertain. A recent study examining 
DAT trafficking in a knock-in mouse encoding a DAT extracellular epitope tag 
observed only modest DAT endocytosis and little/no clathrin co-localization under 
basal conditions (Block et al., 2015). However, it is unclear whether antibody-
bound DAT traffics similar to native DAT, as we investigate here.  Multiple studies 
also demonstrate that DAT partitions into cholesterol-rich membrane 
microdomains (Adkins et al., 2007; Foster et al., 2008; Cremona et al., 2011; 
Navaroli et al., 2011; Jones et al., 2012; Gabriel et al., 2013; Kovtun et al., 2015), 
and that the membrane raft protein flotillin-1 is required for PKC- and AMPH-
mediated DAT internalization (Cremona et al., 2011), consistent with a clathrin-
independent endocytic mechanism. However, a separate study reported that 
flotillin-1 contributes to DAT membrane mobility rather than PKC-stimulated DAT 
internalization (Sorkina et al., 2013). Our findings suggest that basal DAT 
internalization is clathrin-independent, whereas stimulated DAT internalization is 
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clathrin-dependent. Consistent with these data, we previously reported that basal 
and PKC-stimulated DAT internalization are mediated by independent 
mechanisms (Loder and Melikian, 2003; Holton et al., 2005), and that constitutive 
and PKC-stimulated DAT internalization are dynamin-independent and –
dependent, respectively (Gabriel et al., 2013). 
Cdc42 directly activates Ack1 and cdc42 inhibition released the DAT endocytic 
brake in a manner that required Ack1 inactivation (Fig. II-7G). Several forms of 
clathrin-independent endocytosis require cdc42 (Massol et al., 1998; 
Sabharanjak et al., 2002; Gauthier et al., 2005). In contrast, we found that cdc42 
negatively regulates DAT endocytosis via Ack1 activation (Fig. II-5), and that 
stimulated DAT endocytosis in response to Ack1 inactivation is clathrin-
dependent (Fig. II-4). Thus, it appears that cdc42 impacts DAT internalization in 
a unique fashion, in contrast to its more commonly known function in promoting 
endocytosis.  
Given our current findings, and in light of previous reports, we propose the 
following model of basal and PKC-regulated DAT endocytosis (Fig. II-9). Under 
basal conditions, an Ack1-mediated endocytic brake stabilizes DAT at the 
plasma membrane, and cdc42 promotes the braking mechanism via Ack1 
activation. Basal internalization that occurs while the endocytic brake is engaged 
is clathrin-and dynamin-independent. PKC activation decreases Ack1 activity, 
which releases the endocytic brake and accelerates DAT internalization via a 
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clathrin- and dynamin-dependent mechanism, resulting in intracellular DAT 
sequestration.  
What are the molecular players orchestrating the Ack1-imposed DAT endocytic 
brake and PKC-mediated Ack1 inactivation?  PIP2 depletion inactivates Ack1 
(Shen et al., 2011) and both DAT (Hamilton et al., 2014) and SERT (Buchmayer 
et al., 2013) bind to PIP2. However, DAT mutants lacking PIP2 binding exhibited 
plasma membrane instability in HEK cells, whereas disrupting SERT/PIP2 
interactions did not affect SERT membrane trafficking. This raises the possibility 
that PIP2 effects on Ack1 activity may specifically influence DAT surface stability. 
PKC activation also increases DAT ubiquitination via a Nedd4-2-mediated 
mechanism that is required for enhanced DAT endocytosis (Vina-Vilaseca and 
Sorkin, 2010). Nedd4-2 also interacts with Ack1 and is recruited to clathrin-rich 
vesicles (Chan et al., 2009), and Nedd4-2/Ack1 interactions drive Ack1 
degradation in an Ack1 activity-dependent fashion. Thus, it is possible that 
Nedd4-2 serves as a dual function player in the DAT endocytic brake by 
controlling Ack1 protein turnover as well as DAT ubiquitination.  
Multiple DAT coding variants and missense mutants have been reported in 
ADHD, ASD and Infantile Parkinsonism patients, implicating DAT dysfunction as 
a common risk factor for several DA-related disorders (Mazei-Robison et al., 
2008; Sakrikar et al., 2012; Hamilton et al., 2013; Hansen et al., 2014). Many 
DAT coding variants exhibit basal anomalous dopamine efflux and loss of AMPH-
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induced DA efflux. The ADHD-associated DAT(R615C) variant, however, lacks 
plasma membrane stability due to rapid basal endocytosis, and is unable to 
sequester in response to PKC activation or AMPH exposure. We were able to 
capitalize on the Ack1-mediated DAT endocytic brake to restore wildtype surface 
stability to DAT(R615C) (Fig. II-8B). Not unexpectedly, S445P- Ack1 also 
prevented DAT(R615C) from responding to PKC stimulation (Fig. II-8C), similar 
to its effect on wildtype DAT (Fig. II-7F). Nevertheless, our ability to rescue 
DAT(R615C) endocytic dysfunction raises the tantalizing possibility that 
genetically targeting DAT trafficking may hold promise for DAT coding variants 
with inherent membrane trafficking dysregulation. 
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Figure II-1. Ack1 is expressed in dopaminergic SK-N-MC cells and mouse 
striatum, and is inactivated by PKC and the Ack1-specific inhibitor AIM-
100. pY284-Ack1 quantification. Samples were treated as described and 
pY284-Ack1 protein levels were measured by immunoblotting A., B. DAT SK-
N-MC cells (A) and mouse striatal slices (B) were treated ±1μM PMA, 30min, 
37°C. Top: Representative pY284-Ack1 and total Ack1 blots. Bottom: Average 
pY284-Ack1 levels expressed as %vehicle-treated ±S.E.M. **p<0.01, *p<0.02, 
Student’s t test, n=7 (A), n=9 (B). C. AIM-100 dose response curves. DAT SK-
N-MC cells were treated with the indicated AIM-100 concentrations, 30min, 
37°C. Top: Representative pY284-Ack1 and total Ack1 blots. Bottom: Average 
pY284-Ack1 levels, normalized to total Ack1. Data are expressed as %vehicle-
treated ±S.E.M. n=3-4. AIM-100 decreased pY284-Ack1 levels with an IC50 = 
220.5±42.5nM D. Mouse striatal slices were treated with ±20μM AIM-100, 
30min, 37°C. Top: Representative pY284-Ack1 and Ack1 blots. Bottom: 
Average pYAck1 levels expressed as %vehicle-treated ±S.E.M. *p<0.02, 
Student’s t test, n=3. 
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Figure II-2. Ack1 activity stabilizes DAT at the plasma membrane. A. 
[3H]DA uptake: DAT SK-N-MC cells were treated with the indicated AIM-100 
concentrations, 30min, 37°C and [3H]DA uptake was measured as described 
in Methods. Data are expressed as %specific DA uptake ±S.E.M. (n=12). B. 
Ex vivo slice uptake. Striatal slices were treated ±20μM AIM-100, 60min, 37°C 
and [3H]DA uptake was assessed as described in Methods. *p<0.05, Student’s 
t test, n=6 hemislices obtained from 2 independent mice. C. Ex vivo slice 
biotinylation. Striatal slices were treated ±20μM AIM-100, 30min, 37°C and 
surface proteins were isolated by biotinylation. Top: Representative 
immunoblots. Bottom: Average DAT surface levels expressed as %vehicle-
treated levels ±S.E.M. **p<0.01, Student’s t test, n=3. D. Internalization 
assays: DAT and SERT internalization rates were measured in SK-N-MC cells 
±20μM AIM-100 as described in Methods. Top: Representative immunoblots 
showing the total DAT and SERT surface pools at t=0 (T), strip control (S), 
and internalized protein during either vehicle (V) or AIM-100 (A) treatments. 
Bottom: Average internalization rates expressed as %vehicle-treated ±S.E.M. 
*p<0.02, Student’s t test, n=5 (DAT), n=3 (SERT).  
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Figure II-3. AIM-100 is a low affinity, competitive monoamine transporter 
inhibitor. A. Effect of AIM-100 on Na+-dependent alanine uptake and DA 
uptake in DAT-SK-N-MC cells. Cells were treated with the indicated 
concentrations of AIM-100, 30 min, 37°C and [3H]alanine or [3H]DA uptake 
were measured in parallel. Data are expressed as %non-treated controls 
±S.E.M. *indicates a significance from control within each transporter type, 
#indicates a significant difference in uptake between DA and alanine uptake at 
the same AIM-100 dose, two-way ANOVA with Dunnett’s multiple 
comparisons and Bonferroni’s multiple comparison, n=4 . B. Effect of AIM-100 
on [3H]DA and [3H]5-HT uptake in DAT-SK-N-MC and SERT-SK-N-MC cells, 
respectively. Specific uptake is expressed as %non-treated controls ±S.E.M. 
*indicates significantly different DA uptake compared with lowest dose, 
#indicates significantly different 5-HT uptake compared with lowest dose, two-
way ANOVA with Dunnett’s multiple comparisons, n=4. C. Chemical structures 
of AIM-100 and GBR12909. D. Whole Cell Binding Assays. DAT-SK-N-MC 
and SERT-SK-N-MC cells incubated with 1nM [3H]WIN 35428 and 1nM 
[3H]imipramine, respectively, 2 hrs, 4°C, in the presence of the indicated AIM-
100 concentrations. Data are expressed as %bound compared to non-treated 
controls ±S.E.M. AIM-100 dose-dependently inhibited ligand binding with Ki 
values of 27.3±4.9 µM and 33.1±14.2 µM, respectively. E. pY284-Ack1 
quantification. DAT-SK-N-MC cells were treated with either 20µM AIM-100 or 
10µM GBR 12909, 30 min, 37°C and pY284-Ack1 levels were measured by 
immunoblotting as described in Methods. Top: Representative pAck1, total 
Ack1 and actin immunoblots; Bottom: Average pAck1 levels following the 
indicated drug treatments, expressed as %vehicle pAck1 levels ±S.E.M. 
****Significantly different than vehicle control, one-way ANOVA with Dunnett’s 
multiple comparison test, p<0.001, n=4-7. F. Internalization Assay. DAT 
internalization rates were measured as described in Methods, ±2µM AIM-100. 
Top: Representative DAT immunoblot showing total DAT surface pool at t=0 
(T), strip control (S), and internalized DAT during either vehicle (V) or AIM-100 
(A) treatments. Bottom: Average DAT internalization rate expressed 
as %vehicle-treated DAT internalization rate ±S.E.M. **Significantly different 
than vehicle control, Student’s t test, p<0.01, n=4. 
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Figure II-4. Stimulated DAT endocytosis is clathrin-dependent, whereas 
constitutive DAT endocytosis is clathrin-independent. A., B. DAT 
internalization assay. DAT SK-N-MC cells were pretreated ±25μM pitstop2, 
10min, 37°C, rapidly chilled, and DAT internalization rates were measured as 
described in Methods ±20μM AIM-100 (A) or ±1μM PMA (B). Top: 
Representative immunoblots showing total surface DAT at t=0 (T), strip control 
(S), and internalized DAT during vehicle (V), AIM-100 (A) or PMA (P) 
treatments. Bottom: Average DAT internalization rates expressed 
as %vehicle-treated ±S.E.M. Asterisks indicate a significant difference from 
vehicle, *p<0.03, ***p<0.005, one-way ANOVA with Bonferroni’s multiple 
comparison test, n=7 (A), n=4-6 (B). C. TIRF microscopy: Time-lapse TIRF 
images were captured as described in Methods. Top: SK-N-MC cells stably 
expressing eGFP-clathrin labeled with Tf-Alexa594. White arrows indicate 
Tf/clathrin co-localized puncta that move away from the TIRF field during 
image capture. Bottom: SK-N-MC cells stably co-transfected with TagRFP-T-
DAT and eGFP-clathrin.  
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Figure II-5. Cdc42 stabilizes DAT surface expression. A., B. Cell surface 
biotinylation: DAT SK-N-MC cells were pretreated ±10μM casin (A) or ±20μM 
pirl1 (B), 30min, 37°C, followed by treatment ±1μM PMA, 30min, 37°C. 
Relative DAT surface levels were measured by biotinylation as described in 
Methods. Representative immunoblots are shown in the top of each panel. 
Average DAT surface levels expressed as %vehicle levels ±S.E.M. Asterisks 
indicate a significant difference from vehicle control, *p<0.05, **p<0.01, one-
way ANOVA with Bonferroni’s multiple comparison test, n=5-6 (A), n=3 (B). C. 
Ex vivo striatal slice biotinylation: Mouse striatal slices were treated ±10μM 
casin, 30min, 37°C and relative DAT surface levels were measured by 
biotinylation as described in Methods. Top: Representative immunoblot. 
Bottom: Average DAT surface levels expressed as %vehicle-treated ±S.E.M. 
*p<0.05, Student’s t test, n=10. D. Internalization assay: DAT internalization 
rates were measured ±1μM PMA, ±20µM pirl1 or with PMA/pirl1 co-
application, 10min, 37°C. Top: Representative immunoblots showing total 
surface DAT at t=0 (T), strip control (S), and internalized DAT during vehicle 
(V), PMA (P) or pirl1 (PR) treatments. Bottom: Average DAT internalization 
rates expressed as %vehicle rate ±S.E.M. Asterisks indicate a significant 
difference from vehicle control, **p<0.01, ***p<0.005, one-way ANOVA with 
Bonferroni’s multiple comparison test, n=9-13. E. Cdc42 inhibition does not 
affect SERT internalization. Internalization assay: SERT internalization rates 
were measured as described ±20 μM pirl1. Top: Representative SERT 
immunoblot showing total SERT surface pool at t = 0 (T), strip control (S), and 
internalized SERT during either vehicle (V) or pirl1 (P) treatment. Bottom: 
Average SERT internalization rates expressed as percent vehicle-treated rate 
± SEM p = 0.68, Student’s t test, n = 5. 
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Figure II-6. ShRNA-mediated Ack1 depletion increases basal DAT 
internalization and abolishes stimulated DAT endocytosis in response to 
PKC activation or cdc42 inhibition. A. Lentiviral-mediated hAck1 
knockdown in SK-N-MC cells: DAT SK-N-MC cells were transduced with the 
indicated lentiviral particles and hAck1 protein expression was measured 72 h 
posttransduction. Top:  Representative immunoblots showing endogenous 
Ack1 levels in lysates from cells transduced with lentiviral particles expressing 
either pGIPZ vector (vec), nonsilencing shRNA (NS), hAck1 10 (10), or hAck1 
12 (12). Bottom: Average hAck1 protein levels expressed as percent vector-
transduced hAck1 levels ± SEM (normalized to actin loading control). ****P < 
0.001 compared with vector-transduced cells, one way ANOVA with Dunnett’s 
multiple comparison test, n = 4–7. B-D. DAT internalization assays: DAT SK-
N-MC cells were transduced with lentiviral particles expressing either pGIPZ 
vector (vec), non-silencing (NS), hAck1#10 (#10) or hAck1#12 (#12) shRNAs 
and DAT internalization rates were measured ±1μM PMA (D) or ±20μM pirl1 
(E) as described. B. Representative immunoblots for each transduction 
condition showing total surface DAT at t=0 (T), strip control (S), and 
internalized DAT during vehicle (V), PMA (P) or pirl1 (PR) treatments. C. 
Basal DAT internalization rates expressed as %vector-transduced rates 
±S.E.M. *p<0.04, Student’s t test, n=6. D. PKC-stimulated DAT internalization 
rates expressed as %vehicle rate ±S.E.M. for each transduction condition. 
Asterisks indicate a significant difference from vector-transduced control, 
*p<0.03, **p<0.01, one-way ANOVA with Dunnett’s multiple comparison test, 
n=4-7. E. Pirl1-induced DAT internalization rates expressed as %vehicle rate 
±S.E.M. for each transduction condition. Asterisks indicate a significant 
difference from vector-transduced control, *p<0.02, **p<0.01, one-way 
ANOVA with Dunnett’s multiple comparison test, n=4-7. 
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Figure II-7. Ack1 inactivation is required for stimulated DAT endocytosis. 
A. Representative immunoblots showing pY284-Ack1, total Ack1, and actin 
levels in lysates from cells cotransfected with DAT and either vector, wt-Ack1, 
K158A-Ack1, or S445P-Ack1. B. Average total Ack1 levels expressed as 
percent vector-transfected levels ± SEM (normalized to actin loading control). 
Asterisks indicate a significant difference from vector-transfected control, one 
way ANOVA with Dunnett’s multiple comparisons test, **P < 0.01, ***P < 
0.005, ****P < 0.0001, n = 6. C. Average pY284-Ack1 levels expressed as 
percent vector-transfected levels ± SEM (normalized to total Ack1 levels). **P 
< 0.01 compared with vector-transfected control, one-way ANOVA with 
Bonferroni’s multiple comparisons test, n = 6. D-G Internalization assays: SK-
N-MC cells were co-transfected with the indicated DAT and Ack1 isoforms and 
DAT internalization rates were measured during treatment ±1µM PMA or 
20µM pirl1 as described in Methods. A-D. Wildtype DAT co-transfected with 
the indicated Ack1 cDNAs. D. Representative immunoblots showing total 
surface DAT at t=0 (T), strip control (S), and internalized DAT during vehicle 
(V), 1µM PMA (P) or 20µM pirl1 (PR) treatments. E. Average basal DAT 
internalization rate expressed as %vector co-transfected rate ±S.E.M., one-
way ANOVA, p=0.10, n=8-9. F. Average PKC-stimulated DAT internalization 
rate expressed as %vector co-transfected rate ±S.E.M. **Significantly different 
from vector control, p<0.01, one-way ANOVA with Dunnett’s multiple 
comparison test, n=8-9. G. Average pirl1-stimulated DAT internalization rates 
expressed as %vector co-transfected rate ±S.E.M. *Significantly different from 
vector, p<0.02, one-way ANOVA with Dunnett’s multiple comparison test, n=8-
9.  
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Figure II-8. Constitutive Ack1 activation rescues ADHD DAT coding 
variant R615C endocytic dysfunction. DAT vs. DAT(R615) internalization 
rates ±S445P-Ack1. A. Representative immunoblots. B. Average DAT 
internalization rates, expressed as %wildtype DAT control rate ±S.E.M., 
**Significantly different from indicated sample, p<0.01, one-way ANOVA with 
Bonferroni’s multiple comparison test, n=8-11. C. Constitutively Ack1 
activation does not rescue PKC-stimulated DAT(R615C) internalization. 
Internalization assay: DAT(R615C) was coexpressed in SK-N-MC cells with 
either vector or S445P-Ack1 and internalization rates were measured ±1 μM 
PMA (see Fig.I-10 for representative immunoblot). Average PMA-stimulated 
DAT(R615C) internalization rates expressed as percent vehicle-treated ± 
SEM, P = 0.33, Student’s t test, n = 5–7. 
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Figure II-9. Model for a PKC-sensitive, Ack1-mediated DAT endocytic 
brake. Under basal conditions, the cdc42-activated Ack1 pool imposes an 
endocytic brake upon the plasma membrane DAT population, permitting slow, 
clathrin- and dynamin-independent DAT endocytosis. PKC activation 
inactivates Ack1 and releases the DAT endocytic brake, facilitating rapid, 
clathrin- and dynamin-dependent, DAT internalization and intracellular 
sequestration. 
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CHAPTER III 
 The Dopamine Transporter Recycles Via A Retromer-Dependent Post-Endocytic 
Mechanism: Tracking Studies Using A Novel Fluorophore-Coupling Approach 
 
III.A Introduction 
Dopamine (DA) neurotransmission is responsible for vital functions in the central 
nervous system such as locomotion, reward and sleep/arousal (Iversen and 
Iversen, 2007). Dysregulation of DA neurotransmission is coupled to multiple 
neurological and psychiatric disorders such as Parkinson’s disease, 
schizophrenia, ADHD and bipolar disorder (Snyder, 2002; Chen et al., 2004; 
Sulzer, 2007; Sharma and Couture, 2014). The presynaptic dopamine 
transporter (DAT) expresses exclusively in DA neurons and mediates high-
affinity reuptake of synaptically released DA, thus temporally and spatially 
restraining DA neurotransmission (Gether et al., 2006). DAT is the primary target 
for widely abused psychostimulants, cocaine and amphetamine, as well as 
therapeutic agents such as methylphenidate (Ritalin) (Torres and Amara, 2007; 
Kristensen et al., 2011). Loss-of-function DAT coding variants cause dopamine 
transporter deficiency syndrome, which is a Parkinsonism/dystonia subtype 
(Kurian et al., 2009; Kurian et al., 2011). Altered DAT function has also been 
associated with attention deficit hyperactivity disorder (ADHD), autism spectrum 
disorders (ASD) and adult Parkinsonism (Mazei-Robison et al., 2008; Sakrikar et 
al., 2012; Hamilton et al., 2013; Hansen et al., 2014). Thus, regulatory 
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mechanisms that control DAT function may exert impactful consequences on DA 
neurotransmission and DA homeostasis. 
Numerous studies demonstrate that DAT function is acutely regulated by 
membrane trafficking, which provides a potential means to acutely enhance or 
diminish DA signaling (Melikian, 2004; Eriksen et al., 2010a; Bermingham and 
Blakely, 2016). DAT constitutively internalizes and acute stimuli such as PKC 
activation and amphetamine exposure accelerate DAT endocytosis, resulting in 
decreased DAT surface expression and function (Huff et al., 1997; Daniels and 
Amara, 1999; Melikian and Buckley, 1999; Torres et al., 2003a; Eriksen et al., 
2009). Considerable effort has been directed towards understanding DAT’s post-
endocytic fate. Function studies in heterologous expression systems have 
demonstrated that DAT recycles back to the plasma membrane under basal and 
regulated conditions (Loder and Melikian, 2003; Sorkina et al., 2005; Boudanova 
et al., 2008a; Chen et al., 2013; Richardson et al., 2016). Paradoxically, DAT 
post-endocytic tracking studies in heterologous cells and primary neuronal 
cultures using either antibody feeding or fluorescent cocaine analogs, reported 
that DAT targets to pre-lysosomal and lysosomal pathways, but not to classical 
recycling compartments (Eriksen et al., 2010b), while results from an antibody 
feeding assay showed that DAT recycled back to the plasma membrane in 
heterologous cells and primary culture (Rao et al., 2011; Hong and Amara, 2013). 
Moreover, a recent antibody feeding study performed in acute mouse brain slices 
reported little surface DAT internalization, in either DAergic terminals or 
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somatodendritic areas of DA neurons (Block et al., 2015). These discrepancies 
prompted us to 1) interrogate the DAT post-endocytic itinerary in absence of 
inhibitor analog or bound antibodies; 2) identify the molecular mechanisms that 
mediate DAT post-endocytic sorting.  
The retromer complex mediates cargo export from endosomes to either 
the trans-Golgi network (TGN; retrograde transport) or back to the plasma 
membrane (recycling) (Seaman, 2012; Burd and Cullen, 2014). Multiple neuronal 
proteins, such as β2-adrenergic receptor, AMPA-type glutamate receptor, 
wntless and Alzheimer-associated sortilin-related receptor 1 recycle back to the 
plasma membrane mediated in a retromer-dependent manner (Rogaeva et al., 
2007; Zhang et al., 2012; Choy et al., 2014; Loo et al., 2014; Varandas et al., 
2016). Moreover, retromer disruption is closely linked to multiple neurological 
disorders, including Alzheimer’s and Parkinson’s diseases (Tsika et al., 2014; 
Dhungel et al., 2015; Small and Petsko, 2015).  
In the current study, we took advantage of Protein Incorporation Mediated by 
Enzyme (PRIME) labeling to directly couple a small (~700 dalton) fluorophore to 
the DAT surface population, and subsequently tracked DAT’s temporal-spatial 
post-endocytic itinerary in immortalized mesencephalic cells. Taken together, our 
data demonstrate that internalized DAT targets to a retromer-positive endocytic 
compartment, and that retromer is required to maintain DAT surface levels. 
Moreover, our results demonstrate that DAT recycling via retromer requires a C-
terminal PDZ-binding motif.  
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III.B Materials and methods 
Materials: Picolyl azide (pAz) and Bis[(tertbutyltriazoyl)methyl]-[(2-
carboxymethyltriazoyl)methyl]-amine were synthesized as previously reported 
(Uttamapinant et al., 2010; Uttamapinant et al., 2012). Rat anti-DAT antibody 
(MAB369) was from EMD Millipore and mouse anti-actin antibody (sc-56459) 
was from Santa Cruz Biotechnology. Mouse anti-EEA1 (610456) and mouse anti-
rab11 (610656) antibodies were from BD Transduction. Rabbit anti-rab7 antibody 
(D95F2) was from Cell Signaling Technology and goat anti-Vps35 antibody 
(NB100-1397) was from Novus Biologicals. Horseradish peroxidase-conjugated 
secondary antibodies were from EMD Millipore (goat anti-rat), Jackson 
ImmunoReseach (donkey anti-goat, minimal cross-reaction to mouse serum 
proteins) and Pierce (goat anti-mouse). Alexa488-conjugated secondary 
antibodies were from Invitrogen (goat anti-mouse, goat anti-rabbit, goat anti-rat 
and donkey anti-goat (minimal cross-reaction to mouse serum proteins) Alexa 
Fluor488) and donkey anti-rat Alexa Fluor594 (minimal cross-reaction to mouse 
serum proteins) was from Jackson ImmunoResearch. Alkyne-conjugated Alexa 
Fluor594 was from Invitrogen. [3H]DA (dihydroxyphenylethylamine 3,4-[ring-
2,5,6-3H]) was from Perkin Elmer. Sulfo-NHS-SS-biotin, Tris(2-
carboxyethyl)phosphine hydrochloride (TECP), and streptavidin agarose were 
purchased from Thermo Fisher Scientific. Phorbol 12-myristate 13-acetate (PMA), 
AIM-100 and GBR12909 were from Tocris Bioscience. All other chemicals and 
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reagents were from Thermo Fisher Scientific or Sigma-Aldrich and were of 
highest grade possible. 
cDNA Constructs and Mutagenesis: To generate LAP-hDAT-pcDNA3.1(+), hDAT 
was subcloned into pBS-SKII- as a shuttle vector, and degenerate mutations 
were introduced into hDAT codons corresponding to amino acids 193 and 204, 
adding BsaBI and HpaI sites (Quickchange mutagenesis kit, Agilent 
Technologies). Sense and anti-sense oligonucleotides encoding the LAP-peptide 
sequence, flanked by linkers (GSSGSSGGFEIDKVWHDFPAGSSGSSG; LAP 
peptide sequence is underlined), were annealed and ligated into the blunt 
BsaBI/HpaI site, and the final LAP-DAT cDNA was subcloned into pcDNA3.1(+) 
at HindIII/XbaI sites. LAP-DAT-AAA-pcDNA3.1(+) was generated by mutating the 
last three amino acids of hDAT into alanines (LKV to AAA) using a Quickchange 
mutagenesis kit (Agilent Technologies). All DNA sequences were determined by 
the dideoxy chain termination (Genewiz, New Jersey).  
Cell Culture and Transfections:  The rat mesencephalic cell line 1Rb3AN27 was 
a kind gift from Dr. Alexander Sorkin (University of Pittsburgh, Pittsburgh, PA) 
and was maintained in RPMI1640 supplemented with 10% fetal bovine serum, 
2mM glutamine and 100 units/ml penicillin/streptomycin, 37°C, 5% CO2. Pooled 
stable AN27 cell lines expressing either wild-type hDAT, LAP-hDAT or LAP-
hDAT-AAA, respectively, were generated by transfecting 2×105 cells/well in 6-
well culture plate with 1µg plasmid DNA using Lipofectamine 2000, at lipid:DNA 
ratio of 2:1 (w/w). Stably transfected cells were selected with 200 µg/ml G418 
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(Invitrogen) and resistant cells were pooled and maintained under selective 
pressure in 80 µg/ml G418. SK-N-MC cells were from American Type Culture 
Collection (ATCC) and were maintained in MEM (Sigma-Aldrich M2279) 
supplemented with 10% fetal bovine serum (Invitrogen), 2mM L-glutamine, 102 
U/ml penicillin/streptomycin, 37°C, 5% CO2. Pooled #14 stable SK-N-MC cell 
lines expressing hDAT was generated by transfecting 1×106 cells/well in 6-well 
culture plate with 3 µg plasmid DNA using Lipofectamine 2000, at lipid:DNA ratio 
of 2:1 (w/w). Stably transfected cells were selected in 500 µg/ml G418 (Invitrogen) 
and resistant cells were pooled and maintained under selective pressure in 200 
µg/ml G418. 
[3H]DA Uptake Assay: DAT-AN27 and LAP-DAT-AN27 cells were seeded onto 
24-well plates at 8x104 cells per well one day before performing assays. Cells 
were washed twice with KRH buffer (120mM NaCl, 4.7 mM KCl, 2.2 mM CaCl2, 
1.2 mM MgSO4, 1.2 mM KH2PO4,10mM HEPES, pH 7.4) and preincubated in 
KRH buffer supplemented with 0.18% glucose, 0.1% BSA at 37°C for 30min in 
the presence of either vehicle or the indicated drugs. Uptake was initiated by 
adding 1 µM [3H]DA containing 10-5 M pargyline and 10-5 M ascorbic acid and 
proceeded for 10 min, 37°C. Assays were terminated by rapidly washing cells 
thrice with ice-cold KRH buffer. Cells were solubilized in scintillation fluid, and 
accumulated radioactivity was measured by liquid scintillation counting in a 
Wallac Microbeta plate counter. Non-specific uptake was defined in the presence 
of 10 µM GBR12909. 
95 
 
Endocytic Rate Measurements by Reversible Biotinylation: Stable DAT-AN27 
and LAP-DAT-AN27 cells were plated at 3x105 cells per well in 6-well plate 24 
hours prior to conducting experiments. Cells were washed three times with ice-
cold PBS2+ (phosphate-buffered saline, pH 7.4, supplemented with 1mM MgCl2 
and 0.1mM CaCl2), surface proteins were biotinylated twice, 15 min, 4°C, with 
2.5 mg/mL sulfo-NHS-SS-biotin, and were quenched twice, 15 min, 4°C with 100 
mM glycine/PBS2+. Internalization was initiated by washing cells rapidly with 
three times with pre-warmed (37°C) PBS2+/0.18% glucose/0.1% BSA 
(IgG/protease free) containing either  vehicle or the indicated drugs, and 
incubating 10 min, 37°C. Zero timepoint and strip controls were kept at 4°C in 
parallel. Endocytosis was arrested by rapidly washing cells with ice-cold NT 
buffer (150 mM NaCl, 20mM Tris, pH 8.6, 1.0mM EDTA, pH 8.0, 0.2% protease 
free/IgG free BSA). Residual surface biotin was stripped by reducing twice with 
50 mM TCEP/NT buffer, 25 min, 4°C, followed by three washes with PBS2+. Cells 
were lysed in RIPA containing protease inhibitors and protein concentrations 
were determined by BCA protein assay (Thermo) comparing BSA standards. 
Biotinylated proteins were isolated from equivalent amounts of total cellular 
protein by streptavidin-agarose affinity chromatography. Samples were analyzed 
by SDS-PAGE and DAT was detected using a monoclonal rat anti-DAT antibody 
(MAB369; EMD Millipore). Non-saturating DAT bands were detected using a 
VersaDoc gel documentation system and were quantified using Quantity One 
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software (Bio-Rad). Internalization rates were calculated as %biotinylated DAT 
recovered as compared to DAT surface levels at t= 0. 
W37VLplA expression and purification: Expression and purification of His6-tagged 
W37VLplA was described in detail at (Uttamapinant et al., 2013). Briefly, pYFJ16-
His6-
W37VLplA plasmid was transformed into BL21 E. Coli and bacteria were 
incubated at 37°C, with shaking until they attained log phase growth. Protein 
expression was induced by adding 100 μg/ml isopropyl-β-D-
thiogalactopyranoside (IPTG) and proceeded for 8 hrs at room temperature. 
Bacteria were lysed and His6-
W37VLplA was purified by nickel-affinity 
chromatography. Eluted protein was dialyzed for 8 hours, twice, against 20 mM 
Tris base, 1 mM DTT, 10% (v/v) glycerol, pH 7.5, at 4 ºC, and protein 
concentrations were determined by A280 absorbance using NanoDrop (Thermo 
Scientific) using an extinction coefficient of 46250 M-1cm-1. Ligase aliquots were 
stored at -80ºC. 
Probe Incorporation Mediated by Enzymes (PRIME) Labeling and Post-Endocytic 
Tracking Studies: Live AN27 cells stably expressing the indicated LAP-DAT 
constructs were covalently labeled with alkyne-Alexa as described previously 
(Uttamapinant et al., 2013). Briefly, cells were seeded onto glass coverslips in 
24-well plates at a density of 8x104 cell/well, one day prior to assaying. A picolyl 
azide (PAz) ligation mixture was prepared, containing 10 μM W37VLplA, 200 μM 
pAz, 1 mM ATP and 5 mM MgCl2 in PBS/3%BSA and cells incubated with Paz 
ligation mixture, 20min, room temperature, followed by three washes with PBS2+. 
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A low Cu2+ click labeling solution containing 10 mM CuSO4, 50 mM BTTAA and 
100 mM sodium ascorbate and was prepared and incubated with cells at room 
temperature,10min in a closed tube. The labeling solution was diluted 200X with 
PBS2+, alkyne-Alexa594 was added to a final concentration of 20 µM and 
incubated with cells for 10 min, room temperature. Cells were washed three 
times with room temperature PBS2+ and internalization was initiated by rapidly 
washing cells and incubating in pre-warmed (37°C) PBS2+/g/BSA (PBS2+, 0.18% 
glucose, 0.1% IgG/protease-free BSA) containing the indicated drugs. Cells were 
fixed at the indicated post-endocytic timepoints in 4% paraformaldehyde for 10 
min, room temperature and were subsequently blocked, permeabilized and 
stained with indicated primary antibodies and Alexa488-conjugated secondary 
antibodies as previously described (Navaroli et al., 2011). Note that all of the 
antibodies directed against endosomal markers were carefully vetted for 
specificity: 1. By their ability to recognize native and GFP-tagged proteins via 
immunoblot, and 2) by their ability to co-stain GFP-tagged markers in situ. Dried 
coverslips were mounted in ProLong Gold with DAPI to stain and were dried prior 
to performing imaging. 
Wide Field Microscopy and Image Analysis: Cells were visualized with a Zeiss 
Axiovert 200M microscope using a 63X, 1.4 N.A. oil immersion objective and 0.2 
µm optical sections were captured through the z-axis with a Retiga-1300R cooled 
CCD camera (Qimaging). For image presentation, 3-D z-stack images were 
deconvolved with a constrained iterative algorithm using measured point spread 
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functions for each fluorescent channel using Slidebook 5.0 software (Intelligent 
Imaging Innovations). All representative images shown are single 0.2 µm planes 
through the center of each cell. To quantify the percentage of LAP-DAT that co-
localized with different endosomal markers (by volume, i.e. counting voxel), the 
DAT image was used to identify 1) an extracellular background region-of-interest 
(ROI) for background fluorescence estimation, and 2) the range of contiguous 
optical sections (z-axis planes) having infocus DAT information (i.e. the cell). The 
sample fields imaged were chosen to contain at least one extracellular region of 
at least 5 µm across. This background region was automatically determined by 
first taking the maximum intensity projection (in Z) of the DAT stack.  Then the 
(x,y) position of the 2-D region (x±radius, y±radius) having the lowest average 
intensity within this projection was saved.  The radius used was nominally 20 
pixels (±2 µm).  For each of the color image stacks, at each z plane the average 
intensity of this 2-D region was subtracted from all pixels of the plane, leaving as 
positive signal the fluorescence greater than the extracellular background.  The 
outline of the box containing this background region was superimposed on the 
DAT maximum projection image, as well as the maximum projections of the other 
color stacks, for visual inspection and verification before proceeding with the 
analysis. The infocus DAT data planes were also automatically determined, by 
first calculating the normalized total energy Ê of each Z plane, defined as  
 E(z) = (ΣΣI([x,y],z)2 – n(z)·Ī(z)2) / n(z)·I(z)2  
99 
 
And Ê(z) = (E(z)-Emin)/(Emax-Emin),  where I([x,y],z) is a pixel intensity at position 
[x,y] in plane z, Ī(z) is the average intensity of plane z, and n(z) is the total 
number of pixels in plane z. Starting from the bottom of the stack (1st z plane) 
and moving up, the first infocus plane zbot was defined as the z plane where Ê(z) 
exceeds ÊT=0.5.  Similarly, starting from the top (last z plane) and moving down, 
the last infocus plane ztop is where Ê(z) exceeds the threshold ÊT. This was 
generally a conservative threshold, keeping a few out-of-focus planes at the top 
and the bottom. The planes zbot to ztop are extracted from the background-
corrected multi-color stacks for deconvolution.  The point spread function of the 
microscope system was determined from images of slides of 4 color, 175 nm 
diameter beads (PS-Speck Microscope Point Source Kit, Thermo Fisher 
Scientific Inc.)  All images were subjected to regularized, constrained, iterative 
deconvolution with the same smoothness parameter (a=5·10-5) and iterated until 
the algorithm reached convergence (0.001 level).  
Image segmentation (i.e., identification of signal) was performed on each 
restored image (each wavelength separately) via a manually set threshold. Each 
3-D restored image was projected (via maximum intensity projection) to 2-D and 
then displayed using a false color scale manually adjusted for each displayed 
image to maximize contrast between signal and background. Three different 
thresholds were then chosen for each image: the lower threshold allowed some 
diffused background fluorescence, the middle threshold removed all the diffused 
background and the higher threshold eliminated edges of the labeled structures.  
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Pixels above threshold were kept while those below threshold were set to 0.  
Colocalization of DAT with a second protein was calculated by counting the 
number of positive (>0) pixels in the 3-D DAT image which were also positive in 
the corresponding position of the second protein image, and dividing by the 
number of positive DAT pixels. The low and high thresholds were used to 
evaluate whether conclusions drawn from the colocalization results for the best 
(middle) thresholds were dependent on the threshold chosen and the best 
threshold was used for the data presentation and analysis. All image processing 
and analysis was performed using custom software. 
Initial time points of EEA1 and Vps35 data as well as Rab7 data was fit to a 
linear regression equation 𝑌 = 𝑘𝑥 + 𝑎 , where Y = % DAT colocalized with 
endosomal markers, x is the time (min), k is slope and a is %DAT with 
endosomal markers at time zero. 
Brain Slice Immunohistochemistry and Confocal Microscopy: All animals were 
handled according to University of Massachusetts Medical School IACUC 
protocol A1506 (H.E.M.). Adult C57/B6 mice were transcardially perfused with 4% 
paraformaldehyde and brains were removed and post-fixed for one day at 4°C, 
followed by dehydration in PBS/30% sucrose, 4°C, 2-3 days. 25 μm coronal 
sections were taken through the striatum and midbrain using a sliding microtome 
(Leica) and slices were blocked in PBS with 0.2% TritonX-100, 5% normal 
donkey serum and 1% H2O2. For DAT and Vps35 immunofluorescence, sections 
were co-incubated overnight with rat anti-DAT (1:2000) and goat anti-Vps35 
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(1:500) in PBS with 0.2% TritonX-100, 5% normal donkey serum and 1% H2O2. 
Slices were rinsed in PBS, and incubated with donkey anti-goat and donkey anti-
mouse Alexa Fluor (1:2000 each) for 1hr at room temperature. Unbound 
secondary antibodies were washed in PBS and slices were mounted onto glass 
slides, dried and coverslipped in Prolong Gold mounting medium containing 
DAPI (Invitrogen). Images were acquired with a Leica TCS SP5 II laser scanning 
confocal microscope (Cell and Developmental Biology Core, University of 
Massachusetts Medical School) with either a 20X, 0.7 N.A. objective (HCX PL 
APO CS 20.0x0.70 IMM, Leica) or a 63X, 1.4 N.A. oil immersion objective (HCX 
PL APO CS 63.0x1.40 OIL, Leica). 0.4 µm optical sections were captured 
through the z-axis and 3-D z-stack images were imported into ImageJ using Bio-
Format Importer plugin. All images shown are single representative 0.4 µm 
planes. 
shRNA, Lentiviral Production and Transduction:  Human Vps35-targeted short 
hairpin RNA (shRNA), cloned into the pGIPZ lentiviral vector, were from GE 
Healthcare Dharmacon, and were purchased from University of Massachusetts 
Medical School RNAi Core.  
Full length hairpin sequences were as follows: 
Non-silencing (Luciferase 693): 
TGCTGTTGACAGTGAGCGCTCTAAGAACGTTGTATTTATATAGTGAAGCCAC
AGATGTATATAAATACAACGTTCTTAGATTGCCTACTGCCTCGGA 
hVps35 sh#32:  
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TGCTGTTGACAGTGAGCGACTGACAGATGAGTTTGCTAAATAGTGAAGCCA
CAGATGTATTTAGCAAACTCATCTGTCAGGTGCCTACTGCCTCGGA 
Initial shRNA efficacies were determined by immunoblotting cell lysates obtained 
from HEK293T cells transiently transfected (Lipofectamine 2000) with the 
indicated pGIPZ-shRNA vs. control vectors. Replication incompetent lentiviral 
particles were produced as previously described by our laboratory (Wu et al., 
2015) and titers were determined 48 hrs post-transfection by counting GFP-
positive cells in transduced HEK293T cells.  
For Lentiviral Transduction:  5x105 DAT SK-N-MC cells/well were seeded into 6-
well plate one day prior to viral transduction and were infected with 5ml of the 
indicated crude lentivirus supplemented with 8µg/ml polybrene. Virus was 
removed 24 hours post-infection and transduced cells were enriched by selecting 
with 1µg/ml puromycin. Cells were assayed 96 hours post-infection.  
Cell Surface Biotinylation: DAT surface levels in SK-N-MC cells were determined 
by steady state biotinylation as previously described (Navaroli et al., 2011; 
Gabriel et al., 2013; Wu et al., 2015). Briefly, cells were labeled twice, 15 min, 
4°C with 1.0 mg/ml sulfo-NHS-SS-biotin in PBS2+ and excess biotinylation 
reagent was quenched twice, 15 min, 4°C with PBS2+/100mM glycine. Excess 
glycine was removed by washing three times in ice-cold PBS2+ and cells were 
lysed in RIPA buffer (10mM Tris, pH 7.4, 150mM NaCl, 1mM EDTA, 0.1%SDS, 
1%Triton-X-100, 1% sodium deoxycholate) containing protease inhibitors. 
Lysates were cleared by centrifugation and protein concentrations were 
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determined by BCA protein assay kit (Pierce). Biotinylated proteins from 
equivalent amount of cellular protein were recovered by batch streptavidin affinity 
chromatography (overnight, 4°C) and bound proteins were eluted in denaturing 
SDS-PAGE sample buffer, 30 min, room temperature with rotation. Samples 
were analyzed by SDS-PAGE and indicated proteins were detected by 
immunoblotting with the indicated antibodies. Immunoreactive bands were 
detected with SuperSignal West Dura (Pierce) and were captured using the 
VersaDoc Imaging station (Biorad). Non-saturating bands were quantified using 
Quantity One software (Biorad). 
Statistical Analysis: Data were presented as means of results from each 
experimental condition, as indicated in figure legends. For experiments in which 
two conditions were compared, data were analyzed using an unpaired, two-tailed 
Student’s t test. For experiments in which three or more conditions were 
evaluated, statistical significance was calculated using either a one-way or two-
day ANOVA followed by either Tukey’s or Bonferroni’s multiple comparison test 
as indicated in the figure legends. All time course data sets passed normality test. 
Statistical analyses were performed using GraphPad Prism 6.0 software.  
 
III.C Results 
DAT expression, function and trafficking tolerate LAP peptide 
incorporation into extracellular loop 2  
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Previous studies investigating DAT post-endocytic trafficking have relied primarily 
on either antibody feeding or fluorescent competitive DAT inhibitors, both of 
which could potentially target DAT to a physiologically irrelevant post-endocytic 
pathway. Therefore, we aimed to track DAT’s post-endocytic itinerary by 
covalently labeling the DAT cell surface population with small fluorophores, 
thereby creating a “fluorescent DAT”. To accomplish this, we took advantage of 
the recently reported  Protein Incorporation Mediated by Enzyme (PRIME) 
labeling approach (Uttamapinant et al., 2013). This method covalently couples 
fluorophore to cell surface proteins that encode an extracellular ligase acceptor 
peptide (LAP), which is a substrate for bacterial lipoic acid ligase. The PRIME 
strategy for labeling cell surface DAT is illustrated in Figure III-1A. We replaced 
hDAT residues 193-204 in the 2nd extracellular loop (EL2) with a twenty-seven 
amino acid peptide sequence containing LAP, flanked by linker sequence. We 
first tested the specificity of this labeling approach by stably expressing LAP-DAT 
in the rat mesencephalic cell line, 1Rb3AN27, and subsequently performing 
PRIME labeling followed by immunocytochemistry on fixed, permeabilized cells 
using an anti-DAT antibody, to detect total LAP-DAT expression. Alkyne-
Alexa594 coupled specifically to the surface of cells expressing LAP-DAT, 
whereas nearby LAP-DAT-negative cells (identified using DAPI staining) were 
not labeled (Fig.III-1B). Moreover, the alkyne-Alexa594 signal overlapped with 
the anti-DAT antibody signal at the cell surface. These results demonstrate that 
PRIME labeling is both highly efficacious and specific for LAP-DAT. We also 
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performed PRIME labeling on cells expressing wild-type DAT (wt-DAT), and 
observed no labeling (data not shown). Of note, we observed that the 
requirement of a linker between the DAT polypeptide backbone and the LAP 
peptide was absolutely required in order to achieve high efficiency labeling, and 
earlier attempts at labeling LAP-DAT constructs, either without linkers or with 
shorter linkers, failed to efficiently label cells (data not shown). 
We next asked whether LAP-DAT expressed, functioned and downregulated 
comparable to wt-DAT. Immunoblot analysis revealed that LAP-DAT expressed 
at levels comparable to wt-DAT, with a similar ratio of mature (~75kDa) to 
immature (~55kDa) biosynthetic species (Fig.III-1C). LAP-DAT was also 
subjected to PKC-induced function downregulation. PKC activator PMA 
significantly decreased wt-DAT and LAP-DAT function to 68.70 ± 3.42% and 
58.15 ± 7.49% control levels, respectively (Fig.III-1C). To test whether LAP-DAT 
undergoes regulated endocytosis, we stimulated DAT internalization by inhibiting 
Ack1 with 20µM AIM-100, as previously reported (Wu et al., 2015). Basal LAP-
DAT internalization rates were not significantly different from wt-DAT (p=0.2) and 
AIM-100 treatment similarly increased both LAP-DAT (134.48 ± 5.33% of control 
levels) and wt-DAT (162.57 ± 16.8% control levels) internalization rates (Fig.III-
1D). Thus, appending DAT with the LAP peptide did not deleteriously impact 
DAT biosynthesis, function or endocytic trafficking. 
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Tracking DAT temporal-spatial post-endocytic trafficking via PRIME 
labeling 
We next used LAP-DAT to temporally track DAT’s post-endocytic fate by 
fluorescently labeling the surface DAT population at room temperature (18°C - 
22°C; conditions of minimal endocytosis), stimulating internalization by shifting 
cells to 37°C, and fixing/staining cells at various post-endocytic time points to 
measuring DAT co-localization with several endosomal markers (see schematic, 
Fig.III-2A). As a proof of principle, we first characterized DAT trafficking from the 
plasma membrane to early endosomes, given multiple reports that DAT co-
localizes to EEA1/rab5-positive vesicles shortly following internalization (Daniels 
and Amara, 1999; Melikian and Buckley, 1999; Eriksen et al., 2009). At time zero, 
4.01 ± 0.21% of the LAP-DAT signal co-localized with EEA1 (Fig.III-2C). This 
low-level co-localization was observed between DAT and all endocytic markers 
investigated throughout the study, and we attributed this to low-level basal DAT 
internalization that occurred during the room temperature labeling procedure. 
Under basal conditions, DAT/EEA1 co-localization rapidly and significantly 
increased over the first 10 minutes of internalization and peaked at 21.29 ±1.37%, 
which translates to a 430.9% enhancement over baseline. DAT/EEA1 co-
localization plateaued at subsequent time points, although there was a trend for 
decreased DAT/EEA1 colocalization at the 60 minute time point as compared to 
the 10 minute peak (Fig.III-2C; p=0.08) Treatment with AIM-100 to stimulate DAT 
internalization also significantly increased DAT/EEA1 colocalization over time, 
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although the initial rate of entry into EEA1-positives was significantly slower as 
compared to vehicle conditions (slope = veh: 1.73±0.41 vs. AIM-100: 0.87±0.11, 
p<.03, Student’s t test, n=30), with co-localization peaking at 20 minutes post-
endocytosis. We likewise observed no significant decrease in DAT/EEA1 co-
localization after the 20 minute peak. These results demonstrate that the PRIME 
labeling strategy is effective for tracking DAT from the cell surface to endosomal 
destinations. Note that in the interest of space, we have only presented DAT 
internalization images under control conditions, as any AIM-100-induced 
differences are not markedly different by visual inspection.  
Following internalization and localization to early endosomes, proteins are 
targeted to either degradative, recycling, or retrograde (i.e. TGN) pathways. 
Given that DAT recycling and rapid delivery to the plasma membrane has been 
reported by our laboratory and others (Loder and Melikian, 2003; Lee et al., 2007; 
Gabriel et al., 2013; Richardson et al., 2016), we next asked whether DAT is 
targeted to the conventional rab11 recycling endosome (Welz et al., 2014). 
Under basal conditions, we observed no significant DAT/rab11 co-localization 
over baseline at either 5 or 10 minute time points, and a small, but significant 
amount of DAT/rab11 co-localization (7.36 ± 0.42% co-localization; Fig.III-3B) 
that translated to 46.3% over baseline at 20 minutes post-endocytosis, and 
plateaued across all subsequent time points. During AIM-100 treatment, there 
was no significant co-localization with rab11 at early time points, but DAT 
significantly co-localized with rab11 at 45 min and 60 min, as compared to 
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baseline and early time points (Fig.III-3B). Moreover, at 60 min post-endocytosis, 
there was significantly more DAT co-localized with rab11 under AIM-100 
treatment as compared to vehicle treatment. These results indicate although the 
majority of DAT does not go through conventional recycling pathway, a small but 
significant DAT population enters rab11-positive endosomes, and this is 
increased when DAT endocytosis is stimulated by acute Ack1 inhibition. 
Given that the majority of internalized DAT did not co-localize with a rab11-
positive endosome, we next asked whether DAT sorted to degradation by 
staining late endosomes, using rab7 as a marker. Under basal conditions, DAT 
exhibited a slow, significant, linear (r2=0.95) increase in rab7 co-localization over 
time, with 22.11 ± 0.97% DAT/rab7 co-localization observed at the 45 minute 
timepoint, which translated to a 295.5% elevation over baseline (Fig.III-3D). AIM-
100 treatment had no effect on the rate of DAT/rab7 co-localization (slope = 
vehicle: 0.34 ±0.04 vs. AIM-100: 0.31 ±0.04, p=0.62, Student’s t test, n=30). 
These results suggest that a fraction of DAT moves into rab7-positive 
endosomes following internalization, with no difference between the kinetics of 
basal vs. stimulated DAT endocytosis. 
DAT targets to retromer-positive endosomes 
Given that DAT expression is quite stable, we questioned whether DAT post-
endocytic sorting to a rab7-positive compartment was indicative of immediate 
post-endocytic targeting to the degradative pathway. Recent studies indicate that 
rab7 is also part of the cargo-selective trimer (Vps35-Vps29-Vps26) that recruits 
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proteins to the retromer complex from the endosomal membrane (Rojas et al., 
2008; Seaman et al., 2009). Therefore, we hypothesized that DAT may recycle to 
the plasma membrane via a retromer-mediated mechanism. To test this 
hypothesis, we asked whether internalized DAT entered a retromer-positive 
endosome, as indicated by co-localization with Vps35, a retromer core protein for 
cargo recognition (Seaman, 2012; Burd and Cullen, 2014). Under basal 
conditions, DAT/Vps35 co-localization rapidly and significantly increased over 
time, peaking at 24.01 ±0.88% co-localization at 15 minutes post-endocytosis, 
which translates to 413.0% enhanced co-localization over baseline (Fig.III-4B). 
Moreover, DAT/Vps35 co-localization was significantly reduced by 45min 
compared with 15min, likely reflecting DAT exiting from Vps35-positive 
endosomes over time. During AIM-100 stimulation, DAT/Vps35 co-localization 
likewise increased significantly over time (Fig.III-4B). However, the rate of 
DAT/Vps35 increased co-localization was significantly lower in AIM-100 vs. 
vehicle-treated cells (slope = veh: 1.24±0.28 vs. AIM-100: 0.63±0.14, p<.04, one-
tailed Student’s t test, n=24-30). However, in contrast to vehicle-treated cells, 
DAT/Vps35 co-localization continued to increase at later time points (Fig.III-4B). 
These results suggested that DAT is targeted to the retromer complex following 
either basal or stimulated endocytosis.  
We further asked whether native DAT co-localized with Vps35 in situ in bona fide 
DAergic neurons. Immunocytochemistry performed on coronal mouse brain 
slices revealed DAT/Vps35 co-localization in perinuclear regions of substantia 
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nigra DAergic neurons (Fig. 4C). We also observed discrete DAT/Vps35-positive 
puncta in a subset of DAergic terminals in the dorsal striatum (Fig. 4D), 
consistent with DAT targeting to retromer complex. Taken together with our 
cellular LAP-DAT studies, these results indicate that DAT co-localizes with 
retromer in both AN27 cells and intact DA neurons, raising the possibility that 
internalized DAT is sorted and recycled via a retromer-dependent mechanism. 
Retromer complex is required to maintain DAT surface levels  
We next tested whether intact retromer activity was required to recycle DAT back 
to the plasma membrane following internalization. We reasoned that if retromer 
were required for DAT recycling, retromer disruption would decrease DAT 
surface levels, and potentially target DAT to degradation if it were unable to 
recycle back to the plasma membrane. To test this hypothesis, we used shRNA 
to knock down Vps35, an approach previously reported to perturb retromer 
function (Choy et al., 2014; Varandas et al., 2016). We screened several human 
Vps35-targeted shRNA constructs and found that shRNA#32 significantly 
reduced Vps35 expression to 35.17 ± 4.82% of control levels (Fig.III-5A). In DAT-
SK-N-MC cells, Vps35 loss resulted in a significant decrease in DAT surface 
levels (54.90 ±6.43% of control; Fig.III-5B), consistent with a role of retromer in 
maintaining DAT surface expression. Moreover, total DAT levels were also 
reduced to 54.40 ±4.72% control levels following Vps35 knockdown (Fig.III-5C), 
suggesting that compromised retromer activity drives DAT to degradation. Taken 
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together, these results demonstrate that retromer is required to maintain DAT 
surface levels, and implicates retromer as the DAT recycling mechanism. 
DAT exit from retromer is dependent of its C-terminal PDZ-binding motif 
We next asked whether a specific domain targeted to and/or recruited DAT from 
retromer. Many proteins target to retromer via PDZ binding motifs (Lauffer et al., 
2010; Clairfeuille et al., 2016; McGarvey et al., 2016). Interestingly, DAT encodes 
a C-terminal PDZ-binding motif (-LKV), and multiple reports indicate that DAT 
surface stability is dependent upon this motif (Torres et al., 2001; Bjerggaard et 
al., 2004; Rickhag et al., 2013). To test whether the DAT C-terminal PDZ-binding 
motif was required for targeting to the retromer complex, we mutagenized the 
DAT C-terminus within the LAP-DAT background (LAP-DAT-AAA) and tested 
whether DAT retromer targeting was maintained. As seen in Figure III-6B, both 
wildtype LAP-DAT and LAP-DAT-AAA were robustly targeted to Vps35 
compartment. However, there was a significant difference between WT-DAT and 
DAT-AAA co-localization with Vps35 at the 45 minute time point, suggesting that 
the DAT –LKV sequence is necessary to exit retromer-associated endosomes.  
 
III.D Discussion 
Neurons utilize energy-demanding mechanisms to organize and maintain 
functional and plastic presynaptic terminals. DAT is expressed in midbrain 
dopaminergic cell bodies, and is biosynthetically trafficked to distant presynaptic 
boutons in the dorsal and ventral striata, respectively, where it is properly 
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organized adjacent to active release sites. Given the large energy expenditure 
required to construct DAergic terminals, it is evolutionarily advantageous to 
maintain these complex structures as efficiently as possible. Endocytic recycling 
rapidly modulates the synapse, bypassing the requirement for either biosynthesis 
or degradative burden. Evidence from multiple laboratories supports that DAT is 
subject to constitutive and regulated internalization (Melikian, 2004; Bermingham 
and Blakely, 2016). However, DAT's post-endocytic fate has long been debated, 
with numerous reports demonstrating measurable DAT recycling (Loder and 
Melikian, 2003; Boudanova et al., 2008a; Chen et al., 2013; Richardson et al., 
2016). In contrast, several tracking studies found that DAT targets to degradative 
vesicles (Miranda et al., 2005; Eriksen et al., 2010b). These seemingly disparate 
findings may have arisen from the broad variety of approaches used to 
interrogate the DAT trafficking itinerary, including antibody tracking (Hong and 
Amara, 2013; Block et al., 2015), fluorescent high-affinity DAT ligands (Eriksen et 
al., 2009) and DAT-reporter fusion proteins (Eriksen et al., 2010b). Moreover, 
previous studies reported steady-state findings following extended labeling times, 
which might unintentionally overlook early post-endocytic trafficking events. It is 
worth noting that although our studies were highly feasible in the cell line utilized, 
LAP-DAT expression was compromised in both SK-N-MC and SH-SY5Y cell 
lines, possibly due to cleavage of LAP peptide by endogenous transmembrane 
proteases.  
113 
 
Consistent with previous results, we observed robust, rapid DAT entry into EEA1- 
positive endosomes within 5-10 minutes post-endocytosis. Surprisingly, when we 
stimulated DAT endocytosis by acutely inhibiting Ack1, we did not observe more 
rapid or enhanced DAT entry into EEA1-positive endosomes. Rather, we 
observed significantly less DAT/EEA1 colocalization at 5min and 10min, 
compared to vehicle controls (Fig.III-2C). Basal DAT internalization is both 
clathrin- and dynamin-independent (Gabriel et al., 2013; Wu et al., 2015), 
whereas PKC- and AIM-100 stimulated DAT internalization are both clathrin and 
dynamin-dependent (Gabriel et al., 2013; Wu et al., 2015). Thus, a DAT 
subpopulation may target to an EEA1-negative (Hayakawa et al., 2006; 
Lakadamyali et al., 2006; Kalaidzidis et al., 2015) early endosomes following 
stimulated endocytosis. Alternatively, enhanced DAT internalization may saturate 
the early endosomal machinery, and thereby stall entry kinetics into EEA1-
positive early endosomes. 
Although DAT recycling and rab11-dependent DAT delivery to the plasma 
membrane have been reported (Loder and Melikian, 2003; Furman et al., 2009a; 
Sakrikar et al., 2012; Richardson et al., 2016), previous DAT tracking studies 
have not observed robust DAT entry into classic rab11-positive recycling 
endosomes (Eriksen et al., 2010b; Hong and Amara, 2013). We observed a 
small, but significant, enhancement in DAT/rab11 co-localization under basal 
conditions, that increased in response to stimulated DAT endocytosis (Fig.III-3A, 
4B). However, DAT/rab11 co-localization over baseline was relatively modest 
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over time (~46%), did not account for the robust DAT population that entered 
early endosomes (~500% enhanced co-localization over baseline). In contrast, 
we observed robust and significant DAT co-localization in Vps35-positive 
vesicles, that peaked between 15-20 minutes post internalization (Fig.III-4A, 4B), 
with an enhancement of 513% over baseline, comparable to what we observed 
for DAT entry into early endosomes. These data suggest that the majority of 
internalized DAT targets to the retromer complex. Retromer and rab11-
dependence are not necessarily mutually exclusive, as several reports suggest 
that rab11 may function in consort with retromer to facilitate recycling (van 
Weering et al., 2012; Hsiao et al., 2015). Likewise, several reports suggest that 
rab7 is required for retromer recruitment, both in yeast and mammalian cells, and 
acts in consort with rab5 (Rojas et al., 2008; Seaman et al., 2009). Thus, both 
our results, and those from other groups, indicating significant DAT post-
endocytic trafficking through a rab7-positive compartment may also be indicative 
the retromer-mediated recycling mechanism. We cannot, however, rule out the 
possibility that a fraction of DAT is sorted to late endosomes for degradation. 
Indeed, we observed a decrease in total and surface DAT in response to 
retromer disruption, consistent with targeted degradation. However, dissimilar to 
previous reports (Miranda et al., 2005; Hong and Amara, 2013), we did not 
observe any enhanced targeting to rab7-positive endosomes in response to 
stimulated DAT internalization (Fig.III-3C, 3D).  
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Steady state DAT/Vps35 co-localization was detected in perinuclear regions of 
DAergic soma (Fig.III-4C). This could indicate potential DAT recycling in 
somatodendritic compartments via the perinuclear recycling compartment. 
Alternatively, given that retromer is responsible for retrograde transport from the 
plasma membrane to the TGN, DAT/Vps35 co-localization may simply reflect 
close opposition between DAT biosynthesis and retrogradely targeted proteins in 
the TGN. Although DAT expression is strikingly robust in DAergic terminal 
regions, we only detected DAT/Vps35 co-localization in a small subset of DAT 
puncta (Fig.III-4D). Thus, DAT recycling may only occur in the small subset of 
actively releasing terminals. Consistent with this premise, we observe only 
modest, but significant, losses in DAT surface expression following PKC 
activation in ex vivo mouse striatal slices (Gabriel et al., 2013), which could 
reflect larger losses in individual active boutons averaged with a static DAT 
population in the inactive DA terminal population.  Future studies should better 
illuminate this possibility.  
Retromer complex was originally identified as mediating cargo recruitment for 
retrograde trafficking from plasma membrane to the TGN (Seaman et al., 1997; 
Seaman et al., 1998). However, recent studies have revealed that retromer plays 
an equally important role in recruiting membrane protein cargo from endosomes 
for recycling (Seaman, 2012; Choy et al., 2014). Importantly, retromer disruption 
via shRNA-mediated Vps35 knockdown resulted in marked DAT depletion from 
the plasma membrane (Fig.III-5C), consistent with a requirement of retromer to 
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recycle constitutively internalizing DAT and maintain DAT surface expression. 
However, retromer disruption did not completely deplete DAT surface expression 
over a 96 hour knockdown window. Given that we only achieved a partial Vps35 
knockdown, there was likely still some active retromer complex available. 
Moreover, given that some DAT targets to rab11-positive endosomes, there 
could have remained some additional recycling via this endosomal route. 
Retromer-mediated cargo recruitment from the endosomal membrane frequently 
requires interaction of sorting nexin 27 (SNX27) with a PDZ-binding motif on 
cargo proteins (Lauffer et al., 2010). DAT encodes a distal C-terminal PDZ 
binding motif (-LKV), and previous studies implicate this motif in stabilizing 
mature DAT in DAergic terminals (Torres et al., 2001; Bjerggaard et al., 2004; 
Rickhag et al., 2013). We found that DAT required the –LKV signal in order to 
efficiently exit from Vps35-positive endosomes (Fig.III-6B), consistent with 
retromer-mediated DAT recruitment from endosomes for recycling. Retromer 
endosome fission away is promoted by Vps1, a dynamin-related protein in yeast 
(Chi et al., 2014; Arlt et al., 2015), which is consistent with our previous finding 
that DAT endocytic recycling relies on a dynamin-dependent mechanism (Gabriel 
et al., 2013). While we do not currently known whether other SLC6 transporters 
rely upon retromer, a recent proteomic screen identified multiple potential 
members of the retromer interactome (McMillan et al., 2016),  including the DAT 
SLC6 homolog, GLYT2 (SLC6A9). GLYT2 also encodes a C-terminal PDZ 
binding site, which is required for stable plasma membrane expression (Armsen 
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et al., 2007). In contrast, serotonin transporter expression and stability are 
insensitive to C-terminal perturbations (El-Kasaby et al., 2010). 
In summary, we used PRIME labeling to track DAT post-endocytic fate, both 
during constitutive and stimulated internalization. Our results provide compelling 
evidence that DAT surface stability relies upon retromer-mediated endocytic 
recycling. Moreover, these findings coalesce several seemingly disparate 
previous reports, all of which are consistent with a retromer-mediated mechanism 
governing DAT’s post-endocytic fate.  
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Figure III-1. DAT expression, function and trafficking tolerate LAP 
peptide incorporation into extracellular loop 2. A. PRIME strategy for 
labeling surface DAT. A ligase acceptor peptide (LAP) was engineered into the 
DAT 2nd extracellular loop. Picolyl azide (PAz) is coupled to surface DAT 
encoding LAP peptide (LAP-DAT), followed by alkyne-Alexa594 conjugation, 
resulting in fluorescent surface DAT. B. LAP-DAT labeling. Stable LAP-DAT 
AN27 cells were labeled with alkyne Alexa594 as described in Materials and 
Methods, followed by fixation and staining for DAT, in parallel. Two 
representative cells are shown, and all cells in the field are indicated by DAPI 
staining. C. LAP-DAT immunoblots and [3H]DA uptake assays. Top: 
Representative immunoblots showing expression of wt-DAT and LAP-DAT in 
AN27 cells. Bottom: [3H]-DA uptake assay. Stable wt-DAT AN27 or LAP-DAT 
AN27 cells were treated 1µM PMA, 30 min, 37°C and [3H]-DA uptake was 
measured as described in Material and Methods. Average data are presented, 
expressed as %vehicle-treated control uptake ±SEM. **p<0.01, Student’s t 
test, n=4. D. Internalization assay: wt-DAT and LAP-DAT internalization rates 
were measured in AN27 cells 20μM AIM-100, as described in Material and 
Methods. Top: Representative immunoblots showing the total surface protein 
at t=0 (T), strip controls (S), and internalized protein during either vehicle (V) 
or AIM-100 (A) treatments. Bottom: Average internalization rates expressed as 
percent vehicle-treated internalization ±SEM, *p<0.05, Student’s t test, n=6 
(wt-DAT) n=10 (LAP-DAT).  
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Figure III-2. LAP-DAT labeling is highly specific and facilitates DAT post-
endocytic tracking A. Strategy for tracking DAT post-endocytic routes using 
PRIME labeling. Live LAP-DAT AN27 cells were labeled at room temperature 
using the PRIME labeling approach, as described in Material and Methods. 
Internalization was induced by shifting cells to 37°C, ±20µM AIM-100 to induce 
internalization. Cells were then fixed, permeabilized and stained for 
endosomal markers using specific antibodies. B. Representative images 
showing LAP-DAT (red) and early endosome marker EEA1 (green) at the 
indicated time points (vehicle-treated). C. Average data expressed as %DAT 
signal co-localized with EEA1 signals ±SEM. * indicates significant difference, 
**p<0.005, ***p<0.001, two-way ANOVA with multiple comparison Tukey’s and 
Bonferroni’s test, n=19-49 cells, imaged across three independent 
experiments.  
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Figure III-3. A small DAT fraction targets to rab11- and rab-7 positive 
endosomes. A-D. PRIME labeling on live cells. Live LAP-DAT AN27 cells 
were labeled using PRIME labeling approach at room temperature, 
internalized for indicated time, fixed and stained for indicated markers as 
described in Material and Methods. A and C. Representative images showing 
LAP-DAT (red) with recycling endosome marker rab11 (green, A) or late 
endosome marker rab7 (green, C) at the indicated time points. B and D. 
Average data expressed as %DAT signal that co-localized with either rab11 
signal (B) or rab7 signal (D) ±SEM. * indicates significant difference *p<0.05, 
**p<0.005, ***p<0.001, two-way ANOVA with multiple comparison Tukey’s and 
Bonferroni’s test, n=28-30 cells (C), n=30 cells (D), imaged over three 
independent experiments. 
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Figure III-4. DAT is targeted to retromer positive endosomes. A-B. LAP-
DAT is sorted to retromer in AN27 cells. PRIME labeling on live cells. A. 
Representative images showing LAP-DAT (red) and retromer marker Vps35 
(green) at the indicated time points. B. Average data expressed as %DAT-
positive objects that co-localized with Vps35 signal ±SEM. All later time points 
were significant different from baseline; * indicates significant difference under 
basal condition, *p<0.05, **p<0.001, two-way ANOVA with multiple comparison 
Tukey’s and Bonferroni’s test, n=24-30 cells, imaged over three independent 
experiments. C-D. DAT/Vps35 co-localization in mouse DAergic neurons. 
Brains from perfused mice were fixed and stained for DAT and Vps35 as 
described in Material and Methods. C. Representative confocal images 
showing DAT (red) and Vps35 (green) expression in DA neuronal cell bodies 
in substantial nigra, scale bar, 50 μm (top) and 5 μm (bottom). D. 
Representative confocal images showing DAT (red) and Vps35 (green) 
expression in DA terminals in dorsal striatum. Scale bar: 5 μm. White 
arrowheads indicate DAT/Vps35 co-localized puncta. 
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Figure III-5.Retromer complex is required to maintain DAT surface levels. 
A. Lentiviral-mediated hVps35 knockdown in SK-N-MC cells. DAT SK-N-MC 
cells were transduced with the indicated lentiviral particles and hVps35 protein 
expression was measured 96 h posttransduction. Top: Representative 
immunoblots showing endogenous hVps35 levels in lysates from cell 
transduced with lentiviral particles expression either pGIPZ vector (vec), 
nonsilencing shRNA (NS), hVps35 #32 (#32). Bottom: Average hVps35 
protein levels expressed as %vector-transduced hVps35 levels ±SEM. 
****p<0.001, one-way ANOVA with post-hoc Dunnett’s test, n=7. B. Cell 
surface biotinylation. DAT SK-N-MC cells were transduced with indicated 
lentiviral particles and relative DAT surface levels were measured by 
biotinylation as described in Material and Methods. Top: Representative 
immunoblots. Bottom: Average DAT surface levels expressed as %vector 
levels ±SEM (normalized to actin levels). ***p<0.005, One-way ANOVA with 
post-hoc Bonferroni’s test, n=6. C. DAT SK-N-MC cells were transduced with 
indicated lentiviral particles and total DAT levels were quantified by 
immunoblotting normalized to actin loading controls. Top: Representative 
immunoblots. Bottom: Average total DAT levels expressed as %vector levels 
±SEM (normalized to actin levels). **p<0.01, One-way ANOVA with post-hoc 
Bonferroni’s test, n=5.  
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Figure III-6. DAT exit from retromer is dependent upon its C-terminal 
PDZ-binding motif. A. Representative images showing wt-LAP-DAT or LAP-
DAT-AAA (red) with retromer marker Vps35 (green) at indicated time points. 
C. Average data expressed as %DAT objects co-localized with Vps35 signals 
±SEM.* indicates significant difference, *p<0.05, **p<0.001, two-way ANOVA 
with multiple comparison Tukey’s and Bonferroni’s test, n= 29-30 cells,  
imaged over two independent experiments. 
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CHAPTER IV 
Investigating Dopamine Transporter Endocytic Trafficking In Ex Vivo Slice 
Preparations Using A Direct Fluorophore Coupling Approach 
IV.A Introduction 
DAT robustly traffics to and from the plasma membrane via the endocytic 
pathways. Numerous stimuli, including PKC activation and amphetamine 
exposure acutely decreased DAT plasma membrane availability in dopaminergic 
terminals by promoting DAT endocytosis. However, DAT’s post-endocytic fate is 
unclear and conflicting studies report that DAT targets to either recycling or 
degradative endocytic compartments, or that DAT may not traffic in bona fide 
DAergic neurons.  In the previous chapter, using PRIME labeling in a neuronal 
cell line, I generated a temporal-spatial profile of DAT movement along the 
endosomal pathways. To further expand these findings in bona fide DAergic 
neurons, I attempted to use the LAP-DAT construct to examine the DAT 
endocytic trafficking in ex vivo brain slices.  
IV.B Material And Methods 
Material: HA tag from HA-hDAT-pcDNA3.1(+) was cloned into LAP-hDAT-
pcDNA3.1(+) using HindIII and BamHI sites. The resulting construct, HA-LAP-
hDAT-pcDNA3.1(+) was put into pAAV-EF1α-DIO-WPRE vector using the 
BamHI cloning site, generating pAAV-EF1α-DIO-HA-LAP-hDAT-WPRE. Rat anti-
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HA was from Roche. Rat anti-rat (MAB369) and mouse anti-TH were from EMD 
Millipore. Horseradish peroxidase (HRP)-conjugated goat anti-rat was from EMD 
Millipore. Alexa fluorophore-conjugated secondary antibodies were from Jackson 
ImmunoResearch (cross absorbed goat anti-rat Alexa 594, cross absorbed goat 
anti-rat Alexa 488, goat anti-mouse Alexa 488, goat anti-mouse Dylight 405). pAz 
and BTTAA were kindly provided by Dr. Alice Ting (Stanford University, Stanford 
CA). Alkyne-conjugated Alexa Fluor594 was from Invitrogen. 
Viruses and Stereotaxic Intracranial Injection: Conditional expression of HA-LAP-
hDAT in Cre-containing neurons were achieved using recombinant adeno-
associated viruses 2 (AAV2s) encoding a double-floxed inverted open reading 
frame (DIO) of HA-LAP-hDAT. Plasmid DNA was packaged in the viral core of 
University of Massachusetts Medical School. All animals were handled according 
to University of Massachusetts Medical School IACUC protocol A-1506 (H.E.M.). 
P21-30 male C57/B6 mice were anesthetized with 100mg/kg ketamine 10mg/kg 
xylazine and placed in a digital stereotaxic frame (Stoelting). After puncturing the 
skull under aseptic conditions, AAV2 viral particles were injected (1μL total 
volume) unilaterally through a microliter syringe (Hamilton) at a rate of 0.2μL/min. 
Injection coordinates were -3.08mm anterior/posterior, 1.0mm medial/lateral and 
4.5mm dorsal/ventral for the Substantia Nigra Pars Compacta (SNpc). After 
surgical procedures, mice were returned to their home cage for >21 days to allow 
for maximal gene expression. 
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Immunohistochemistry for floating sections: Viral injected TH-Cre C57/B6 mice 
were transcardially perfused with 4% paraformaldehyde for fixation. Brains were 
post-fixed overnight at 4°C, followed by dehydration in PBS/30% sucrose, 2-3 
days prior to sectioning at 25 μm on a sliding microtome (Leica). Coronal 
sections at SNc or striatum were incubated overnight at 4°C with rat anti-HA 
(1:2000) and mouse anti-TH (1:1000) in PBS with 0.2% TritonX-100, 5% normal 
goat serum, 1%BSA (protease and IgG free) and 1% H2O2. Slices were rinsed in 
PBS, and incubated with goat anti-rat and goat anti-mouse Alexa Fluor (1:500 
each) for 1hr at room temperature. Excess secondary antibodies were washed in 
PBS and slices were mounted onto glass slides, dried and coverslipped in 
Prolong Gold mounting medium containing DAPI (Invitrogen).  
Ex vivo Mouse Striatal Slice PRIME labeling: Viral injected TH-cre C57BL/6 mice 
were sacrificed by cervical dislocation and decapitation. Mouse brains were 
rapidly removed and chilled in ice cold sucrose- and kynurenic acid (1mM)- 
supplemented artificial CSF (SACSF) (2.5mM KCl, 1.2mM NaH2PO4, 1.2mM 
MgCl2, 2.4mM CaCl2, 26mM NaHCO3, 11mM glucose, 250mM sucrose) 
saturated with 95% O2/5% CO2. Brains were mounted on Leica VT1200S 
Vibratome and 300µm coronal sections were obtained at both striatal regions and 
midbrain regions. Slices recovered for 40min, at 31°C in 95%O2/5%CO2-
saturated ACSF (125mM NaCl, 2.5mM KCl, 1.2mM NaH2PO4, 1.2mM MgCl2, 
2.4mM CaCl2, 26mM NaHCO3, 11mM glucose) containing 1mM kynurenic acid. 
Surface DAT was labeled using the PRIME method as described in Chapter III. 
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Briefly, a pAz ligation mix was prepared in ACSF with 10 μM W37VLplA, 200 μM 
pAz, 1 mM ATP and 5 mM MgCl2 and was incubated with slices, 20min, room 
temperature. Slices were rinsed three times with ACSF. A low Cu2+ click labeling 
solution containing 10 mM CuSO4, 50 mM BTTAA and 100 mM sodium 
ascorbate was prepared in ACSF and incubated at room temperature for 10min 
in a closed tube. Labeling solution was diluted 200X with ACSF and alkyne-
Alexa594 was added to a final concentration of 20 µM. The labeling solution was 
added to slices and incubated for 10 min, room temperature followed by three 
rinses with room temperature ACSF. 95% O2/5% CO2  was provided to slices at 
all labeling steps. Slices were then fixed in 4% paraformaldehyde overnight, 4°C, 
dehydrated in PBS/30%sucrose and further sectioned into 12 µm subslices. 
Subslices were blocked, permeabilized and stained with indicated antibodies and 
Alexa fluorophore-conjugated secondary antibodies. Floating slices were 
mounted onto glass slides, dried and coverslipped in Prolong Gold mounting 
medium containing DAPI (Invitrogen).  
Wide field microscopy: Brain slices were visualized with a Zeiss Axiovert 200M 
microscope using either a 20X, 0.75 N.A. objective or a 63X, 1.4 N.A. oil 
immersion objective and images were captured with a Retiga-1300R cooled CCD 
camera (Qimaging). For images captured with a 63X objective, 0.4 µm optical 
sections were obtained through the z-axis and 3D z-stack images were 
deconvolved with a constrained iterative algorithm using measured point spread 
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functions for each fluorescent channel using Slidebook 5.0 software (Intelligent 
Imaging Innovations). All images shown are single representative 0.4 µm planes. 
IV.C Results 
HA-LAP-DAT expresses as a mature protein and is targeted to DAergic 
terminals in the dorsal striatum 
We first asked whether the AAV2 virus containing HA-LAP-DAT conditionally 
expressed in DA neurons of TH-Cre mice. Western blots showed that DAT 
protein was expressed in the DAergic terminals in the dorsal striatum and less in 
the midbrain somatodendritic compartments (Fig. IV-1A). Note that only mature 
(~75 KDa) DAT protein was detected in the terminals whereas both mature 
(~75KDa) and immature (~55 KDa) DAT was expressed in the midbrain. The HA-
LAP-DAT construct was only detected in the injected hemisphere, but not in the 
control hemisphere and mature HA-LAP-DAT was robustly expressed in the 
DAergic terminals. Immunostaining further confirmed that viral expression was 
exclusively in DA neurons shown by colocalization between HA and TH staining 
and readily detected in both dorsal striatum and substantial nigra (Fig. IV-1B, IV-
1C). These results suggest that LAP-DAT expresses as a mature protein and is 
targeted to DAergic terminals in the dorsal striatum. 
HA-LAP-DAT cannot efficiently be labeled in ex vivo midbrain slices using 
the PRIME approach 
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We next asked whether surface expressed HA-LAP-DAT could be labelled using 
the PRIME approach in ex vivo midbrain slices. The PRIME strategy for labeling 
surface DAT on ex vivo slices and subsequent immunostainings is illustrated in 
Figure IV-2A. Acute 300 µm mouse midbrain slices were subjected to PRIME 
labeling and subsequent immunohistochemistry in parallel to identify DA neurons, 
as wells as expression of the HA-LAP-DAT construct. As shown in Figure IV-2B, 
HA-LAP-DAT was expressed in DA neuron cell bodies whereas alkyne-Alexa594 
failed to be coupled to the surface of DA neurons expressing HA-LAP-DAT. 
IV.D Discussion 
In this study, we generated AAV2 virus expressing DIO-HA-LAP-DAT that 
enables selective expression of this transgene in DA neurons in an intact animal. 
LAP-DAT expressed as a mature protein and was targeted to the DAergic 
terminals in the dorsal striatum (Fig. IV-1). Despite the fact that we successfully 
tracked DAT post-endocytic itinerary using the PRIME labeling in neuronal cell 
lines, we were unable to efficiently label LAP-DAT in ex vivo midbrain slices, 
making it not feasible to assess DAT post-endocytic targeting in bona fide DA 
neurons (Fig. IV-2). A possible reason for our negative result is that the 38kDa 
lipoic acid ligase may not be able to efficiently permeate a 300 µm brain slice. A 
recent comprehensive study from Sorkin and colleagues used antibody feeding 
to characterize DAT endocytic trafficking in a knock-in mouse expressing DAT 
with an extracellular HA epitope, and found little antibody localization with 
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endosomal markers in dopaminergic terminal regions (Block et al., 2015). It is 
possible that this result is due to challenges in permeating a relatively thick brain 
slice (1.0 mm) with a large, globular antibody, similar to what we encountered 
with LplA-mediated LAP-DAT labeling. Moreover, it is unclear whether 
internalized DAT bound to a large immunoglobulin would accurately reflect native 
DAT endocytic targeting, particularly in light of recent studies demonstrating that 
antibody binding targets membrane proteins to degradation, despite their 
endogenous endocytic route (St Pierre et al., 2011; Bien-Ly et al., 2014). 
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Figure IV-1. HA-LAP-hDAT expresses as a mature protein and is targeted to 
DAergic terminals in the dorsal striatum. A. Representative blots showing HA-
LAP-DAT expression in dorsal striatum (DS), midbrain (MB) and ventral striatum (VS) 
3 weeks after intracranial viral injection as described in Methods. Note no HA 
expression was detected in the non-injected hemisphere. B and C. Representative 
immunohistochemistry images showing HA-LAP-DAT expression exclusively in DA 
neurons in substantia nigra and dorsal striatum. B. Top: representative HA (red) and 
DA neuron marker TH (green) staining in substantia nigra under 20X objective, 
Middle and Bottom: representative HA (red) and TH (green) staining in dorsal striatum 
under 20X objective (middle) and 63X objective (bottom). C. Representative HA (red) 
and TH (green) stainings in dorsal striatum, an enlarged view. 
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Figure IV-2. HA-LAP-hDAT cannot efficiently be labeled in ex vivo midbrain 
slices using PRIME approach. A. Strategy for labeling surface DAT in ex vivo 
midbrain slices using the PRIME approach. Live acute 300 μm midbrain slices were 
labeled using PRIME approach at room temperature as described in Methods. Slices 
were fixed, dehydrated and subject to microtome sectioning into 12 μm subslices. 
Subslices were permeabilized and stained for TH to identify DA neurons. B. 
Representative images showing LAP-DAT (red), DA neuron marker TH (blue) and 
HA-LAP-DAT contruct expression (green). White arrow heads indicate expression of 
HA-LAP-DAT in TH positive DA neurons. Note no specific Alkyne Alexa conjugation 
to the surface DAT. 
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CHAPTER V 
CONCLUSION, DISCUSSION AND FUTURE DIRECTIONS 
 
DA neurotransmission modulates key brain functions such as voluntary 
movement, reward and desire (Iversen and Iversen, 2007). Dysregulation of DA 
neurotransmission leads to various neuropsychiatric disorders that affect millions 
of people worldwide (Snyder, 2002; Sulzer, 2007). DAT-mediated high-affinity 
reuptake of synaptic DA is the primary mechanism to modulate DA 
neurotransmission and maintain DA homeostasis in the CNS (Rudnick et al., 
2014; Bermingham and Blakely, 2016). DAT is the primary target for the wildly 
abused psychostimulants cocaine and amphetamine (Amara and Sonders, 1998). 
Loss-of-function DAT mutations cause dopamine transporter deficiency 
syndrome, a subtype of parkinsonism dystonia (Kurian et al., 2009). Multiple DAT 
coding variants are associated with ADHD, ASD, schizophrenia and adult 
parkinsonism (Mazei-Robison et al., 2008; Sakrikar et al., 2012; Hamilton et al., 
2013; Hansen et al., 2014). All three lines of evidence support that changes in 
DAT function could exert impactful consequences on DA neurotransmission and 
behavior. 
Numerous studies have worked on molecular mechanisms that regulate DAT 
function. Among them, molecular mechanisms of DAT endocytic trafficking are 
the primary interest of our lab. DAT plasma membrane expression is requisite for 
efficacious synaptic DA removal and replenishing of presynaptic DA. 
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Mechanisms that govern DAT membrane trafficking enable acute modulation of 
DAT plasma membrane availability, providing means of diminishing or enhancing 
DA neurotransmission.  
V.A DAT Endocytosis: Ack1 as an Endocytic Brake Molecule 
We and others have shown that DAT is subject to constitutive and regulated 
endocytosis (Daniels and Amara, 1999; Melikian and Buckley, 1999; Loder and 
Melikian, 2003; Sorkina et al., 2005). Stimuli such as PKC and amphetamine 
promote DAT endocytosis that results in a loss of DAT membrane availability and 
function. A negatively regulatory mechanism, or an “endocytic brake”, controls 
DAT plasma membrane availability. PKC activation releases the endocytic brake, 
stimulating DAT endocytosis. Both the intracellular N- and C-termini are required 
for this negative regulatory mechanism (Boudanova et al., 2008b; Sorkina et al., 
2009), however, cellular factors that control the DAT endocytic brake are 
completely undefined.  
In Chapter II, through a candidate gene approach, I discovered that a non-
receptor tyrosine kinase, Ack1, negatively controls DAT endocytosis (Fig. II-2). 
Tyrosine kinases caught interest in the field years ago when Zahniser’s group 
used a non-selective tyrosine kinase inhibitor, genistein, to acutely block tyrosine 
kinase activity in either Xenopus oocytes or rat synaptosomes and reported 
decrease of DAT function (Doolen and Zahniser, 2001; Hoover et al., 2007). Our 
144 
 
findings demonstrated that Ack1’s effect was specific to DAT and that SERT, a 
SLC6 DAT homolog, was not subject to Ack1 controlled endocytosis (Fig. II-2).  
Using pharmacological and genetic approaches, I further showed that Ack1 
inactivation was required to release the DAT endocytic brake, downstream of 
PKC and cdc42 (Fig. II-7). PKC activation decreased Ack1 activity in both SK-N-
MC cells and mouse striatum (Fig. II-1), but PKC does not directly phosphorylate 
Ack1 (Linseman et al., 2001). Thus, it is likely that another signaling molecule 
exists between PKC and Ack1, probably an Ack1-targeted protein tyrosine 
phosphatase that can be activated by PKC. How Ack1 stabilizes DAT at the 
plasma membrane also remains unclear. I showed that when Ack1 is inactivated, 
DAT internalizes through clathrin-mediated endocytosis (Fig. II-4). Since Ack1 
directly interacts with clathrin (Teo et al., 2001; Yang et al., 2001), it is possible 
that Ack1 controls the DAT endocytic brake through interaction with clathrin 
machinery. Another tentative hypothesis is that Ack1 interacts directly with DAT, 
so that when Ack1 is inactivated, its disassociation from DAT triggers DAT 
endocytosis. Our lab tested this hypothesis by co-IP and found no association 
between Ack1 and plasma membrane DAT (Sweeney and Melikian, unpublished 
result). We also did not observe any DAT/Ack1 co-localization using 
immunohistochemistry, arguing against a DAT/Ack1 complex (Marshall and 
Melikian, unpublished result). Future studies elucidating molecular mechanisms 
of how Ack1 stabilizes DAT on the plasma membrane will provide us more 
information on the Ack1-controlled DAT endocytic brake. 
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Another intriguing question is whether Ack1 inactivation is also required for 
amphetamine-stimulated DAT endocytosis. To test that, I overexpressed 
constitutively active form of Ack1 (S445P-Ack1) and measured DAT 
internalization rate in presence of 10 µM amphetamine. Preliminary results 
showed that overexpressing S445P-Ack1 mutants had a trend to revert the 
amphetamine-induced increase in DAT endocytosis (p=0.055, n=3), suggesting 
Ack1 may also negatively regulate amphetamine-stimulated DAT endocytosis. 
By identifying Ack1 as a DAT endocytic brake molecule, I was able to restore 
normal trafficking to a DAT coding variant (R615C) identified in an ADHD 
proband by constitutively activating Ack1 (Fig. II-10). These findings support the 
idea that targeting DAT regulatory mechanism may be a viable approach to treat 
trafficking dysregulated DAT. Other than the DAT-R615C mutant, the DAT-
A559V mutant, that is associated with ADHD and ASD, is insensitive to 
amphetamine-induced cell surface redistribution (Bowton et al., 2014). Given that 
Ack1 may also negatively regulate amphetamine-stimulated DAT endocytosis, 
Future studies should test whether inhibiting Ack1 activity or knocking down Ack1 
would rescue amphetamine’s effect on DAT-A559V. 
V.B DAT Endocytosis: Differential Dependence on Clathrin 
There have been conflicting results in the field about the requirement of clathrin 
in basal and regulated DAT endocytosis. Both clathrin-dependent and –
independent mechanisms have been implicated in heterologous cell lines as well 
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as primary cultured DA neurons (Daniels and Amara, 1999; Sorkina et al., 2005; 
Cremona et al., 2011). However, they either used non-selective clathrin inhibitors 
or shRNAs to chronically deplete clathrin over days, which could globally disrupt 
both clathrin-dependent and –independent endocytic mechanisms. Using a 
selective dynamin inhibitor, our laboratory recently demonstrated in intact mouse 
DA neuron terminals that PKC-stimulated DAT endocytosis was dynamin-
dependent while basal DAT endocytosis did not require dynamin (Gabriel et al., 
2013). These results suggested that constitutive and PKC-stimulated DAT 
internalization might also be differentially dependent on clathrin.  In Chapter II, I 
used a selective clathrin inhibitor, Pitstop2, to test this hypothesis, and found that 
PKC-stimulated DAT endocytosis was clathrin-dependent, whereas basal DAT 
endocytosis was clathrin-independent (Fig. II-5). Furthermore, when directly 
visualizing DAT surface dynamics using TIRF microscopy, l observed little/no co-
localization between DAT and clathrin, supporting that basal DAT endocytosis 
does not require clathrin (Fig. II-5). However, mechanisms mediating basal DAT 
endocytosis remain unclear.  
A number of endocytic pathways internalize cargos independent of clathrin. 
Understandings of these pathways mainly came from morphology studies using 
electron microscopy, pharmacology studies examining sensitivity to 
pharmacological agents or biochemical and cell biology studies determining their 
dependence on certain kinases and GTPases. Key proteins have been identified 
to mediate clathrin-independent endocytosis. Lipid raft residing integral 
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transmembrane proteins caveolin and flotillin mediate caveolin- and flotillin-
dependent endocytosis, respectively (Parton, 2003; Glebov et al., 2006). DAT 
has been shown to distribute in both lipid raft and non-raft microdomains within 
the plasma membrane and is associated with flotillin-1 (Adkins et al., 2007; 
Foster et al., 2008; Cremona et al., 2011; Navaroli et al., 2011). Lipid raft 
microdomains were reported to constrain DAT lateral mobility (Adkins et al., 2007; 
Sorkina et al., 2013) and influence DAT conformation (Hong and Amara, 2010). 
Moreover, an ADHD-linked DAT coding variant, R615C, displayed reduced 
flotillin-1 association and lipid raft localization (Sakrikar et al., 2012). Given that 
this DAT mutant has enhanced endocytic trafficking rates, lipid raft localization 
probably stabilizes DAT at the plasma membrane. Consistent with this, using 
TIRF to measure DAT plasma membrane distribution, our lab showed that PKC 
activation significantly decreased raft localized DAT, suggesting that PKC-
stimulated DAT endocytosis occurs in the non-raft microdomain (Gabriel et al., 
2013). Whether basal DAT endocytosis preferentially occurs in the lipid raft 
microdomains and the molecular mechanisms behind it remains to be elucidated. 
There are also phagocytosis and macropinocytosis that involve uptake of larger 
membrane areas than clathrin- or caveolin-dependent pathways (Chimini and 
Chavrier, 2000; Dharmawardhane et al., 2000; Shao et al., 2002). Fundamental 
questions such as how membrane invagination is formed and how endocytic pits 
are pinched off the plasma membrane are unclear for some of these clathrin-
independent pathways. The BIN/amphiphysin/Rvs (BAR) domain-containing 
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protein endophilin has recently been shown to control a fast-acting 
tubulovesicular endocytic pathway that is independent of clathrin and its 
accessary protein AP2 (Boucrot et al., 2015; Renard et al., 2015). Multiple G-
protein coupled receptors such as β1-adrenergic, dopamine D3 and D4 receptors, 
muscarinic acetylcholine receptor 4, the receptor tyrosine kinases EGFR, 
PDGFR as well as interleukin-2 receptor all require endophilin for their ligand-
induced internalization. Thus, future studies investigating these different clathrin-
independent endocytosis pathways would shed light on basal DAT endocytosis 
mechanisms. 
V.C DAT post-endocytic sorting: retromer-mediated recycling 
Multiple investigators aiming to elucidate DAT’s endocytic fate generated 
disparate results. Functional studies demonstrated that the DA D2 receptor 
activation promoted surface expression of DAT, supporting the idea of an 
endocytic DAT pool that is readily inserted into the plasma membrane (Bolan et 
al., 2007; Lee et al., 2007). Our lab has shown that globally blocking endocytic 
recycling using either lower temperature (18ºC) or vacuolar H+ ATPase inhibitor 
monensin decreased DAT surface levels, suggesting a constitutive recycling 
process (Loder and Melikian, 2003; Gabriel et al., 2013). More recently, 
Richardson et al. reported that changes in membrane potential alone can rapidly 
drive DAT endocytosis and reinsertion into the plasma membrane. However, 
dynamic imaging studies visualizing which compartments DAT go through using 
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either inhibitor analog or bulky antibodies implicated both degradation and 
recycling pathways (Eriksen et al., 2010b; Hong and Amara, 2013; Block et al., 
2015). Multiple groups reported that PKC activation drove DAT to lysosomal 
degradation (Daniels and Amara, 1999; Miranda et al., 2005; Hong and Amara, 
2013). In Chapter III, I took advantage of a small molecule labeling technique 
called PRIME to directly couple fluorophore to DAT that minimally disturbs DAT 
expression and function (Fig. III-1). This labeling technique enables selective 
labeling of the cell surface population of DAT. Instead of tracking DAT with 
endosomal markers following steady state redistribution of labeled DAT, as 
previously described, I generated a temporal profile of DAT with distinct 
endosomal markers to track its movement along the endocytic pathways. 
Rather than observing entry and exit into the endocytic vesicles, I observed 
enhanced DAT colocalization with early endosome marker (i.e. EEA1-positive) 
that plateaued over time. This suggests that cell surface population of DAT did 
not internalize simultaneously but reached steady-state distribution over time (Fig. 
III-2). The majority of DAT does not recycle through the conventional (i.e. rab11-
positive) recycling endosomes, although I did observe a small, but significant, 
entry into rab11-positive vesicles (Fig. III-3). In contrast, DAT showed robust 
colocalization with retromer marker Vps35, suggesting DAT was targeted to 
retromer (Fig. III-4). Further Vps35 knockdown experiments in intact cells 
showed that impairing retromer function significantly reduced both cell surface 
DAT levels as well as total DAT levels (Fig. III-5), indicating retromer mediates 
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DAT recycling back to the plasma membrane. I also observed a slow, but linear 
increase, of DAT movement into Rab7-positive vesicles (Fig. III-3). Retromer and 
rab7-targeting are not mutually exclusive since Rab7 has also been reported to 
recruit retromer complex core proteins for cargo sorting (Rojas et al., 2008; 
Seaman et al., 2009). However, this study does not rule out the possibility that a 
fraction of DAT is sorted to late endosomes for degradation. The fact that 
impairing retromer function reduced total DAT levels indicating targeted 
degradation. Future experiments using lysosome marker such as lysoTracker are 
needed to test this possibility.  
Using the PDZ-binding domain mutant DAT (DAT-AAA), I showed that this 
mutant did not exit retromer as efficiently as wt-DAT, suggesting DAT PDZ-
binding motif in retromer-mediated DAT recycling. However, the molecular 
mechanisms mediating this process remain unknown. The first question that 
needs to be tested is whether DAT also direct binds SNX27 for retromer 
recruitment like β2-adrenergic receptors (Lauffer et al., 2010). Also, given that 
both degradation and recycling pathways have been indicated in this study, what 
are the signal sequences/motifs in DAT that determines the distinct post-
endocytic sorting destinations (recycling vs, degradation)? To answer these 
questions, high resolution microscopy and robust image quantification techniques 
are required to direct visualize DAT sorting at the endosomes and distinguish the 
retromer exit domain from the sorting endosomes. 
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Study in Chapter III tested DAT post-endocytic route under basal and Ack1-
controlled conditions and I observed similar targeting but distinct colocalzation 
kinetics for EEA1, Vps35 and rab11.  Hong et al. showed that DAT was targeted 
to different destinations under PKC- or amphetamine- regulated endocytosis 
(Hong and Amara, 2013).  Therefore, future studies using the PRIME labeling-
based single cell endocytosis assay will elucidate what happens in PKC- and 
amphetamine- stimulated DAT endocytosis and whether retromer still mediates 
DAT recycling under these conditions. 
Mutations in retromer core protein Vps35 have been identified in autosomal 
dominant, late-onset Parkinson’s disease (Vilarino-Guell et al., 2011; Zimprich et 
al., 2011).  Since retromer is important for the post-endocytic sorting of many 
proteins including DAT, DAT membrane trafficking may also be altered under 
pathological conditions such as Parkinson’s disease.  
 
V.D Studying DAT Endocytic Trafficking in vivo:  
Challenges and Future Directions 
Majority of studies on DAT membrane trafficking have been performed using 
non-neuronal heterologous expression systems rather than intact DA neurons. 
The reason is that it is notoriously difficult to obtain neuronal cultures that contain 
a high faction of DA neurons. In dissociated postnatal midbrain neuron culture, 
50% or less neurons were dopaminergic (Rayport et al., 1992) and even so, 
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these cultured DA neurons are not suitable for biochemical assays. The 
intracellularly located N- and C- termini make it technically challenging to 
introduce tags in the extracellular domain without perturbation of the transporter 
expression and function. Sorkin and colleagues first successfully incorporated a 
HA tag to DAT EL2 without altering DAT function (Sorkina et al., 2006). They 
further generated a KI mouse line that expressed HA-EL2-DAT to track DAT 
membrane trafficking in ex vivo  brain slices and reported a very low level of 
basal DAT endocytic trafficking in the striatum and no amphetamine-regulated 
DAT trafficking (Block et al., 2015). However, their experiments lack inherent 
controls for the overall healthiness of the acute sagittal brain slices during the 
labeling procedure. Our lab and others used biochemical analysis on acute 
coronal brain slices that are enriched in DAergic nerve terminals and reported 
significant DAT surface reduction in response to PKC and amphetamine 
(Cremona et al., 2011; Gabriel et al., 2013; Wu et al., 2015).  
To resolve these controversial results and gain insight of how DAT membrane 
trafficking is regulated in vivo, I proposed to express the LAP-DAT containing 
AAV2 virus selectively in the adult DA neurons in mouse brain and track the DAT 
endocytic itinerary in both somatodendritic and terminal parts of DA neurons. 
Althrough the LAP-DAT containing AAV2 virus expressed in adult DA neurons 
and was targeted to terminals, the PRIME labeling was not successful in acute 
brain slices, probably due to insufficient penetration of the lipoic acid ligase, the 
38kDa enzyme necessary for the first labeling step (Fig. IV1, IV2). These results 
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additionally raise the possibility that lack of robust labeling in the studies by Block 
et al. may be due to difficulty in achieving efficient antibody permeation of their 
thicker, 1 mm acute slices. Therefore, alternative approaches are needed to 
study DAT endocytic trafficking in vivo.  
Combining in vivo DAT approach with the latest microscopy techniques such as 
super-resolution microscopy would enable us to investigate some of the 
fundamental questions regarding DAT membrane trafficking at individual 
synapses. It is well established that receptor membrane trafficking at the 
postsynaptic membrane is a key mechanism underlying different forms of 
postsynaptic plasticity (Kennedy and Ehlers, 2006). An intriguing question, then, 
is whether there is a relationship between DAT endocytic trafficking and DA 
synaptic vesicle release/recycling.  It is already reported that changes in 
membrane potential alone rapidly altered DAT endocytic trafficking (Richardson 
et al., 2016), raising the possibility that DAT endocytic trafficking is acutely 
regulated during DA neurotransmission and this could be an essential 
mechanism to maintain presynaptic DA homeostasis.  
To address this question, the first step would be to test whether DAT membrane 
trafficking occurs in every DA synapses. A recent study using a Fluorescent 
False Neurotransmitters (FFN) that resolves individual DA synapses revealed 
that less than 20% of labeling DA synapses was able to release DA in response 
to stimulation, suggesting that the majority of DA synapses were silent synapses 
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(Pereira et al., 2016). Testing this question requires simultaneously measuring 
DAT membrane trafficking and DA vesicle release at the same synapse. 
Since synaptic vesicle recycling and regulated DAT endocytosis both utilize 
clathrin machineries, the next intriguing question is whether these two processes 
occur at the same presynaptic membrane domain. In other words, is the 
presynaptic membrane compartmentalized into active zone and endocytic zone? 
DAT has been shown to locate at the perisynaptic zone, adjacent to the active 
synaptic vesicle release zone (Nirenberg et al., 1997b; Nirenberg et al., 1997a), 
supporting the idea of presynaptic membrane compartmentalization. However, 
considering DAT is highly mobile on the membrane (Eriksen et al., 2009), it is 
also possible that a fraction of DAT transiently moves into the active zone though 
lateral diffusion. I attempted to investigate DAT surface dynamics using PRIME 
labeling and TIRF microscopy but could not obtain quantifiable images, mostly 
due to the diffuse DAT surface distribution. Considering that the individual DA 
synapse is extremely fine (~0.3 µm in diameter), super resolution microscopy 
techniques will be necessary to test these hypotheses in real time. 
Other than the DA nerve terminals, DAT is also expressed in somatodendritic 
compartments and it is not clear what DAT function is there and whether DAT 
regulatory mechanisms are the same compared with DAT in the terminals. The 
LAP-DAT expressing AAV2 virus had very little mature DAT expression in the 
midbrain, suggesting very little DAT would be inserted in the somatodendritic 
155 
 
plasma membrane (Fig. IV1). Our lab has begun to investigate brain region 
specific membrane trafficking of DAT. The first question is whether regulated 
DAT endocytic trafficking is different between dorsal striatum and ventral striatum 
(NAc). To test that, coronal striatal slices will be dissected into dorsal and ventral 
(NAc) subslices and PKC- or amphetamine-stimulated DAT endocytosis will be 
examined using steady-state biotinylation on acute coronal brain slices. Similarly, 
to test whether DAT undergoes regulated endocytosis in somatodentritic 
compartments, acute coronal brain slices containing substantial nigra or VTA will 
be treated with PKC activator PMA or amphetamine and DAT surface levels will 
be assessed using ex vivo slice biotinylation.  
Functional importance of DAT membrane trafficking in vivo is also poorly 
resolved. How does altered DAT membrane trafficking affect DA 
neurotransmission and behavior? What happens in psychostimulant addicted 
brain? Does DAT trafficking contribute to these pathological conditions?  It is 
recently reported that Vav2, a Rho family guanine nucleotide exchange factor 
protein, negatively regulated DAT surface levels and that Vav2 KO mice 
selectively increased DAT function in NAc and diminished cocaine-induced 
locomotor and reward behavior response, suggesting DAT endocytic regulatory 
mechanisms contribute to cocaine response in rodents (Zhu et al., 2015). Our lab 
has started to look into some of these questions by manipulating proteins 
required for stimulated DAT endocytosis such as Ack1 and Rin in intact mouse 
brain and correlating data of DAT surface level, DA release and DA-related 
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behavior. By doing so, we aim to get a comprehensive understanding of DAT 
endocytic trafficking mechanisms and their functional importance in vivo. 
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